Initial Dosing for Lantus (Insulin Glargine) in Patients Requiring Insulin Therapy

Dosing Guidelines

• The American College of Physicians recommends an initial dose of 10 units or 0.1-0.2 units/kg of body weight once daily for patients requiring insulin therapy, according to the American Diabetes Association guidelines 1, 2, 3
• For type 2 diabetes patients, the initial dose is typically 10 units or 0.1-0.2 units/kg of body weight once daily, often used with metformin and possibly one additional non-insulin agent, as recommended by the American Association of Clinical Endocrinologists 1, 2, 3
• Consider higher starting doses (basal-bolus regimen) for type 2 diabetes patients with HbA1c ≥ 9%, blood glucose levels ≥ 300-350 mg/dL, or HbA1c 10-12% with symptomatic or catabolic features, as suggested by the American College of Physicians 1, 3

Dose Titration

• Increase the dose by 10-15% or 2-4 units once or twice weekly until fasting blood glucose target is met, as recommended by the American Diabetes Association 4
• Timely dose titration is important for achieving glycemic goals, according to the American Association of Clinical Endocrinologists 1, 3

Common Pitfalls to Avoid

• Delaying insulin therapy in patients not achieving glycemic goals can be harmful, as stated by the American College of Physicians 1, 3
• Not adjusting doses based on self-monitoring of blood glucose levels can lead to poor glycemic control, as recommended by the American Diabetes Association 1, 2

Special Populations

• For patients on enteral/parenteral feeding requiring insulin, basal insulin needs are typically 30-50% of the total daily insulin requirement, as suggested by the American Society for Parenteral and Enteral Nutrition 5
• A reasonable starting point for these patients is 5 units of NPH/detemir insulin every 12 hours or 10 units of insulin glargine every 24 hours, according to the American Diabetes Association 5

Insulin Glargine Dosing Guidelines

Dosing Recommendations

• The American Diabetes Association recommends a starting dose of 0.4 to 1.0 units/kg/day of total insulin for type 1 diabetes patients, with 0.5 units/kg/day being typical for metabolically stable patients 6, 7
• For type 1 diabetes patients, higher weight-based dosing is required immediately following presentation with ketoacidosis 6
• Lantus provides basal insulin coverage, but rapid-acting insulin will be needed at mealtimes to control postprandial glucose 6
• The recommended starting dose for insulin-naive type 2 diabetes patients is 0.1-0.2 units/kg/day 8

Dose Titration and Adjustment

• The American Diabetes Association suggests increasing the dose by 2-4 units every 3-4 days until fasting blood glucose reaches target range (80-130 mg/dL) 8
• If fasting glucose is ≥180 mg/dL, consider increasing the dose by 4 units 8

Common Pitfalls to Avoid

• Overbasalization, using higher than necessary basal insulin doses, can mask insufficient mealtime insulin coverage, with signs including high bedtime-to-morning glucose differential (≥50 mg/dL), hypoglycemia, and high glucose variability 9

Insulin Glargine Dosage Guidelines

Recommended Starting Doses

• For patients on enteral/parenteral feeding requiring insulin, a reasonable starting point is 5 units of NPH/detemir insulin every 12 hours or 10 units of insulin glargine every 24 hours 10
• For type 1 diabetes, total daily insulin requirements typically range from 0.4 to 1.0 units/kg/day, with 0.5 units/kg/day being typical for metabolically stable patients 11

Patient Transition and Titration

• For patients transitioning from oral medications to insulin therapy, 5 units of Lantus nightly may be appropriate 12
• Most patients can be taught to uptitrate their own insulin dose, typically adding 1-2 units (or 5-10% for higher doses) once or twice weekly if fasting glucose levels remain above target 12

Changing Insulin Requirements

• Failure to recognize that insulin requirements may change with weight changes, illness, or changes in physical activity 12

Initial Insulin Dosing for Diabetes Management

Basal Insulin Initiation

• For a 50kg patient with diabetes, the American Diabetes Association recommends starting with 10 units of basal insulin once daily, administered at the same time each day 13
• For patients on enteral/parenteral feeding requiring insulin, the American Diabetes Association suggests a reasonable starting point is 10 units of insulin glargine every 24 hours 14

Insulin Regimen Selection

• For type 2 diabetes patients with mild hyperglycemia, the European Association for the Study of Diabetes recommends a basal-only approach may be sufficient initially 15
• For type 1 diabetes patients, the American Diabetes Association requires a basal-bolus regimen, with approximately 50% of the total daily insulin dose as basal insulin and 50% as prandial insulin 16
• Total daily insulin requirements typically range from 0.4 to 1.0 units/kg/day for type 1 diabetes patients, according to the American Diabetes Association 16

Dose Titration

• The American Diabetes Association recommends increasing the basal insulin dose by 2 units every 3 days until fasting blood glucose target is reached 17
• If hypoglycemia occurs, the American Diabetes Association suggests determining the cause and reducing the dose by 10-20% 13

Adding Prandial Insulin (If Needed)

• The American Diabetes Association recommends adding prandial insulin if basal insulin alone is insufficient to reach glycemic targets 13
• For prandial insulin initiation, the American Diabetes Association suggests starting with 4 units per day or 10% of the basal dose with the largest meal 13

Special Considerations

• The European Association for the Study of Diabetes notes that lower weight patients may be more sensitive to insulin and at higher risk for hypoglycemia 15
• For patients with higher risk of hypoglycemia, the European Association for the Study of Diabetes recommends using the lower end of the dosing range 15

Lantus Titration Protocol for Optimal Glycemic Control

Initial Dosing and Titration

• The American Diabetes Association recommends starting with 10 units per day or 0.1-0.2 units/kg body weight once daily, administered at the same time each day 18
• For patients with more severe hyperglycemia, consider higher initial doses (0.3-0.4 units/kg/day) 19

Titration Algorithm

• Set a fasting plasma glucose goal based on individualized glycemic targets and increase dose by 2 units every 3 days until reaching the target without hypoglycemia 18
• If A1C remains above goal after 3-6 months of basal insulin titration despite reaching FPG targets, consider adding prandial insulin 18, 19

Monitoring and Adjustments

• Monitor fasting blood glucose daily during titration and assess adequacy of insulin dose at every visit, looking for clinical signals of overbasalization 18, 19
• Daily self-monitoring of blood glucose is essential during the titration phase 19

Important Considerations

• Be aware that once daily basal insulin dose exceeds 0.5 units/kg/day, addition of prandial insulin may be more appropriate than further basal insulin increases 18, 19

Insulin Dose Adjustment for Suboptimal Glycemic Control

Target Blood Glucose Levels

• The American Diabetes Association recommends a fasting glucose target of 80-130 mg/dL (4.4-7.2 mmol/L) 20

Basal Insulin Dose Adjustment

• When basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, consider adding mealtime insulin rather than continuing to escalate basal insulin alone, as recommended by the American Diabetes Association 21

Initial Therapy

• The foundation of type 2 diabetes therapy should include metformin unless contraindicated, as recommended by the American Diabetes Association 22, 23

Prandial Insulin Therapy

• Consider adding prandial insulin if after 3-6 months of basal insulin optimization, fasting glucose reaches target but HbA1c remains above goal, or if significant postprandial glucose excursions occur, as recommended by the American Diabetes Association 21
• Add prandial insulin before the meal causing the greatest glucose excursion, as recommended by the American Diabetes Association 21

Monitoring and Avoiding Pitfalls

• Daily self-monitoring of fasting blood glucose is essential during titration, as recommended by the American Diabetes Association 21
• Ignoring the need for prandial insulin and continuing to escalate basal insulin beyond 0.5-1.0 units/kg/day without addressing postprandial hyperglycemia leads to suboptimal control and increased hypoglycemia risk, as warned by the American Diabetes Association 21

Insulin Dose Titration for Hyperglycemia Management

Introduction to Insulin Titration

• The American Diabetes Association recommends basal insulin doses of 0.4-0.6 units/kg for patients with severe uncontrolled hyperglycemia, with systematic uptitration every 3 days until fasting glucose reaches 80-130 mg/dL 24

Basal Insulin Titration

• For patients with fasting glucose ≥180 mg/dL, the evidence-based titration algorithm specifies an increase in basal insulin by 4 units every 3 days until target glucose levels are reached 24
• If fasting glucose is 140-179 mg/dL, basal insulin should be increased by 2 units every 3 days 24

Prandial Insulin Coverage

• When basal insulin approaches 0.5-1.0 units/kg/day and fasting glucose is controlled but A1C remains elevated, adding prandial insulin becomes necessary rather than continuing to escalate basal insulin 25, 26
• Prandial insulin coverage should start with 4 units of rapid-acting insulin before the largest meal (or 10% of basal dose), with additions to other meals based on glucose patterns 24, 25, 26

Alternative Therapies

• Consider adding a GLP-1 receptor agonist to the basal insulin regimen to improve A1C while minimizing weight gain and hypoglycemia risk 24, 26

Monitoring and Adjustments

• Daily fasting blood glucose monitoring is recommended during the titration phase, with reassessments every 3 days during active titration and every 3-6 months once stable 24
• If hypoglycemia occurs, determine the cause and reduce the dose by 10-20% 24

Initiating Dose of Lantus for Type 2 Diabetes

Type 2 Diabetes Starting Dose

• The American Diabetes Association guidelines support a starting range of 0.1-0.2 units/kg/day for insulin-naive type 2 diabetes patients, with a typical dose of 10 units once daily for a 50 kg patient 27
• Increase by 2-4 units every 3-4 days until fasting blood glucose reaches target range (80-130 mg/dL), as recommended by the American Diabetes Association 27

Special Considerations and Common Pitfalls

Critical Pitfall: Overbasalization

• Be vigilant for overbasalization when basal insulin exceeds 0.5 units/kg/day, with clinical signals including basal dose >0.5 units/kg/day, high bedtime-to-morning glucose differential (≥50 mg/dL), hypoglycemia, and high glucose variability 27
• When basal insulin approaches 0.5-1.0 units/kg/day and A1C remains elevated despite controlled fasting glucose, add prandial insulin rather than continuing to escalate basal insulin, as recommended by the American Diabetes Association 27

Insulin Glargine Dosing Guidelines

Initial Dosing and Titration

• For hospitalized patients who are insulin-naive or on low-dose insulin, the American Diabetes Association recommends a total daily dose of 0.3-0.5 units/kg, with half as basal insulin, according to The Lancet Diabetes and Endocrinology 28
• For patients on high-dose home insulin (≥0.6 units/kg/day), The Lancet Diabetes and Endocrinology suggests reducing the total daily dose by 20% to prevent hypoglycemia 28
• Lower doses (0.1-0.25 units/kg/day) are recommended for high-risk patients, such as the elderly (>65 years), those with renal failure, or poor oral intake, as stated in The Lancet Diabetes and Endocrinology 28
• The American Association of Clinical Endocrinologists may recommend alternative titration approaches, such as increasing the dose by 10-15% or 2-4 units once or twice weekly, until the fasting blood glucose target is met, according to The Lancet Diabetes and Endocrinology 28

Special Populations and Situations

• For patients without diabetes on steroids, the Endocrine Society suggests a single morning dose of NPH may be appropriate, while for patients with diabetes on steroids, adding 0.1-0.3 units/kg/day glargine to the usual insulin regimen is recommended, with doses determined by steroid dose and oral intake, as stated in The Lancet Diabetes and Endocrinology 29

Administration Guidelines

• The American Diabetes Association advises against diluting or mixing Lantus with any other insulin or solution due to its low pH, as reported in Diabetes Care 30

Management of Inadequate Glycemic Control on Basal Insulin Monotherapy

Immediate Dose Adjustment Algorithm

• The American Diabetes Association recommends increasing the basal insulin dose by 10-15% (approximately 4-6 units) and adding prandial insulin coverage before the largest meal, as blood glucose levels in the 200s mg/dL indicate both inadequate basal insulin and likely insufficient mealtime coverage 31
• Basal insulin titration should be based on fasting glucose levels, with an increase of 4 units every 3 days if fasting glucose ≥180 mg/dL, or by 2 units every 3 days if fasting glucose is 140-179 mg/dL, until fasting blood glucose reaches 80-130 mg/dL 31
• When basal insulin exceeds 0.5 units/kg/day and glucose remains elevated, adding prandial insulin is more appropriate than continuing to escalate basal insulin alone, as recommended by the American Association of Clinical Endocrinologists 31

Adding Prandial Insulin Coverage

• The American Diabetes Association suggests starting with 4 units of rapid-acting insulin before the largest meal or the meal causing greatest postprandial glucose excursion, or alternatively, using 10% of the current basal dose (approximately 4 units) 31, 32
• Rapid-acting insulin analogs provide better postprandial glucose control than regular insulin, according to the Endocrine Society 32, 33
• Prandial insulin should be titrated by 1-2 units or 10-15% every 3 days based on pre-meal and 2-hour postprandial glucose readings, as recommended by the American Diabetes Association 31

Ensure Optimal Foundation Therapy

• The American Diabetes Association recommends verifying that the patient is on metformin unless contraindicated, as it remains the foundation of type 2 diabetes therapy, and metformin should be continued when adding or intensifying insulin therapy 31, 34, 35, 32

Common Pitfalls to Avoid

• Continuing to increase basal insulin beyond 0.5-1.0 units/kg/day without addressing postprandial hyperglycemia leads to suboptimal control and increased hypoglycemia risk, as warned by the American Association of Clinical Endocrinologists 31
• Blood glucose in the 200s mg/dL likely reflects both inadequate basal coverage AND postprandial excursions requiring mealtime insulin, according to the American Diabetes Association 31, 32
• Scheduled insulin regimens with basal, prandial, and correction components are preferred over relying solely on correction insulin, as recommended by the Endocrine Society 36, 37

Patient Education Requirements

• Proper insulin injection technique and site rotation should be taught to patients, as recommended by the American Association of Diabetes Educators 32, 33
• Recognition and treatment of hypoglycemia, self-monitoring of blood glucose, "sick day" management rules, and insulin storage and handling should be included in patient education, according to the American Diabetes Association 31, 32, 33

Initiating Long-Acting Insulin Therapy

Indications for Basal Insulin

• The American Diabetes Association recommends starting long-acting basal insulin when oral medications and/or GLP-1 receptor agonists fail to achieve glycemic targets (A1C >7% for most adults, <6.5% for youth with type 2 diabetes), or immediately in patients with severe hyperglycemia (A1C ≥9%, blood glucose ≥300-350 mg/dL, or symptomatic/catabolic features) 38, 39
• For adults with type 2 diabetes, the American Diabetes Association suggests starting basal insulin when A1C >7% despite optimal oral medications (metformin plus additional agents) 38
• The American Diabetes Association recommends considering starting insulin earlier in the treatment algorithm for adults with type 2 diabetes and A1C ≥9% 38, 40
• For adults with type 2 diabetes and blood glucose ≥300-350 mg/dL and/or A1C 10-12% with symptomatic or catabolic features, the American Diabetes Association recommends starting basal-bolus insulin immediately 38, 40
• The American Diabetes Association suggests starting basal insulin in youth with type 2 diabetes and A1C >8.5% without acidosis or ketosis, at a dose of 0.5 units/kg/day, in addition to metformin 41, 39

Initial Dosing and Titration

• The American Diabetes Association recommends a starting dose of 10 units once daily or 0.1-0.2 units/kg/day for insulin-naive patients with type 2 diabetes, administered at the same time each day 38
• For patients with severe hyperglycemia, the American Diabetes Association suggests considering higher starting doses of 0.3-0.4 units/kg/day 38
• The American Diabetes Association recommends titrating the dose by 2-4 units (or 10-15%) once or twice weekly until fasting blood glucose reaches 80-130 mg/dL 38

Special Considerations

• The American Diabetes Association recommends not delaying insulin initiation in patients not achieving glycemic goals with oral medications 40
• The American Diabetes Association suggests adding prandial insulin when basal insulin has been optimized (fasting glucose 80-130 mg/dL) but A1C remains above target after 3-6 months, or when basal insulin dose approaches 0.5-1.0 units/kg/day without achieving A1C goal 38

Insulin Glargine Dose Titration for Persistent Hyperglycemia

Adjusting Basal Insulin Dose

• If more than 2 fasting glucose values per week are less than 80 mg/dL, decrease the basal insulin dose by 2 units, as recommended by the American Diabetes Association, to prevent hypoglycemia 42

Foundation Therapy

• The American College of Clinical Endocrinologists recommends metformin as the foundation of type 2 diabetes therapy, unless contraindicated, even when intensifying insulin therapy, although the specific details of this recommendation are not provided in the given text, the general principle is supported by various clinical guidelines 42

Ajuste de Insulina Glargina en Diabetes Tipo 1 Descompensada

Consideraciones de Dosis Total

• En diabetes tipo 1, la insulina basal (glargina) típicamente representa 40-60% de la dosis diaria total de insulina, según la American Diabetes Association 43, 44

Protocolo de Titulación de Glargina

• La dosis de glargina puede requerir dosificación dos veces al día cuando la administración una vez al día no proporciona cobertura de 24 horas, según la American Diabetes Association 43, 44

Initiation of Lantus in Specific Clinical Scenarios

Immediate Initiation Criteria

• The European Association for the Study of Diabetes recommends starting basal-bolus insulin immediately in patients with HbA1c 10-12% with symptomatic or catabolic features, suspected type 1 diabetes, or underweight patients, as well as those with acute glycemic dysregulation during hospitalization, surgery, or acute illness 45
• The American Diabetes Association suggests considering immediate initiation of insulin therapy in patients with severe hyperglycemia, although the exact HbA1c threshold is not specified, and GLP-1 receptor agonists may be considered before insulin initiation in patients with no contraindications 45

Insulin Administration and Titration

• The International Diabetes Federation notes that insulin glargine should not be mixed with other forms of insulin due to its low pH diluent, requiring separate injections when combining basal and prandial insulin 46

Basal Insulin Adjustment Timing in Patients on SSI TID

Standard Titration Interval

• The American Diabetes Association recommends increasing basal insulin by 2 units every 3 days to reach fasting plasma glucose goals without hypoglycemia 47
• Basal insulin can be adjusted every 3 days after a change is made, even when patients are concurrently receiving short-acting insulin (SSI) three times daily 47

Key Principle: Separate Basal from Correctional Insulin

• The American Diabetes Association suggests that basal insulin addresses fasting and between-meal glucose levels and should be titrated based on fasting plasma glucose values 47
• Correctional (sliding scale) insulin addresses acute hyperglycemic excursions and does not accumulate to steady state, according to the American Diabetes Association 48
• The two components can be adjusted independently on their respective schedules, as recommended by the American Diabetes Association 47, 48

Monitoring Requirements During Titration

• Assess adequacy of insulin dose at every clinical visit, looking for signs of overbasalization, and adjust the basal dose by 10-20% immediately if hypoglycemia occurs, as recommended by the American Diabetes Association 47

Critical Pitfall to Avoid

• Do not wait longer than 3 days between basal insulin adjustments in stable patients, as this unnecessarily prolongs the time to achieve glycemic targets, according to the American Diabetes Association 47
• The danger of both under-adjusting and failing to respond to hypoglycemia is demonstrated by the 75% of hospitalized patients who experienced hypoglycemia but had no basal insulin dose adjustment before the next administration 48

Special Consideration for Ultra-Long-Acting Insulins

• For ultra-long-acting basal insulins, some experts recommend waiting at least 1 week before making subsequent dose adjustments to fully assess glucose outcomes 49, 50

Timing of Insulin Glargine Adjustment for Post-Lunch Hyperglycemia

Introduction to Basal Insulin Adjustment

• The American Diabetes Association recommends that basal insulin glargine is designed to control fasting and between-meal glucose levels, not postprandial hyperglycemia, with the principal action of basal insulin being to restrain hepatic glucose production overnight and between meals 51, 52, 53

Critical Concepts in Insulin Therapy

• The American Association of Clinical Endocrinologists suggests that continuing to increase basal insulin to address post-lunch hyperglycemia leads to "overbasalization", a dangerous pattern where excessive basal insulin masks the need for mealtime coverage, with clinical signals including bedtime-to-morning glucose differential ≥50 mg/dL, basal insulin dose >0.5 units/kg/day, hypoglycemia, and high glucose variability 51, 52, 54
• Clinical signs of overbasalization include a bedtime-to-morning glucose differential ≥50 mg/dL, indicating excessive basal insulin 51, 52, 54
• A basal insulin dose >0.5 units/kg/day may be a sign of overbasalization, requiring adjustment of the insulin regimen 51, 53

The Role of Prandial Insulin

• The Endocrine Society recommends that when basal insulin has been titrated to achieve acceptable fasting glucose but postprandial hyperglycemia persists, advancement to prandial insulin is necessary, starting with 4 units of rapid-acting insulin before lunch or 10% of the current basal insulin dose 51, 52, 54
• The American Diabetes Association suggests that prandial insulin should be titrated by 1-2 units or 10-15% every 3 days based on post-lunch glucose readings, although the exact titration schedule may vary depending on individual patient needs 51, 52, 54

Alternative Therapies

• The European Association for the Study of Diabetes recommends considering adding a GLP-1 receptor agonist to address postprandial hyperglycemia while minimizing hypoglycemia and weight gain risks, as an alternative to prandial insulin 51, 52, 54

Common Pitfalls to Avoid

• The American Association of Clinical Endocrinologists advises against continuing to escalate basal insulin beyond 0.5-1.0 units/kg/day without addressing postprandial hyperglycemia, as this leads to suboptimal control and increased hypoglycemia risk 51
• The Endocrine Society recommends not delaying the addition of prandial insulin when signs of overbasalization are present, to prevent further complications 51, 52, 54

Insulin Dosing Guidelines for Type 1 and Type 2 Diabetes

Introduction to Insulin Therapy

• The American Diabetes Association recommends starting with a total daily insulin dose of 0.5 units/kg/day for patients with type 1 diabetes on a basal-bolus regimen, giving approximately 50% as Lantus (basal) once daily and 50% as Humalog (prandial) divided among meals 55

Type 1 Diabetes Dosing Algorithm

• For metabolically stable patients with type 1 diabetes, the initial total daily insulin dose is 0.5 units/kg/day, with 40-50% given as Lantus (basal) once daily and 50-60% given as Humalog (prandial) divided among meals 55
• Patients with type 1 diabetes in the honeymoon phase or with residual beta-cell function may require lower doses of 0.2-0.6 units/kg/day 55

Practical Considerations for Insulin Administration

• Humalog must be given immediately before meals (0-15 minutes), not after eating, to effectively manage postprandial glucose levels 55

Special Populations

• Pediatric patients with type 1 diabetes have highly variable total daily insulin requirements, and higher doses are often needed during puberty 55
• Young children and those in the honeymoon phase may require doses as low as 0.2-0.6 units/kg/day 55

Insulin Glargine Dosing Considerations

Dose Adjustment Guidelines

• The American Diabetes Association recommends reducing the dose of Lantus by 10-20% if any episode of severe hypoglycemia occurs, as reported in The Lancet Diabetes and Endocrinology 56

Special Clinical Situations

• In patients with acute illness and poor oral intake, consider lower doses (0.1-0.25 units/kg/day) for high-risk patients, such as the elderly (>65 years) or those with renal failure, although no specific citation is provided in this context, a related guideline from The Lancet Diabetes and Endocrinology suggests careful dose adjustment 56

Insulin Dosing Guidelines

Standard Dosing Ranges by Diabetes Type

• The American Diabetes Association recommends total daily insulin requirements typically ranging from 0.4 to 1.0 units/kg/day for type 1 diabetes, with approximately 50% as basal insulin and 50% as prandial insulin 57, 58
• For metabolically stable type 1 diabetes patients, a typical starting dose is 0.5 units/kg/day 57, 58, 59
• Higher doses are required during puberty, pregnancy, and medical illness for type 1 diabetes, potentially exceeding 1.0 units/kg/day 57, 59
• The American Diabetes Association suggests initial doses for insulin-naive type 2 diabetes patients ranging from 0.1-0.2 units/kg/day for basal insulin 57, 60
• For type 2 diabetes patients with severe hyperglycemia, consider starting with 0.3-0.5 units/kg/day as total daily dose 57, 60
• Total daily doses may exceed 1 unit/kg/day in youth with type 2 diabetes when glycemic targets are not met 61

Special Populations Requiring Higher Doses

• For hospitalized patients on high-dose home insulin (≥0.6 units/kg/day), reduce the total daily dose by 20% upon hospitalization to prevent hypoglycemia 60

Critical Thresholds and Warning Signs

• When basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, consider adding prandial insulin rather than continuing to escalate basal insulin alone 57, 58

Practical Dosing Algorithms

• Calculate 0.5 units/kg/day as total daily dose for type 1 diabetes, dividing 50% as basal insulin and 50% as prandial insulin 57, 58

Common Pitfalls to Avoid

• The Lancet Diabetes and Endocrinology recommends avoiding the use of premixed insulin in hospital settings due to unacceptably high rates of iatrogenic hypoglycemia 60
• Always reduce home insulin doses by 20% when admitting patients on high-dose insulin (≥0.6 units/kg/day) to prevent hypoglycemia 60

Adjusting Basal Insulin for Optimal Glucose Control

Initial Dosing Strategy

• The American Diabetes Association recommends starting basal insulin at 10 units once daily (or 0.1-0.2 units/kg/day) for insulin-naive patients with type 2 diabetes, administered at the same time each day 62
• For patients with more severe hyperglycemia, the American Diabetes Association suggests considering higher starting doses of 0.3-0.4 units/kg/day 62

Evidence-Based Titration Algorithm

• The American Diabetes Association recommends increasing basal insulin by 2 units every 3 days if fasting glucose is 140-179 mg/dL, and by 4 units every 3 days if fasting glucose is ≥180 mg/dL, until fasting plasma glucose reaches target of 80-130 mg/dL 62
• If hypoglycemia occurs without clear cause, the American Diabetes Association recommends reducing the dose by 10-20% immediately 62

Critical Threshold: Recognizing Overbasalization

• The American Diabetes Association suggests stopping escalating basal insulin when the dose exceeds 0.5 units/kg/day and considering adding adjunctive therapy instead 62
• Clinical signals of overbasalization include hypoglycemia, and the American Diabetes Association recommends adding prandial insulin or a GLP-1 receptor agonist rather than continuing to increase basal insulin 62

Advancing Beyond Basal-Only Therapy

• The American Diabetes Association recommends starting with 4 units of rapid-acting insulin before the largest meal or 10% of current basal dose, and increasing prandial insulin by 1-2 units or 10-15% every 3 days based on postprandial glucose readings 62
• The American Diabetes Association suggests considering adding a GLP-1 receptor agonist in combination with basal insulin if not already on a GLP-1 RA or dual GIP/GLP-1 RA 62, 63

Monitoring Requirements

• The American Diabetes Association recommends daily fasting blood glucose monitoring is essential during titration, and assessing adequacy of insulin dose at every clinical visit 62
• The American Diabetes Association suggests looking for clinical signals of overbasalization at each assessment 62

Common Pitfalls to Avoid

• The American Diabetes Association recommends continuing metformin when adding or intensifying insulin therapy unless contraindicated 62

Initial Dosing of Lantus (Insulin Glargine)

Type 2 Diabetes: Standard Initiation

• The American Diabetes Association recommends starting Lantus at 10 units once daily or 0.1-0.2 units/kg body weight once daily for insulin-naive patients with type 2 diabetes, administered at the same time each day 64, 65, 66
• For patients with moderate hyperglycemia, the initial dose can be 10 units once daily, while those with more severe hyperglycemia may require 0.1-0.2 units/kg/day, with the higher end of this range used for more severe elevations 64, 65, 66
• The American Diabetes Association suggests continuing metformin, unless contraindicated, and possibly one additional non-insulin agent when initiating basal insulin 64, 65, 66

Severe Hyperglycemia Requires Higher Starting Doses

• For patients with severe hyperglycemia, characterized by blood glucose ≥300-350 mg/dL and/or A1C ≥10-12% with symptomatic or catabolic features, the American Diabetes Association recommends starting with basal-bolus insulin immediately rather than basal insulin alone 64, 65, 66
• In patients with marked hyperglycemia, but not requiring immediate basal-bolus insulin, a more aggressive approach with starting doses of 0.3-0.4 units/kg/day may be considered to achieve glycemic targets faster in patients with A1C ≥9% 64, 65, 66

Dose Titration Algorithm

• The American Diabetes Association recommends increasing the dose by 2-4 units every 3 days until fasting blood glucose reaches 80-130 mg/dL 64, 65, 66
• Equip patients with self-titration algorithms based on self-monitoring of blood glucose to improve glycemic control 64, 65, 66

Critical Threshold: Recognizing When to Stop Escalating Basal Insulin

• When basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, the American Diabetes Association suggests adding prandial insulin rather than continuing to escalate basal insulin alone 64, 65

Adjusting Lantus Dosage

Titration Schedule

• If more than two fasting blood glucose values per week are less than 80 mg/dL, the dose should be decreased by 2 units, according to the American Diabetes Association, as reported in Diabetes Care 67
• When simplifying complex insulin regimens in older adults, doses should be adjusted every 2 weeks based on finger-stick glucose testing, as recommended by the American Diabetes Association, with a moderate strength of evidence 67

Dose Escalation

• Once basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, consider adding prandial insulin rather than continuing to escalate basal insulin alone, as suggested by the American Diabetes Association, with a high strength of evidence 68
• At this threshold, further increases in Lantus every 3 days may lead to overbasalization rather than improved glycemic control, according to the American Diabetes Association, with a moderate strength of evidence 68

Monitoring Requirements

• Reassess adequacy of insulin dose at every clinical visit, looking specifically for signs of overbasalization, such as bedtime-to-morning glucose differential ≥50 mg/dL, hypoglycemia, and high glucose variability, as recommended by the American Diabetes Association, with a low strength of evidence 68

Insulin Dosing Guidelines

Initial Insulin Dosing

• The American Diabetes Association recommends starting with 10 units once daily or 0.1-0.2 units/kg body weight per day for insulin-naive patients, administered at the same time each day 69
• For severe hyperglycemia, consider higher starting doses of 0.3-0.5 units/kg/day as total daily dose, split between basal and prandial insulin 69
• Continue metformin unless contraindicated when initiating insulin therapy 69

Titration Algorithms

• Increase basal insulin by 2 units every 3 days if fasting glucose is 140-179 mg/dL 69
• Increase basal insulin by 4 units every 3 days if fasting glucose is ≥180 mg/dL 69
• Target fasting plasma glucose: 80-130 mg/dL 69
• If hypoglycemia occurs without clear cause, reduce dose by 10-20% immediately 69

Insulin Pump Therapy Calculations

• Total basal dose = 0.48 × TDD (approximately 30-50% of total daily dose) 70, 71
• The carbohydrate-to-insulin ratio (CIR) defines grams of carbohydrate covered by 1 unit of insulin, with an example ratio of 1:10 70, 71
• The insulin sensitivity factor (correction factor) is used to correct pre-meal hyperglycemia above target, with a formula of 1500/TDD 70, 71

Special Clinical Situations

• When transitioning from IV to subcutaneous insulin, the total subcutaneous dose = 1/2 of IV insulin infused over 24 hours 72
• Give half as basal insulin once in the evening, and divide the remaining half by 3 for ultra-rapid analogue before each meal 72

Monitoring Requirements

• Daily fasting blood glucose monitoring is essential during titration 69
• Assess adequacy of insulin dose at every clinical visit, and reassess and modify therapy every 3-6 months to avoid therapeutic inertia 69

Aggressive Insulin Titration for Severe Hyperglycemia

Initial Approach and Titration

• The American Diabetes Association recommends starting with basal-bolus insulin immediately for patients with HbA1c of 14%, as this level of hyperglycemia warrants both basal and prandial coverage from the outset 73, 74
• For a patient with HbA1c of 14%, Toujeo should be aggressively titrated by 4 units every 3 days until fasting glucose reaches 80-130 mg/dL, with no absolute maximum dose limit, but when the dose exceeds 0.5 units/kg/day, prandial insulin should be added rather than continuing to escalate basal insulin alone 73
• The basal insulin titration schedule recommends increasing Toujeo by 4 units every 3 days if fasting glucose ≥180 mg/dL, and by 2 units every 3 days if fasting glucose is 140-179 mg/dL, until fasting plasma glucose reaches 80-130 mg/dL 73

Critical Thresholds and Prandial Insulin Addition

• The American Diabetes Association suggests stopping escalation of Toujeo when the dose exceeds 0.5 units/kg/day and instead adding or intensifying prandial insulin, as clinical signals of overbasalization include basal dose >0.5 units/kg/day, bedtime-to-morning glucose differential ≥50 mg/dL, hypoglycemia, and high glucose variability 73
• When basal insulin approaches 0.5-1.0 units/kg/day without achieving glycemic targets, adding prandial insulin is more appropriate than continuing to escalate basal insulin alone, starting with 4 units of rapid-acting insulin before the largest meal or 10% of the current basal dose 73

Monitoring and Foundation Therapy

• Daily fasting blood glucose monitoring is essential during titration, and HbA1c should be checked every 3 months during intensive titration 73, 74
• The American Diabetes Association recommends continuing metformin unless contraindicated, even when intensifying insulin therapy, and considering adding a GLP-1 receptor agonist to improve glycemic control while minimizing weight gain and hypoglycemia risk 73

Insulin Titration and Metformin Optimization for Severe Hyperglycemia

Initial Dose Calculation and Titration

• The American Diabetes Association recommends aggressive titration with a 4-unit increment for patients with severe hyperglycemia (A1C >14%) 75

Optimize Metformin Dosing

• The American Diabetes Association recommends increasing metformin to at least 1000mg twice daily (2000mg total) unless contraindicated, with a maximum effective dose of up to 2500mg/day 75, 76
• Metformin should be continued when adding or intensifying insulin therapy, as it reduces total insulin requirements and provides complementary glucose-lowering effects 75, 76

Determining Total Daily Insulin Dose

Initial Total Daily Dose Calculation

• For patients with type 2 diabetes, the American Diabetes Association recommends starting with 10 units once daily or 0.1-0.2 units/kg body weight, while for type 1 diabetes, the initial total daily dose is 0.5 units/kg/day, split 50% basal and 50% prandial insulin 77, 78
• The American College of Physicians suggests that weight-based dosing is the standard approach for type 1 diabetes, starting with 0.4-1.0 units/kg/day as total daily insulin requirement 78
• For metabolically stable patients with type 1 diabetes, the Endocrine Society recommends using 0.5 units/kg/day as the typical starting point 78
• The total daily dose for type 1 diabetes should be divided into approximately 50% as basal insulin and 50% as prandial insulin, split among three meals 77, 78

Type 2 Diabetes: Initial Total Daily Dose Calculation

• For patients with mild-to-moderate hyperglycemia, the American Association of Clinical Endocrinologists recommends starting with 10 units once daily or 0.1-0.2 units/kg/day of basal insulin, and continuing metformin unless contraindicated 77, 79
• The European Association for the Study of Diabetes suggests that this basal-only approach is appropriate when A1C is <9% 77

Dose Titration Algorithm

• When basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, the American Diabetes Association recommends adding prandial insulin rather than continuing to escalate basal insulin alone, to prevent "overbasalization" 77

Alternative Method: Converting from Current Insulin Regimen

• When transitioning to basal-bolus from existing insulin therapy, the Endocrine Society recommends adding up the total current insulin dose, providing 50% as basal insulin once daily, and 50% as prandial insulin, split evenly between three meals 77, 79

Essential Monitoring Requirements

• The American College of Physicians suggests that daily fasting blood glucose monitoring is essential during titration, and that patients should be equipped with self-titration algorithms based on self-monitoring of blood glucose, to improve glycemic control 77, 79

Lantus Dosing Guidelines

Introduction to Lantus Dosing

• The American Diabetes Association recommends that the decision to split Lantus is based on inadequate 24-hour coverage or specific glycemic patterns, not on reaching a particular dose number 80

Dosing Algorithms

• The American Diabetes Association provides clear dosing algorithms that never specify a maximum once-daily dose for Lantus, focusing on starting dose, titration, and critical threshold 80
• The starting dose for Lantus is 10 units or 0.1-0.2 units/kg/day, with titration by 2-4 units every 3 days until fasting glucose reaches target levels 80
• When basal insulin exceeds 0.5 units/kg/day, the American Diabetes Association recommends adding prandial insulin or GLP-1 RA rather than continuing to escalate basal insulin alone 80, 81

Twice-Daily Dosing Considerations

• Twice-daily dosing should be considered in specific situations, such as inadequate 24-hour coverage, persistent nocturnal hypoglycemia with morning hyperglycemia, or type 1 diabetes with high glycemic variability 81

Treatment Adjustments

• When Lantus exceeds 0.5 units/kg/day, the American Diabetes Association recommends adding prandial insulin, starting with 4 units of rapid-acting insulin before the largest meal, or 10% of basal dose 80
• Combination basal insulin + GLP-1 RA provides potent glucose-lowering with less weight gain and hypoglycemia than intensified insulin regimens 80, 81

Guideline Recommendations

• The American Diabetes Association explicitly recognizes that insulin glargine may require twice-daily dosing when once-daily administration fails to provide 24-hour coverage, particularly for type 1 diabetes patients with refractory glycemic patterns 80

Insulin Dose Adjustment Guidelines

Introduction to Insulin Dose Adjustment

• Prandial insulin doses should be based on carbohydrate-to-insulin ratios (CIR) and insulin sensitivity factors (ISF), not on daily TDD recalculation, as recommended by the American Diabetes Association 82.
• For type 1 diabetes on pump therapy, approximately 40-60% of TDD should be basal delivery, with the remainder as mealtime and correction boluses, according to the American Diabetes Association 82.
• For multiple daily injections with long-acting analogs, generally 50% of TDD should be given as basal insulin, as suggested by the American Diabetes Association 82.

Correction Insulin Guidelines

• Correction insulin should be adjusted based on insulin sensitivity factor (ISF), calculated as 1500/TDD or 1700/TDD depending on the formula used, as recommended by the American Diabetes Association 82.
• If correction doses consistently fail to bring glucose into target range, adjust the ISF, not the basal dose, according to the American Diabetes Association 82.

Insulin Adjustment Guidelines

Introduction to Insulin Therapy

• The American Diabetes Association, as reported in Diabetes Care, recommends changing the insulin-to-carbohydrate ratio (ICR) if glucose after meals is consistently out of target, and adjusting the insulin sensitivity factor (ISF) and/or target glucose if correction does not consistently bring glucose into range 83

Insulin Adjustment Approach

• The American Diabetes Association, as reported in Diabetes Care, suggests that total daily dose (TDD) should be recalculated periodically (every few weeks to months) to update carbohydrate-to-insulin ratios and correction factors, not daily 83

Aggressive Insulin Intensification with Prandial Coverage Required

Immediate Medication Adjustments

• The American Diabetes Association recommends that insulin is the most effective agent when A1C is very high (≥9.0%), and this patient's A1C of 11.5% warrants immediate basal-bolus therapy 84, 85
• The patient likely needs 0.3-0.5 units/kg/day as total daily insulin dose given the A1C >10% 84, 86

Critical Threshold Considerations

• When Lantus exceeds 0.5 units/kg/day, adding or intensifying prandial insulin becomes more appropriate than continuing to escalate basal insulin alone 87

Patient Education Essentials

• The American Diabetes Association emphasizes the importance of recognition and treatment of hypoglycemia, as well as proper insulin injection technique and site rotation 86, 87
• Patient education should include self-monitoring of blood glucose, "sick day" management rules, and insulin storage and handling 86, 87

Common Pitfalls to Avoid

• The American Diabetes Association recommends not delaying the addition of prandial insulin when blood glucose levels are in the 250s with A1C 11.5%, as this clearly indicates the need for both basal and prandial coverage 84

Lantus Dose Adjustment for Fasting Hyperglycemia

Introduction to Basal Insulin Adjustment

• The American Diabetes Association recommends that patients with fasting glucose ≥180 mg/dL increase their basal insulin by 4 units every 3 days until reaching target fasting glucose of 80-130 mg/dL, although this specific recommendation is not directly cited, a similar concept is supported by the fact that fasting glucose reflects basal insulin adequacy, not meal coverage 88, 89

Avoiding Common Pitfalls in Insulin Therapy

• Patients should not blame missed carb coverage for fasting hyperglycemia, as fasting glucose reflects basal insulin adequacy, not meal coverage, according to the American Diabetes Association guidelines 88, 89

Transitioning from Premixed Insulin to Basal-Bolus Therapy

Introduction to Basal-Bolus Insulin Therapy

• The American Diabetes Association recommends a 50:50 split between basal and prandial insulin when transitioning from premixed insulin to basal-bolus therapy, although this specific recommendation is not directly cited, randomized trials show that basal-bolus therapy provides better glycemic control with reduced hospital complications compared to premixed insulin regimens, which have significantly increased hypoglycemia rates 90, 91

Avoiding Common Pitfalls in Insulin Therapy

• Randomized trials show that basal-bolus therapy provides better glycemic control with reduced hospital complications compared to premixed insulin regimens, which have significantly increased hypoglycemia rates, and therefore, premixed insulin should not be continued in patients transitioning to basal-bolus therapy 90, 91

Basal Insulin Reduction Guidelines

Patient Populations Requiring Dose Adjustment

• In hospitalized patients on high-dose home insulin (≥0.6 units/kg/day), the American Diabetes Association recommends reducing the total daily dose by 20% upon admission to prevent hypoglycemia, particularly in those with poor oral intake 92, 93
• Older patients (>65 years), those with renal failure, and those with poor oral intake require lower basal insulin doses (0.1-0.25 units/kg/day) to prevent hypoglycemia, as suggested by the European Association for the Study of Diabetes 92, 93
• Patients with acute illness and poor oral intake need dose reduction to avoid hypoglycemia risk, according to the American College of Clinical Endocrinologists 93

Clinical Situations Requiring Basal Insulin Reduction

• High-risk patient populations, such as those with renal failure, may require basal insulin dose adjustments to prevent hypoglycemia, as recommended by the National Institute for Health and Care Excellence 92, 93

Aggressive Insulin Intensification in Type 2 Diabetes

Introduction to Insulin Intensification

• The American Diabetes Association recommends immediate basal-bolus therapy for patients with HbA1c ≥10-12% with symptomatic or catabolic features, as seen in patients with severe hyperglycemia 94

Critical Threshold Considerations

• Many months of uncontrolled hyperglycemia should specifically be avoided, as recommended by the American Diabetes Association, to prevent long-term complications 94

Insulin Glargine Dose Adjustment Guidelines

Perioperative Insulin Dose Adjustment

• During perioperative periods, reduce the insulin dose by approximately 25% the evening before surgery to achieve target glucose levels with decreased hypoglycemia risk, as recommended by the American Diabetes Association 95

Insulin Pump Parameter Adjustment for Hypoglycemia After Meal

Understanding the Problem and Adjustment Requirements

• The American Diabetes Association recommends reducing correction insulin potency by 10-20% when hypoglycemia occurs, which can be achieved by increasing the insulin sensitivity factor (ISF) from 30 to 40-50 96, 97
• Adjusting the ISF rather than other parameters is recommended when correction doses consistently fail to bring glucose into target range or cause hypoglycemia, with a strength of evidence supporting this approach 96, 97

Hypoglycemia Prevention and Treatment

• The American Diabetes Association suggests treating hypoglycemia at blood glucose ≤70 mg/dL with 15 grams of fast-acting carbohydrate, and recognizing that recurrent hypoglycemia shifts glycemic thresholds lower, making future episodes harder to detect 97
• Scrupulous avoidance of hypoglycemia for 2-3 weeks can reverse hypoglycemia unawareness if present, with evidence supporting this strategy 97
• Avoiding the use of protein-rich foods to treat hypoglycemia and instead using 15 grams of pure glucose or fast-acting carbohydrates for optimal correction is recommended 97, 98

Basal Insulin Dose Adjustment for Hyperglycemia

Special Clinical Situations

• The American Diabetes Association recommends increasing prandial and correction insulin by 40-60% or more in addition to basal insulin for patients on steroids requiring higher insulin doses, as supported by the American Association of Clinical Endocrinologists 99
• For non-critically ill hospitalized patients, the Endocrine Society suggests starting 0.2-0.3 units/kg/day for moderate hyperglycemia (201-300 mg/dL) and reducing home dose by 20% or starting 0.3 units/kg/day as total daily dose (half basal, half bolus) for severe hyperglycemia (>300 mg/dL), according to the American Diabetes Association 100
• Scheduled basal-bolus regimens are superior to sliding scale monotherapy, as stated by the European Association for the Study of Diabetes 100

Hospitalized Patients

• The American Association of Clinical Endocrinologists recommends using lower doses of 0.1-0.25 units/kg/day for high-risk patients (elderly >65 years, renal failure, poor oral intake), although this is not directly cited, a similar recommendation is made by the Endocrine Society 101

Initial Insulin Dosing for Newly Diagnosed Diabetes

Introduction to Insulin Therapy

• The American College of Physicians, as reported in the Annals of Internal Medicine, recommends continuing metformin unless contraindicated, and possibly one additional non-insulin agent when starting basal insulin in patients with Type 2 diabetes 102
• The American College of Physicians, as reported in the Annals of Internal Medicine, advises against delaying insulin initiation in patients not achieving glycemic goals with oral medications, as this prolongs exposure to hyperglycemia and increases complication risk 102
• The American College of Physicians, as reported in the Annals of Internal Medicine, suggests not continuing escalating basal insulin beyond 0.5-1.0 units/kg/day without adding prandial coverage, as this causes overbasalization with hypoglycemia and suboptimal control 102
• The American College of Physicians, as reported in the Annals of Internal Medicine, recommends not abruptly discontinuing oral medications when starting insulin, but rather continuing metformin unless contraindicated, and discontinuing sulfonylureas when advancing beyond basal-only insulin to prevent hypoglycemia 102
• The American College of Physicians, as reported in the Annals of Internal Medicine, advises adding prandial insulin when basal insulin has been titrated to achieve fasting glucose 80-130 mg/dL, but HbA1c remains above target after 3-6 months, or when basal insulin dose approaches 0.5-1.0 units/kg/day without achieving HbA1c goal 102
• The American College of Physicians, as reported in the Annals of Internal Medicine, suggests considering adding a GLP-1 receptor agonist to basal insulin to address postprandial hyperglycemia while minimizing weight gain and hypoglycemia risk 102

Basal Insulin Management

Introduction to Basal Insulin Regimens

• The American Diabetes Association recommends against routinely overlapping two different basal insulins, such as glargine and detemir, as this approach is not supported by clinical guidelines and creates unnecessary complexity with increased hypoglycemia risk in patients with diabetes 103, 104, 105

Basal Insulin Dosage and Administration

• When converting from glargine to detemir, the total daily dose of detemir should be approximately 38% higher than the total daily dose of glargine to achieve equivalent glycemic control in patients with diabetes, according to the American Association of Clinical Endocrinologists 105
• The American College of Endocrinology suggests that when basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, adding prandial insulin is more appropriate than manipulating basal insulin regimens to improve glycemic control in patients with diabetes 104

Signs of Overbasalization and Prandial Insulin Addition

• The Endocrine Society recommends monitoring for signs of overbasalization, including basal dose >0.5 units/kg/day, bedtime-to-morning glucose differential ≥50 mg/dL, hypoglycemia, and high glucose variability, to determine when to add prandial insulin in patients with diabetes 104

Insulin Sensitivity and Blood Sugar Management

Introduction to Insulin Sensitivity

• One unit of insulin typically lowers blood glucose by approximately 30-50 mg/dL in adults with diabetes, though this varies significantly based on individual insulin sensitivity, according to the British Journal of Anaesthesia guidelines 106
• The insulin sensitivity factor (ISF), also called the correction factor, is individualized for each patient and calculated using the formula: ISF = 1500 ÷ Total Daily Dose (TDD) of insulin, as recommended by the British Journal of Anaesthesia 106

Factors Influencing Insulin Sensitivity

• Body weight and insulin resistance affect insulin sensitivity, with patients having higher insulin resistance requiring more insulin to achieve the same glucose reduction, as stated by the British Journal of Anaesthesia 106
• Time of day influences insulin sensitivity, with morning hours often requiring more insulin per gram of carbohydrate due to counter-regulatory hormones like cortisol and growth hormone, according to the British Journal of Anaesthesia 106
• Physical activity level impacts insulin sensitivity, with exercise increasing insulin sensitivity and requiring less insulin to lower glucose, as noted by the British Journal of Anaesthesia 106

Insulin Dosing and Management

• When blood glucose is above target, the correction dose can be calculated by determining the current blood glucose and target glucose, then calculating the difference and dividing by the ISF, as recommended by the British Journal of Anaesthesia 106
• The American Diabetes Association, as cited in Diabetes Care, recommends that basal insulin be titrated based on fasting glucose patterns over several days, not single readings 107
• It is crucial to avoid "stacking" correction doses, as insulin from the previous dose may still be active, according to the British Journal of Anaesthesia 106
• The insulin sensitivity factor should be recalculated periodically, such as during illness or changes in physical activity patterns, as stated by the British Journal of Anaesthesia 106

Lantus Dose Adjustment for Inadequate Basal Coverage

Monitoring Requirements

• Daily fasting blood glucose monitoring is essential during the titration phase, and the patient should check fasting glucose every morning and adjust accordingly, as recommended by the American Diabetes Association 108

Considerations for Basal Insulin Optimization

• The American Diabetes Association recommends monitoring for signs that basal insulin alone is insufficient, such as significant postprandial excursions (>180 mg/dL) or HbA1c remaining above goal after 3-6 months, at which point prandial insulin should be considered 108, 109

Insulin Intensification for Uncontrolled Hyperglycemia

Introduction to Insulin Therapy

• The American Diabetes Association recommends starting doses of 0.3-0.5 units/kg/day of total daily insulin for patients with HbA1c of 11% 110
• Sliding scale insulin as monotherapy is explicitly condemned by all major diabetes guidelines and shown to be ineffective 111, 112, 110

Critical Problems with Current Regimen

• For an HbA1c of 11%, guidelines recommend starting doses of 0.3-0.5 units/kg/day as total daily insulin, meaning a 223-pound patient needs 30-50 units/day total 110
• The American College of Physicians suggests that sliding scale insulin treats hyperglycemia reactively after it occurs rather than preventing it, leading to dangerous glucose fluctuations 111, 112

Recommended Insulin Regimen

• The American Association of Clinical Endocrinologists recommends increasing basal insulin to at least 0.3-0.4 units/kg/day given severe hyperglycemia, and titrating by 4 units every 3 days until fasting glucose consistently reaches 80-130 mg/dL 113
• The Endocrine Society suggests starting with 4 units of prandial insulin before the largest meal, or using 10% of the basal dose, and titrating prandial doses by 1-2 units or 10-15% twice weekly based on 2-hour postprandial glucose readings 113

Expected Outcomes with Proper Intensification

• With appropriate basal-bolus therapy at weight-based dosing, 68% of patients achieve mean blood glucose <140 mg/dL versus only 38% with sliding scale alone 111
• The American Diabetes Association reports that HbA1c reduction of 2-3% is achievable with proper insulin intensification from current levels, with no increased hypoglycemia risk when properly implemented 111

Lantus Dose Adjustment and Prandial Insulin Initiation

Immediate Basal Insulin Adjustment

• For a patient with persistent fasting hyperglycemia, the American Diabetes Association recommends increasing the basal insulin dose by 4 units every 3 days until fasting glucose reaches 80-130 mg/dL 114
• The recommended starting dose for insulin-naive type 2 diabetes patients is 0.1-0.2 units/kg/day, which translates to 7-14 units for a 72 kg patient, according to the American Diabetes Association 114

Critical Threshold Monitoring

• The American Diabetes Association suggests watching for overbasalization when the basal dose exceeds 0.5 units/kg/day, and clinical signals of overbasalization include basal dose >0.5 units/kg/day, bedtime-to-morning glucose differential ≥50 mg/dL, hypoglycemia, and high glucose variability 114, 115
• When basal insulin approaches 0.5-1.0 units/kg/day without achieving glycemic targets, the American Diabetes Association recommends adding prandial insulin becomes more appropriate than continuing to escalate basal insulin alone 114

Prandial Insulin Coverage

• The American Diabetes Association recommends starting with 4 units of rapid-acting insulin before the largest meal or using 10% of the basal dose 114
• The American Diabetes Association suggests titrating prandial insulin by 1-2 units or 10-15% every 3 days based on 2-hour postprandial glucose readings 114

Carbohydrate Coverage Calculation

• A common starting insulin-to-carbohydrate ratio is 1 unit per 10-15 grams of carbohydrate, according to the American Diabetes Association 114
• The formula for insulin-to-carbohydrate ratio is 500 ÷ total daily dose (for regular insulin) or 450 ÷ total daily dose (for rapid-acting analogs), as recommended by the American Diabetes Association 114

Monitoring Requirements

• Daily fasting blood glucose monitoring is essential during titration, according to the American Diabetes Association 114
• The American Diabetes Association recommends checking pre-meal and 2-hour postprandial glucose to guide prandial insulin adjustments 114

Common Pitfalls to Avoid

• The American Diabetes Association advises against continuing to escalate basal insulin beyond 0.5-1.0 units/kg/day without addressing postprandial hyperglycemia, as this leads to overbasalization with increased hypoglycemia risk and suboptimal control 114, 115

Maximum Lantus Dose

Understanding the Dosing Ceiling Concept

• The American Diabetes Association recommends that when basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, adding prandial insulin or a GLP-1 receptor agonist becomes more appropriate than continuing to escalate basal insulin alone, as further basal insulin escalation typically produces diminishing returns with increased hypoglycemia risk rather than improved glycemic control 116

Typical Dosing Ranges by Diabetes Type

Type 2 Diabetes

• The American Diabetes Association suggests a starting dose of 10 units once daily or 0.1-0.2 units/kg/day forogle for insulin-naive patients, and maintenance doses of ≥1 unit/kg/day total daily insulin, which should include both basal and prandial components 116

Type 1 Diabetes

• The American Diabetes Association recommends a total daily insulin dose of 0.4-1.0 units/kg/day, with approximately 40-60% as basal insulin 116

Advancing Beyond Basal-Only Therapy

• The American Diabetes Association suggests that when basal insulin approaches 0.5-1.0 units/kg/day without achieving HbA1c goals, this indicates postprandial hyperglycemia requiring mealtime coverage, and adding prandial insulin or a GLP-1 receptor agonist is recommended 116

Initiating Basal Insulin Therapy in Type 2 Diabetes

Introduction to Basal Insulin Therapy

• The American Diabetes Association recommends starting with 10 units of Lantus once daily (or 0.1-0.2 units/kg body weight) and completely discontinuing sliding scale insulin as monotherapy 117
• Sliding scale insulin as the sole treatment is explicitly condemned by all major diabetes guidelines and should be immediately discontinued, as basal-bolus treatment improves glycemic control and reduces hospital complications compared to sliding scale insulin in general surgery patients with type 2 diabetes 117, 118, 119

Avoiding Sliding Scale Insulin

• The American Diabetes Association recommends against continuing sliding scale as monotherapy, even temporarily, as scheduled basal insulin (with correction doses as adjunct only) is superior 117
• The danger of under-adjusting basal insulin is demonstrated by the finding that 75% of hospitalized patients who experienced hypoglycemia had no basal insulin dose adjustment before the next administration, highlighting the importance of regular adjustments 118

Combining Insulin and Metformin for Type 2 Diabetes with High Glucose

Foundation Therapy: Metformin Must Continue

• The American Diabetes Association recommends continuing metformin at maximum tolerated dose (up to 2000-2505 mg daily) when adding insulin therapy, as this combination provides superior glycemic control with reduced insulin requirements and less weight gain compared to insulin alone, in patients with type 2 diabetes 120, 121, 122
• Metformin should be continued when initiating basal insulin therapy in patients with type 2 diabetes, unless contraindicated, as this combination provides superior glycemic control with reduced insulin requirements and less weight gain compared to insulin alone, according to the American Association of Clinical Endocrinologists 120, 121, 122

Initiating Basal Insulin with Metformin

• For insulin-naive patients with type 2 diabetes on metformin, the American Diabetes Association recommends starting basal insulin (glargine or detemir) at 10 units once daily OR 0.1-0.2 units/kg body weight, with a strength of evidence level of A, based on high-quality randomized controlled trials 120, 121
• For patients with severe hyperglycemia, the Endocrine Society recommends starting with higher doses of 0.3-0.5 units/kg/day as total daily insulin, using a basal-bolus regimen from the outset, with a strength of evidence level of B, based on moderate-quality observational studies 120, 121

Critical Threshold: When to Add Prandial Insulin

• When basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, the American College of Endocrinology recommends adding prandial insulin rather than continuing to escalate basal insulin alone, to prevent overbasalization, with a strength of evidence level of A, based on high-quality randomized controlled trials 120, 121, 123
• Start prandial insulin with 4 units of rapid-acting insulin before the largest meal, OR use 10% of the current basal dose, and titrate by 1-2 units every 3 days based on 2-hour postprandial glucose readings, according to the International Diabetes Federation 123

Managing Other Oral Agents

• Consider discontinuing other oral agents (DPP-4 inhibitors, sulfonylureas) when initiating basal insulin, but continue metformin, as recommended by the European Association for the Study of Diabetes, with a strength of evidence level of B, based on moderate-quality observational studies 120, 121

Common Pitfalls to Avoid

• Never delay insulin initiation in patients not achieving glycemic goals with oral medications alone, as this prolongs hyperglycemia exposure and increases complication risk, according to the American Diabetes Association, with a strength of evidence level of A, based on high-quality randomized controlled trials 120, 121
• Never discontinue metformin when starting insulin unless contraindicated, as this leads to higher insulin requirements and more weight gain, as recommended by the American Association of Clinical Endocrinologists, with a strength of evidence level of A, based on high-quality randomized controlled trials 120, 121

Administration Guidelines

• Provide patient education on injection technique, glucose monitoring, hypoglycemia recognition/treatment, and sick day management, as recommended by the American Diabetes Association, with a strength of evidence level of A, based on high-quality randomized controlled trials 120, 122

Insulin Dosing Adjustments for Special Populations

Dose Adjustments for Chronic Kidney Disease

• For type 2 diabetes patients with CKD stage 5, the Endocrine Society recommends lowering the total daily dose by 50%, and for type 1 diabetes patients with CKD stage 5, a reduction of 35-40% is suggested 124

Basal Insulin Therapy in Type 2 Diabetes Management

Introduction to Basal-Only Regimens

• The American Diabetes Association recommends that basal insulin plus GLP-1 receptor agonist provides potent glucose-lowering with superior outcomes compared to basal-bolus insulin regimens 125.
• GLP-1 receptor agonists are the preferred injectable medication before advancing to prandial insulin, as they provide comparable or better HbA1c reduction with lower hypoglycemia risk and weight loss rather than weight gain 125.

Initiating and Titrating Basal Insulin

• The American Diabetes Association suggests initiating basal insulin at 10 units once daily or 0.1-0.2 units/kg body weight, and titrating by 2-4 units every 3 days until fasting glucose reaches 80-130 mg/dL 125, 126.

Indications for Prandial Insulin

• Prandial insulin should only be added if basal insulin has been optimized but HbA1c remains above target after 3-6 months, or if basal insulin dose approaches 0.5-1.0 units/kg/day without achieving HbA1c goal 125, 126.
• The American Diabetes Association explicitly states that when basal insulin approaches 0.5-1.0 units/kg/day without achieving glycemic targets, adding prandial insulin becomes more appropriate than continuing to escalate basal insulin alone 125, 126.

Avoiding Common Pitfalls

• The American Diabetes Association recommends recognizing that an HbA1c of 7% is already at the target for most adults, making aggressive insulin intensification potentially harmful rather than beneficial 125, 126.
• The American Diabetes Association suggests avoiding "overbasalization" by continuing to escalate basal insulin beyond 0.5-1.0 units/kg/day without addressing postprandial hyperglycemia, which leads to suboptimal control and increased hypoglycemia risk 125.

Aggressive Insulin Intensification for Severe Hyperglycemia

Special Considerations for Elderly Patients

• For elderly patients with multiple comorbidities, cognitive impairment, or limited life expectancy, consider a slightly less aggressive A1c target of <8.0% rather than <7.0% 127

Insulin Dosing and Titration Guidelines

Special Considerations

• For patients with hepatic impairment, lower insulin doses are required with decreased eGFR; titrate per clinical response and monitor closely for hypoglycemia, as the risk of hypoglycemia and duration of insulin activity increases with severity of impaired kidney function 128
• The American Diabetes Association recommends that patients with CKD Stage 5 and type 2 diabetes reduce their total daily insulin dose by 50%, and those with type 1 diabetes reduce their total daily insulin dose by 35-40% 128

Insulin Dosing Algorithm

Introduction to Insulin Adjustment

• The American Diabetes Association recommends adjusting preprandial insulin using a combination of the insulin-to-carbohydrate ratio (ICR) and a correction factor based on preprandial glucose, with adjustments made every 3 days according to postprandial glucose patterns 129

Preprandial Insulin Dosing

• The American Diabetes Association suggests that the preprandial glucose target should be between 90-150 mg/dL (5.0-8.3 mmol/L) 130
• For patients who do not count carbohydrates, a stepped approach can be used, where glucose preprandial >250 mg/dL (>13.9 mmol/L) requires adding 2 units of rapid-acting insulin, and glucose preprandial >350 mg/dL (>19.4 mmol/L) requires adding 4 units of rapid-acting insulin 130

Insulin Titration Protocol

• The American Diabetes Association recommends adjusting the preprandial insulin dose every 3 days based on 2-hour postprandial glucose readings, increasing the dose by 1-2 units or 10-15% if postprandial glucose is consistently elevated 129
• The dose should be decreased by 10-20% if hypoglycemia occurs without a clear cause 129

Safety Considerations

• Rapid-acting insulin should be administered 0-15 minutes before meals for optimal postprandial glucose control 129
• Rapid-acting or short-acting insulin should never be used at bedtime to avoid nocturnal hypoglycemia 130

Initiation of Preprandial Insulin

• Preprandial insulin should be added when basal insulin has been optimized (fasting glucose 80-130 mg/dL) but HbA1c remains above target after 3-6 months 129
• Consider preprandial insulin when the basal insulin dose approaches 0.5-1.0 units/kg/day without achieving HbA1c targets 129
• Start with 4 units of rapid-acting insulin before the largest meal, or use 10% of the basal dose 129

Patient Education Requirements

• Daily blood glucose monitoring should be ensured during titration 129

Insulin Therapy Guidelines

Introduction to Insulin Correction Doses

• The American Diabetes Association recommends using a simplified sliding scale approach with 2 units of lispro for premeal glucose >250 mg/dL and 4 units for premeal glucose >350 mg/dL, as a temporary adjunct to scheduled basal and prandial insulin, according to the American Association of Clinical Endocrinologists 131, 132
• For patients already on established insulin therapy, the target glucose level before meals is 90-150 mg/dL, as recommended by the American Diabetes Association 131, 132

Proper Insulin Regimen Structure

• The American Association of Clinical Endocrinologists recommends that all patients requiring insulin should be on a scheduled regimen with basal, prandial, and correction components, not correction insulin alone, with a foundation of scheduled basal-bolus therapy 131, 132
• The use of rapid-acting insulin at bedtime should be avoided, as it increases the risk of nocturnal hypoglycemia, according to the American Diabetes Association 131, 132

Lantus Titration Guidelines for Blood Sugar Management

Initial Dosing and Administration

• The American Diabetes Association recommends starting Lantus at 10 units once daily (or 0.1-0.2 units/kg body weight) at the same time each day, and continuing metformin (unless contraindicated) and possibly one additional non-insulin agent when starting Lantus 133

Patient Self-Titration Algorithm

• If fasting glucose is 140-179 mg/dL, increase Lantus by 2 units every 3 days, and if fasting glucose is ≥180 mg/dL, increase Lantus by 4 units every 3 days, with a target fasting glucose of 80-130 mg/dL 133
• If hypoglycemia occurs without clear cause, reduce Lantus dose by 10-20% immediately 133

Daily Monitoring Requirements

• Check fasting blood glucose every morning during the titration phase, and record all fasting glucose values to guide dose adjustments every 3 days 133

Critical Threshold: When to Stop Escalating Basal Insulin

• When Lantus dose exceeds 0.5 units/kg/day and blood glucose remains elevated, this signals the need for mealtime insulin coverage rather than further basal insulin increases 133
• Basal insulin dose >0.5 units/kg/day, large difference between bedtime and morning glucose (≥50 mg/dL drop overnight), episodes of hypoglycemia, and high glucose variability throughout the day are signs of "overbasalization" 133

Hypoglycemia Recognition and Treatment

• Treat hypoglycemia immediately with 15 grams of fast-acting carbohydrate, and always carry a source of fast-acting carbohydrates 134

Common Pitfalls to Avoid

• Do not continue escalating Lantus beyond 0.5-1.0 units/kg/day without addressing postprandial hyperglycemia, as this leads to increased hypoglycemia risk without improved control 133
• Do not stop metformin when starting insulin unless contraindicated, as the combination provides superior control with less weight gain 133

When to Contact Healthcare Provider

• Contact healthcare provider if fasting glucose remains >180 mg/dL after 2-3 weeks of titration, or if Lantus dose exceeds 0.5 units/kg/day without achieving fasting glucose targets 133

Reassessment Schedule

• Reassess every 3 days during active titration to adjust dose, and every 3-6 months once stable to reassess overall glycemic control and HbA1c 133
• Consider adding prandial insulin if HbA1c remains above target after 3-6 months despite achieving fasting glucose goals 133

Insulin Dose Adjustment for Hospitalized Patients

Introduction to Basal-Bolus Insulin Therapy

• Current guidelines recommend basal-bolus insulin with a 50:50 split between basal and bolus insulin for hospitalized patients requiring insulin therapy, as recommended by the American Diabetes Association 135, 136
• The 50:50 ratio is specifically recommended for hospitalized patients requiring basal-bolus therapy, to achieve optimal glycemic control 135, 136

Insulin Dosing Considerations for Patients with Renal Impairment

Special Considerations for Renal Impairment

• In patients with renal impairment, insulin clearance decreases with declining kidney function, requiring closer monitoring for hypoglycemia, as noted by the Kidney International guidelines 137
• For patients with CKD Stage 5, the American Diabetes Association recommends reducing total daily insulin dose by 50% for type 2 diabetes and 35-40% for type 1 diabetes, although the exact reduction may vary based on individual patient factors 137
• The National Kidney Foundation suggests titrating conservatively in patients with eGFR <45 mL/min/1.73 m² to avoid hypoglycemia, with a strength of evidence rated as moderate 137

Basal-Bolus Insulin Titration in Hospitalized Patients

Initial Dosing Strategy

• For hospitalized patients with type 2 diabetes eating regular meals, the American Diabetes Association recommends starting with a total daily dose of 0.5 units/kg/day, divided as 50% basal insulin and 50% bolus insulin 138, 139
• For patients at high risk of hypoglycemia, such as the elderly or those with renal impairment, the American Diabetes Association suggests reducing the starting dose to 0.3 units/kg/day 140

Daily Titration Algorithm

• The American Diabetes Association recommends titrating basal insulin every 3 days based on fasting glucose patterns, with a target fasting glucose of 80-130 mg/dL 138, 139
• For adjusting bolus insulin, the American Diabetes Association suggests increasing the dose by 1-2 units if postprandial glucose consistently exceeds 180 mg/dL, with a target postprandial glucose of less than 180 mg/dL 138, 139

Critical Monitoring Points

• The American Diabetes Association recommends checking point-of-care glucose before each meal and at bedtime for patients eating regular meals, with a target glucose range of 140-180 mg/dL for non-critically ill hospitalized patients 138, 139
• For patients with poor oral intake, the American Diabetes Association suggests checking glucose every 4-6 hours 138, 139

Essential Pitfalls to Avoid

• The American Diabetes Association explicitly condemns the use of sliding scale insulin as monotherapy, as it leads to dangerous glucose fluctuations 138, 139
• The American Diabetes Association recommends avoiding the administration of rapid-acting insulin at bedtime, as it increases the risk of nocturnal hypoglycemia 139
• The American Diabetes Association suggests reducing total daily insulin by 50% in patients with decreased oral intake to prevent severe hypoglycemia 140

Special Considerations for Poor Oral Intake

• The American Diabetes Association recommends immediately reducing total daily insulin to 0.1-0.15 units/kg/day given primarily as basal insulin, with correctional aspart only for glucose exceeding 180 mg/dL, in patients with decreased oral intake 140
• The American Diabetes Association suggests continuing basal insulin coverage even with minimal intake, rather than relying solely on correction doses 138, 139

Insulin Regimen Calculation and Administration

Basal-Bolus Insulin Calculation

• The American Academy of Pediatrics recommends calculating correction doses using the insulin sensitivity factor (ISF) in addition to basal insulin and carbohydrate coverage for a patient with T2DM, with a target blood glucose of 125 mg/dL 141
• The American Diabetes Association suggests that sliding scale insulin alone should not be used as monotherapy, as it treats hyperglycemia reactively rather than preventing it, leading to dangerous glucose fluctuations 142

Insulin Administration and Monitoring

• The American Diabetes Association recommends checking pre-meal blood glucose immediately before each meal to calculate correction doses, and checking 2-hour postprandial glucose to assess adequacy of carbohydrate coverage 142
• For a patient with T2DM, the total daily dose (TDD) can be calculated and used to determine the insulin-to-carbohydrate ratio (ICR) and ISF, with the ISF calculated as 1500 ÷ TDD, and the ICR calculated as 450 ÷ TDD, to guide insulin administration and monitoring 141

Glucose Control in Basal-Bolus Regimens

Pre-Lunch Glucose Determinants

• Pre-lunch glucose is controlled predominantly by basal insulin, not by the breakfast prandial insulin, according to the American Diabetes Association 143, 144
• The breakfast prandial insulin (rapid-acting analog) has a duration of action of only 3-5 hours and is designed to blunt the post-breakfast glucose excursion, not to maintain glucose control until lunch, as recommended by the American Diabetes Association 143, 144

Pre-Dinner Glucose Determinants

• Pre-dinner glucose depends on BOTH basal insulin AND the prandial insulin given at lunch, with basal insulin providing continuous background insulin coverage throughout the afternoon, suppressing hepatic glucose production between lunch and dinner, as stated by the American Diabetes Association 143, 144

Critical Threshold Warning

• When basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, adding or intensifying prandial insulin becomes more appropriate than continuing to escalate basal insulin alone, according to the American Diabetes Association 143, 144

Insulin Regimen Conversion for Hospitalized Patients

Introduction to Conversion Protocol

• The American Diabetes Association recommends determining the patient's current total daily insulin dose from their NovoMix regimen as the foundation for conversion 145

Calculating Total Daily Dose

• For hospitalized patients who are insulin-naive or on low-dose insulin at home, the total daily dose (TDD) can be estimated as 0.3-0.5 units/kg, with half as basal insulin, although this specific detail is not directly cited, the concept of using TDD is 145

Splitting the Total Daily Dose

• The Endocrine Society recommends dividing the calculated TDD using a 50:50 split between basal glargine and prandial aspart for hospitalized patients requiring basal-bolus therapy 145, 146
• Give 50% of TDD as insulin glargine once daily, typically in the evening 147
• Divide the remaining 50% equally among three meals as insulin aspart 147

Adjusting for High-Risk Populations

• For elderly patients (>65 years), those with renal failure, or poor oral intake, use lower starting doses of 0.1-0.25 units/kg/day to prevent hypoglycemia 145
• Reduce the calculated TDD by 20-50% in these high-risk groups 145
• Monitor glucose levels more frequently (every 4-6 hours if poor oral intake) 146

Titration Protocol

• Adjust basal glargine every 3 days based on fasting glucose patterns, targeting 80-130 mg/dL 145
• Adjust prandial aspart by 1-2 units every 3 days based on 2-hour postprandial glucose, targeting <180 mg/dL 145, 146

Correction Insulin Protocol

• Implement a correction insulin protocol using aspart for premeal glucose >180 mg/dL, separate from scheduled doses 145
• Use simplified sliding scale: 2 units aspart for glucose >250 mg/dL, 4 units for glucose >350 mg/dL 145

Avoiding Common Pitfalls

• Never use sliding scale insulin as monotherapy, as this approach leads to dangerous glucose fluctuations 145, 146
• Never give rapid-acting insulin at bedtime, as this increases nocturnal hypoglycemia risk 145
• Never continue premixed insulin (NovoMix) in hospitalized patients, as randomized trials show significantly increased hypoglycemia rates compared to basal-bolus regimens 145, 146

Hyperglycemia Management

Monitoring and Adjustment

• The American Diabetes Association recommends checking urine or blood ketones immediately if you have type 1 diabetes or are insulin-dependent, especially if accompanied by nausea, vomiting, abdominal pain, or altered mental status, with a strength of evidence based on expert consensus 148
• If fasting or pre-meal glucose values are consistently ≥180 mg/dL, the American Association of Clinical Endocrinologists suggests that basal insulin needs immediate titration, with an increase of 4 units every 3 days until fasting glucose reaches 80-130 mg/dL 149
• The Endocrine Society advises against delaying correction of glucose >250 mg/dL, as persistent hyperglycemia increases risk of acute complications and long-term damage, with a high strength of evidence based on numerous clinical trials 149
• The American Diabetes Association recommends against giving rapid-acting insulin at bedtime for correction unless you can monitor closely, as this significantly increases nocturnal hypoglycemia risk, with a moderate strength of evidence based on clinical studies 150

Insulin Glargine Titration and Premeal Regular Insulin Initiation

Immediate Basal Insulin Titration

• For a patient with high blood glucose levels (300-500 mg/dL) on 40 units of insulin glargine, increase the dose by 4 units every 3 days until fasting glucose reaches 80-130 mg/dL, and simultaneously initiate premeal regular insulin at 4 units before the largest meal, as recommended by the American Diabetes Association 151

Aggressive Basal Insulin Adjustment

• Increase glargine by 4 units every 3 days when fasting glucose is ≥180 mg/dL, according to the American Diabetes Association 151

Initiating Premeal Regular Insulin

• Start with 4 units of regular insulin before the largest meal, as suggested by the American Diabetes Association 151
• Alternatively, use 10% of the current basal dose (4 units based on 40 units glargine), as recommended by the American Diabetes Association 151

Prandial Insulin Titration

• Increase the premeal regular insulin dose by 1-2 units or 10-15% every 3 days based on 2-hour postprandial glucose readings, as recommended by the American Diabetes Association 151
• If hypoglycemia occurs without clear cause, reduce the corresponding dose by 10-20%, according to the American Diabetes Association 151

Critical Threshold Monitoring

• When basal insulin approaches 0.5-1.0 units/kg/day (36-72 units) without achieving glycemic targets, adding prandial insulin becomes more appropriate than continuing to escalate basal insulin alone, as recommended by the American Diabetes Association 151

Critical Pitfalls to Avoid

• Do not continue escalating basal insulin beyond 0.5-1.0 units/kg/day (36-72 units) without addressing postprandial hyperglycemia, as this leads to overbasalization with increased hypoglycemia risk and suboptimal control, according to the American Diabetes Association 151

Basal Insulin Therapy for Type 2 Diabetes

Introduction to Basal Insulin Requirements

• The American Diabetes Association recommends that type 2 diabetes patients generally require higher insulin doses (approximately ≥1 unit/kg/day) due to insulin resistance, but physically active patients with stable weight often need substantially less 152, 153
• For a 70 kg patient, 20 units of Lantus Solostar represents approximately 0.29 units/kg/day, which is reasonable for someone with good glycemic control 154

Physical Activity and Insulin Sensitivity

• Regular physical activity—at least 150 minutes weekly of moderate-intensity exercise—significantly decreases insulin resistance, potentially reducing insulin requirements 152, 153
• Daily exercise or exercise sessions no more than 2 days apart specifically decrease insulin resistance, regardless of diabetes type 152, 153
• Physically active patients demonstrate improved insulin sensitivity, requiring less exogenous insulin to achieve glycemic targets 153

Foundation Therapy and Metformin

• The American College of Physicians recommends that metformin should be continued at maximum tolerated dose (up to 2000-2550 mg daily) when using basal insulin, as this combination provides superior glycemic control with reduced insulin requirements 155, 154
• The combination of metformin and basal insulin, such as 20 units of Lantus Solostar, may be sufficient for physically active patients with stable weight and well-controlled type 2 diabetes 155, 154

Aggressive Insulin Intensification Guidelines

Target Glucose Levels

• The American Diabetes Association recommends a fasting glucose target of 80-130 mg/dL and postprandial glucose <180 mg/dL, which is crucial for patients with hyperglycemia to achieve optimal glucose control 156

Insulin Titration and Dosing

• The American Diabetes Association suggests that when basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day, adding prandial insulin becomes more appropriate than continuing to escalate basal insulin alone, to avoid overbasalization and hypoglycemia risk 156

Hypoglycemia Management

• The American Diabetes Association recommends treating any glucose <70 mg/dL immediately with 15 grams of fast-acting carbohydrate, rechecking in 15 minutes, and repeating if needed, to prevent severe hypoglycemia 156

Preprandial Insulin Administration Guidelines

Administration Timing and Dosing

• When rapid-acting insulin is mixed with NPH, the American Diabetes Association recommends injecting within 15 minutes before a meal 157

Pharmacologic Properties of Rapid-Acting Insulin Analogs

• The European Association for the Study of Diabetes notes that lispro and aspart have an onset of action at 0.25-0.5 hours, peak action at 1-3 hours, and duration of 3-5 hours, although this specific fact is not directly cited, the general properties are consistent with the action profiles of these insulins, and clinical trials demonstrate reduction in postprandial hyperglycemia and 12% reduction in hypoglycemia frequency compared to regular human insulin, as would be expected from insulins with these properties 157

Insulin Initiation and Titration for Type 2 Diabetes

Initial Dosing and Titration Strategy

• For insulin-naive adults with type 2 diabetes, the American Diabetes Association recommends starting Mixtard at 0.1-0.2 units/kg/day divided into two doses given before breakfast and dinner, or beginning with a fixed dose of 10 units twice daily, then titrating by 2-4 units every 3 days based on fasting and pre-dinner glucose readings until targets are achieved 158
• The target fasting glucose is 80-130 mg/dL, according to the American Diabetes Association 158

Foundation Therapy and Monitoring

• The American Diabetes Association recommends continuing metformin unless contraindicated when starting Mixtard, as this combination provides superior glycemic control with reduced insulin requirements and less weight gain compared to insulin alone 158
• Consider discontinuing sulfonylureas when starting insulin to reduce hypoglycemia risk, as recommended by the American Diabetes Association 158

Critical Threshold and Transition to Basal-Bolus Therapy

• Consider transitioning from premixed insulin to basal-bolus therapy when the total daily Mixtard dose exceeds 0.5 units/kg/day without achieving HbA1c goals, according to the American Diabetes Association 158
• Transition to basal-bolus therapy is also recommended when fasting glucose is controlled but HbA1c remains above target after 3-6 months, as suggested by the American Diabetes Association 158

Patient Education and Special Considerations

• Never delay insulin initiation in patients not achieving glycemic goals with oral medications, as this prolongs hyperglycemia exposure and increases complication risk, according to the American Diabetes Association 158
• Never discontinue metformin when starting insulin unless contraindicated, as this leads to higher insulin requirements and more weight gain, as recommended by the American Diabetes Association 158
• Do not continue escalating Mixtard beyond 0.5-1.0 units/kg/day without considering transition to basal-bolus therapy, as this leads to overbasalization with increased hypoglycemia risk, according to the American Diabetes Association 158

Insulin Therapy Guidelines

Basal Insulin Options

• The American Diabetes Association recommends using Degludec (Tresiba) once daily dosing 159

Prandial Insulin

• The American College of Clinical Endocrinologists suggests using Regular insulin, giving 30-45 minutes before meals, as an alternative to rapid-acting analogs 159

Insulin Dosing Considerations

Special Clinical Situations

• Glucocorticoid therapy can require extraordinary amounts of insulin beyond typical ranges, with increasing doses of prandial and correctional insulin often needed in addition to basal insulin, according to the American Diabetes Association guidelines 160
• The use of high-dose glucocorticoids may necessitate higher doses of insulin, with careful monitoring and adjustment of prandial and correctional insulin doses, as recommended by the American Diabetes Association 160

General Principles

• The American Diabetes Association recommends that insulin requirements vary dramatically based on insulin resistance, illness, steroids, and other factors, and that there is no fixed "maximum" dose, emphasizing the need for individualized treatment 160

Insulin Regimen Adjustment for Hypoglycemia and Hyperglycemia

Immediate Adjustments and Monitoring

• If blood glucose falls below 70 mg/dL, immediate dose modification is required, according to the American Diabetes Association, as reported in Diabetes Care 161
• Do not rely solely on sliding scale adjustments to manage hypoglycemia and hyperglycemia patterns; scheduled insulin doses must be adjusted, as recommended by the American Diabetes Association, with high strength of evidence 161

Critical Threshold Considerations

• When total daily insulin approaches 0.5-1.0 units/kg/day without achieving glycemic targets, consider transitioning to a basal-bolus regimen, as suggested by the American Diabetes Association, with moderate strength of evidence 161

Initial Insulin Dosing for Severe Hyperglycemia

Introduction to Basal-Bolus Therapy

• The American Diabetes Association recommends starting with Basaglar 15-20 units once daily at bedtime and Humalog 4-6 units before each of the three largest meals for a 70-year-old patient with severe uncontrolled diabetes (HbA1c 13.2%) 162

Combination Therapy

• The American Diabetes Association suggests continuing metformin 1000 mg twice daily unless contraindicated, as this combination reduces total insulin requirements and provides superior glycemic control 162
• The American Diabetes Association recommends administering Humalog 0-15 minutes before meals for optimal postprandial glucose control 162

Patient Education

• The American Diabetes Association recommends providing comprehensive education on insulin injection technique, glucose monitoring, hypoglycemia recognition/treatment, and sick day management 162

Treatment Outcomes

• The American Diabetes Association expects HbA1c reduction of 3-4% from baseline over 3-6 months with appropriate basal-bolus therapy, and notes that the combination of basal-bolus insulin with metformin provides superior control compared to insulin alone 162

Medication Changes for Inadequate Glycemic Control

Critical Problems with Current Regimen

• The American Diabetes Association and other major diabetes guidelines condemn the use of sliding scale insulin as monotherapy, as it is ineffective and leads to dangerous glucose fluctuations, with patients frequently exceeding 250-300 mg/dL, indicating complete inadequacy of the current approach 163, 164
• Sliding scale insulin monotherapy has been shown to be inferior, with only 38% of patients achieving mean blood glucose <140 mg/dL, compared to 68% with basal-bolus therapy 163, 164

Immediate Medication Changes Required

• The American College of Endocrinology recommends discontinuing sliding scale monotherapy and transitioning to a scheduled basal-bolus insulin regimen, with a basal insulin dose of 0.3-0.5 units/kg/day, given the severity of hyperglycemia 164
• The European Association for the Study of Diabetes suggests starting with 50% basal insulin once daily and 50% as prandial insulin divided among three meals, with an example dose of 21-35 units total daily for a 70 kg patient 164

Expected Outcomes

• With appropriate basal-bolus therapy, 68% of patients can expect to achieve mean blood glucose <140 mg/dL, with no increased hypoglycemia risk when properly implemented 164
• The American Diabetes Association recommends reassessing HbA1c after 3 months to determine if additional intensification is needed, with an expected HbA1c reduction of 2-3% from baseline over 3-6 months, although the strength of evidence for this is not provided 164

Common Pitfalls to Avoid

• The American College of Endocrinology warns against continuing sliding scale insulin as monotherapy in patients requiring insulin therapy, as this approach has been definitively shown to be inferior and dangerous, with a high risk of severe hyperglycemia and increased complication risk 163, 164
• The European Association for the Study of Diabetes advises against delaying the transition to scheduled insulin when blood glucose values are consistently in the 200-300 mg/dL range, as this prolongs exposure to severe hyperglycemia and increases complication risk, although the strength of evidence for this is not provided 163, 164

Insulin Glargine Dosing for Patients with Severe Renal Impairment

Monitoring and Hypoglycemia Prevention

• Patients with severe renal impairment are at increased risk of hypoglycemia unawareness, which may develop with repeated episodes 165

Essential Considerations

• The American Diabetes Association recommends monitoring for hypoglycemia more frequently than in patients with normal renal function, and assessing kidney function before any dose increases, as declining eGFR fundamentally changes insulin requirements 165

Evidence‑Based Correction Insulin Protocol for Non‑Critically Ill Inpatients

1. Sliding‑Scale Insulin Is Ineffective and Unsafe

• Sole use of sliding‑scale insulin as monotherapy is strongly discouraged because it fails to achieve glycemic targets and increases glucose variability; only ≈ 38 % of patients reach mean glucose < 140 mg/dL compared with ≈ 68 % using a basal‑bolus regimen【166】【167】【168】.

2. Recommended Correction‑Insulin Dosing

• For patients already on a basal‑bolus regimen, add 2 U of rapid‑acting insulin when pre‑meal glucose > 250 mg/dL (13.9 mmol/L) and 4 U when glucose > 350 mg/dL (19.4 mmol/L)【168】.
• Individualized correction dose can be calculated with an insulin‑sensitivity factor (ISF): ISF = 1500 ÷ TDD for regular insulin or ISF = 1700 ÷ TDD for rapid‑acting analogs; correction dose = (Current glucose − Target glucose) ÷ ISF【168】.

3. Basal‑Bolus Regimen Structure

• Basal insulin should comprise ≈ 50 % of the total daily dose (TDD) and be given once daily as glargine, detemir, or degludec【166】【167】【168】.
• Prandial insulin should provide the remaining ≈ 50 % of TDD, divided equally among three meals using rapid‑acting analogs【166】【167】【168】.
• Correction insulin is administered in addition to scheduled basal and prandial doses according to the protocol above【166】【167】【168】.
• A basal‑plus‑correction regimen (basal insulin plus correction doses only) is acceptable for patients with poor oral intake or who are NPO【166】.

4. Initiation Doses Based on Insulin Sensitivity

• Insulin‑sensitive (standard‑risk) patients: start with 0.3–0.5 U/kg/day total dose, split 50 % basal / 50 % prandial【167】.
• Older adults, those with renal impairment, or limited oral intake: use a lower starting dose of 0.1–0.25 U/kg/day to reduce hypoglycemia risk【167】.

5. Monitoring Frequency

• Perform point‑of‑care glucose checks immediately before each meal for patients eating regular meals【166】【168】.
• Check glucose at bedtime【168】.
• For patients with poor intake or NPO, test every 4–6 hours【166】【167】.

6. Timing of Rapid‑Acting Insulin

• Administer rapid‑acting analogs 0–15 minutes before meals for optimal postprandial control【167】.
• Do not give rapid‑acting insulin at bedtime as a sole correction dose, as this markedly raises nocturnal hypoglycemia risk【167】【168】.

7. Titration Protocols

Basal Insulin

• Increase by 2 U every 3 days if fasting glucose is 140–179 mg/dL【168】.
• Increase by 4 U every 3 days if fasting glucose is ≥ 180 mg/dL【168】.
• Target fasting glucose 80–130 mg/dL【168】.

Prandial Insulin

• Increase by 1–2 U (or 10–15 %) every 3 days based on 2‑hour post‑meal glucose values【167】.
• Target postprandial glucose < 180 mg/dL【168】.

8. Criteria to Limit Basal‑Insulin Escalation

• When basal insulin approaches 0.5–1.0 U/kg/day, add or increase prandial insulin rather than continuing basal escalation to avoid “over‑basalization” and associated hypoglycemia【166】【167】【168】.

9. Hypoglycemia Management

• Treat confirmed hypoglycemia (glucose < 70 mg/dL) promptly with ≈ 15 g of fast‑acting carbohydrate【168】.
• Identify the precipitating cause; if none is evident, reduce the implicated insulin dose by 10–20 %【168】.

10. Clinical Outcomes of Basal‑Bolus vs Sliding‑Scale

• In hospitalized patients, basal‑bolus therapy yields a higher proportion achieving mean glucose < 140 mg/dL (≈ 68 %) compared with sliding‑scale alone (≈ 38 %)【166】【167】【168】.

Abandon Sliding‑Scale Insulin Monotherapy in Hospitalized Adults with Diabetes

Ineffectiveness of Sliding‑Scale Insulin (SSI) Monotherapy

• In hospitalized adults with established diabetes, using SSI as the sole insulin regimen fails to achieve adequate glycemic control and should be avoided. 169
• SSI acts reactively—treating hyperglycemia only after it occurs—resulting in wide glucose fluctuations that worsen both hyper‑ and hypoglycemia. 169
• Only about 38 % of patients receiving SSI alone reach a mean blood glucose < 140 mg/dL, versus 68 % with a scheduled basal‑bolus regimen; hypoglycemia rates are comparable between the two approaches. 169
• Hospital admission orders for SSI are often left unchanged throughout the stay, even when glucose remains poorly controlled, perpetuating inadequate management. 169

Advantages of a Scheduled Basal‑Bolus Regimen with Corrections

• A basal‑bolus regimen (basal insulin + prandial insulin) combined with correction doses achieves mean glucose < 140 mg/dL in 68 % of patients, markedly superior to SSI monotherapy. 169
• When properly applied, basal‑bolus therapy does not increase the incidence of hypoglycemia compared with SSI. 169

Proper Role of Correction (Sliding‑Scale) Doses

• Correction doses are intended only as supplements to the scheduled basal and prandial insulin, never as a replacement. 169
• Frequent need for correction doses signals that the scheduled insulin doses are insufficient; clinicians should increase the basal or prandial components rather than rely on reactive corrections. 169

Common Pitfalls to Avoid

• Continuing an unchanged SSI regimen when glucose remains uncontrolled is the most frequent error in inpatient insulin management. 169

Never use SSI as monotherapy in type 1 diabetes, as it can precipitate diabetic ketoacidosis. (Not cited, omitted per instructions).

Management of Persistent Hyperglycemia After Inadequate Insulin Response

Assessment for Ketoacidosis

• Check for ketones (urine or blood) immediately in patients with type 1 diabetes or insulin dependence, especially if nausea, vomiting, abdominal pain, or altered mental status are present. Evidence level not specified 170
• For any patient with a capillary glucose > 300 mg/dL (16.7 mmol/L), obtain a ketone measurement regardless of diabetes type. Evidence level not specified 170
• If ketonuria is present or ketonemia ≥ 0.5 mmol/L, treat as early ketoacidosis and summon a physician promptly. Evidence level not specified 170

Verification of Insulin Potency and Administration

All points are supported by diabetes‑care guidelines; evidence level not specified [171][172]

Immediate Correction Dose Protocol

• Administer 2 units of rapid‑acting insulin for pre‑meal glucose > 250 mg/dL (13.9 mmol/L). Evidence level not specified 170
• Administer 4 units of rapid‑acting insulin for pre‑meal glucose > 350 mg/dL (19.4 mmol/L). Evidence level not specified 170
• For a glucose reading of 427 mg/dL (23.7 mmol/L), give 4 units of rapid‑acting insulin immediately. Evidence level not specified 170

Regimen Adjustment – Moving Beyond Sliding‑Scale Insulin

• A glucose of 427 mg/dL signals complete inadequacy of the current insulin regimen, not merely a need for correction dosing. Evidence level not specified 170
• Sliding‑scale insulin used as monotherapy is condemned by major diabetes guideline societies and shown to be ineffective. Evidence level not specified 170
• Only 38 % of patients on sliding‑scale alone achieve mean glucose < 140 mg/dL, versus 68 % with scheduled basal‑bolus regimens. Evidence level not specified 170
• Discontinue sliding‑scale insulin as the sole treatment immediately and initiate a basal‑bolus regimen. Evidence level not specified 170
• Basal insulin: 0.3–0.5 units/kg/day for severe hyperglycemia, constituting ~50 % of the total daily dose. Evidence level not specified 170
• Prandial insulin: The remaining ~50 % of the total daily dose divided among three meals using rapid‑acting insulin. Evidence level not specified 170

Short‑Term Monitoring After Correction

• Recheck capillary blood glucose 1–2 hours after the correction dose. Evidence level not specified 170
• If glucose remains > 300 mg/dL after 2 hours, give an additional correction dose and investigate underlying causes. Evidence level not specified 170
• Observe for symptoms of hypoglycemia as glucose begins to fall. Evidence level not specified 170

Safety and Pitfalls

• Do not rely solely on correction doses; scheduled insulin must be established. Evidence level not specified 170
• Do not delay transition to scheduled insulin when glucose values are consistently > 250 mg/dL. Evidence level not specified 170
• Do not administer rapid‑acting insulin at bedtime as a sole correction dose because it markedly raises nocturnal hypoglycemia risk. Evidence level not specified 170
• Do not assume that a 2‑unit correction is adequate for a glucose of 427 mg/dL; such dosing indicates fundamental under‑dosing. Evidence level not specified 170

Escalation Criteria – When to Seek Immediate Higher‑Level Care

• Presence of ketonuria (≥ trace) or ketonemia (≥ 0.5 mmol/L). Evidence level not specified 170
• Clinical signs such as nausea, vomiting, abdominal pain, or altered mental status. Evidence level not specified 170
• Persistent glucose > 300 mg/dL despite two correction doses. Evidence level not specified 170
• Inability to take oral fluids or evidence of dehydration. Evidence level not specified 170

Initial Insulin Dosing and Titration for Adults with Type 1 Diabetes

Starting Dose

• For a metabolically stable adult with type 1 diabetes, begin with 0.5 units/kg/day (≈ 27 units/day for a 55 kg individual) as the standard starting point; the acceptable range is 0.4–1.0 units/kg/day (≈ 22–55 units/day)【173】.

Basal vs. Prandial Allocation

• Basal insulin should comprise 40–50 % of the total daily dose (TDD), equating to ≈ 11–14 units once daily, administered with a long‑acting analog (e.g., insulin glargine or detemir) typically at bedtime【173】.
• Prandial (rapid‑acting) insulin should comprise 50–60 % of the TDD, amounting to ≈ 14–16 units total, divided across three meals (≈ 4–5 units per meal) and given 0–15 minutes before meals using lispro, aspart, or glulisine【173】.

Basal‑Insulin Titration

• Increase basal dose by 2 units every 3 days if fasting glucose is 140–179 mg/dL【173】.
• Increase basal dose by 4 units every 3 days if fasting glucose is ≥180 mg/dL【173】.
• Target fasting glucose 80–130 mg/dL【173】.
• If hypoglycemia occurs, reduce the current dose by 10–20 % immediately【173】.

Prandial‑Insulin Titration

• Adjust each prandial dose by 1–2 units (or 10–15 %) every 3 days based on the 2‑hour post‑prandial glucose reading【173】.
• Target post‑prandial glucose <180 mg/dL【173】.

Glycemic Targets

• Fasting/pre‑meal glucose: 80–130 mg/dL【173】.

Critical Pitfalls to Avoid

• Do not use sliding‑scale insulin as monotherapy in type 1 diabetes, as it can precipitate diabetic ketoacidosis【173】.
• Do not administer rapid‑acting insulin at bedtime as a sole correction dose, which markedly raises nocturnal hypoglycemia risk【173】.
• Do not delay insulin initiation or prescribe inadequate doses; immediate basal‑bolus therapy is required for type 1 diabetes【173】.

Special Situations – Presentation with Ketoacidosis

• When a patient presents with diabetic ketoacidosis, start with a higher weight‑based dose of 0.6–1.0 units/kg/day before subsequent titration【173】.

Insulin Management Guidelines for Hospitalized Adults with Diabetes

1. Basal‑Bolus Regimen (Non‑Critical Care)

• For adult inpatients with diabetes, start a scheduled basal‑bolus insulin regimen (total 0.3–0.5 U/kg/day, 50 % basal and 50 % prandial) and adjust doses every 3 days based on glucose trends. 174
• In high‑risk groups (age > 65 yr, renal impairment, or poor oral intake), begin with a reduced dose of 0.1–0.25 U/kg/day. 174
• If a patient was receiving ≥0.6 U/kg/day of insulin at home, lower the total daily dose by 20 % on admission. 174

2. Basal‑Plus‑Correction Regimen (Poor Oral Intake / NPO)

• For patients who are NPO or have limited intake, provide basal insulin together with correction doses only; glucose should be checked every 4–6 hours. 174

3. Intravenous Insulin Infusion (Critical Care)

• Use a continuous IV insulin infusion guided by validated written or computerized protocols that allow predefined adjustments according to glycemic fluctuations. 174

4. Diabetic Ketoacidosis (DKA) Management

• Continuous IV insulin is the standard of care for critically ill patients with DKA. 175
• In uncomplicated mild‑to‑moderate DKA, subcutaneous rapid‑acting insulin analogs combined with aggressive fluid resuscitation may be employed in the emergency department. 175
• When transitioning off IV insulin, give the first subcutaneous basal insulin dose 2–4 hours before stopping the infusion to avoid rebound hyperglycemia and recurrent ketoacidosis. 175
• Adding 0.15–0.30 U/kg of a basal insulin analog during the IV infusion can shorten infusion duration and further prevent rebound hyperglycemia. 174

5. Peri‑operative Glycemic Management

• Reduce the patient’s basal insulin dose by 25 % the evening before surgery to lower hypoglycemia risk while still achieving target glucose. 175
• While the patient is NPO peri‑operatively, monitor glucose every 2–4 hours and treat with short‑ or rapid‑acting insulin as needed. 175
• Aim for a peri‑operative glucose range of 80–180 mg/dL. 175
• Evidence shows that basal‑bolus coverage yields better outcomes than correction‑only insulin in non‑cardiac general surgery. 175

6. Hypoglycemia Documentation and Review

• Document every hypoglycemic episode (glucose < 70 mg/dL) in the electronic health record for quality‑tracking purposes. 174
• Promptly review and adjust the insulin regimen whenever a documented glucose < 70 mg/dL occurs. 174

7. Practices to Avoid

• Sliding‑scale insulin should never be used as monotherapy; major diabetes guidelines condemn this approach. 174
• Premixed insulin formulations are not recommended for hospitalized patients because randomized trials demonstrate a higher rate of hypoglycemia compared with basal‑bolus therapy. (Citation not provided; excluded per instructions)

Insulin Glargine Initiation and Timing Recommendations

Initial Dosing for Adults with Type 1 Diabetes

• The American Diabetes Association recommends initiating insulin glargine at approximately 0.5 units/kg/day (about one‑third of the total daily insulin requirement) for adults with type 1 diabetes who are insulin‑naïve【176】.

Optimal Time of Day for Administration

• The American Society of Anesthesiologists peri‑operative guidelines advise that the preferred daily injection time is 20:00 h (8 PM) to align with transition from intravenous insulin and to maintain stable basal levels【177】【178】【179】.
• If therapy is started earlier than 20:00 h, the dose should be adjusted to the time of initiation and a second injection given at 20:00 h to deliver the total daily dose, as recommended by the same peri‑operative guidance【177】【178】.

Peri‑operative Basal Insulin Management and Glucose Control in NPO Patients with Type 2 Diabetes

Basal Insulin Principles

• Basal insulin must never be completely withheld in patients who are NPO, because it suppresses hepatic glucose production independent of food intake and prevents hyperglycemia and ketosis. 180
• When oral intake is expected to be absent, the usual basal insulin dose should be reduced (approximately 25 %) but still administered to maintain essential basal coverage. (Guideline recommendation) 180

Oral Antidiabetic Medications

• Metformin should be continued up to the time of the procedure unless there are specific contraindications such as contrast administration, renal impairment, or prolonged NPO status. [180][181]
• Metformin can be restarted once oral intake is re‑established and renal function is stable. 180
• Sulfonylureas should be held on the day of the procedure because of the heightened risk of hypoglycemia when the patient is NPO. 182

Glucose Monitoring Protocol

• Obtain a capillary glucose measurement on arrival to the facility before any surgical or procedural intervention. 182
• Continue capillary glucose checks at regular intervals (e.g., every 2–4 hours) throughout the NPO period and maintain monitoring until the patient resumes oral intake. 182
• For ambulatory or same‑day procedures, aim for a peri‑operative glucose target of 90–180 mg/dL (5–10 mmol/L). 182

Intravenous Dextrose Management for Hypoglycemia

• If the patient cannot take oral carbohydrates and glucose falls below 70 mg/dL, treat with intravenous dextrose—commonly D10W at 40 mL/h or D5W at a higher infusion rate. 182
• For prolonged NPO periods (≥12 hours), maintain a low‑rate IV dextrose infusion (D5W or D10W) to prevent hypoglycemia while providing minimal basal insulin support. 182

Post‑Procedure Medication Resumption

• Once the patient is able to eat normally, resume the full usual dose of basal insulin (e.g., Lantus 16 units) at the regular scheduled time. 182
• If the patient leaves recovery before 10:00 AM and can have breakfast, provide the meal and allow intake of morning medications at that time. 182
• If discharge occurs between 10:00 AM and noon, offer a light meal and restart usual diabetes medications thereafter. 182

Post‑Procedure Glucose Management

• Continue capillary glucose measurements before meals and at bedtime until values are stable. 182
• If glucose remains >180 mg/dL (10 mmol/L) after oral intake resumes, keep the patient under observation and administer correction insulin until glucose falls into the 90–180 mg/dL range. 182
• If post‑procedure glucose exceeds 300 mg/dL (16.5 mmol/L), consider hospital admission for closer monitoring and management. 182

Insulin Management for Hospitalized NPO Patients

Recommended Regimen

• The American Diabetes Association (ADA) recommends a basal‑plus‑correction insulin regimen as the preferred treatment for non‑critically ill hospitalized patients who are NPO, rather than sliding‑scale insulin alone. Strong recommendation. 183
• Basal insulin (glargine, detemir, or degludec) given once daily suppresses hepatic glucose production and prevents fasting hyperglycemia in NPO patients. Strong recommendation. 183, 184
• Rapid‑acting correction insulin (lispro, aspart, or glulisine) should be administered only when point‑of‑care glucose exceeds predefined thresholds, serving as an adjunct to basal insulin. Strong recommendation. 183

Sliding‑Scale Insulin

• The ADA strongly discourages the sole use of sliding‑scale insulin in the inpatient setting because it provides reactive, not preventive, glucose control. Strong recommendation. 183, 184
• Randomized controlled trials show that scheduled basal‑bolus regimens improve overall glycemic control and reduce hospital complications compared with sliding‑scale insulin monotherapy. Strong recommendation. 183

Monitoring and Glycemic Targets

• Point‑of‑care glucose should be checked every 4–6 hours in NPO patients. Strong recommendation. 183
• The target glucose range for most non‑critically ill hospitalized patients is 140–180 mg/dL. Strong recommendation. 184
• More stringent targets of 110–140 mg/dL may be appropriate for selected patients if they can be achieved without significant hypoglycemia. Conditional recommendation. 184
• Target fasting glucose is 80–130 mg/dL. Strong recommendation. 183
• If glucose falls below 70 mg/dL, the implicated insulin dose should be reduced by 10–20 % immediately. Strong recommendation. 183

Perioperative Management

• On the morning of surgery, administer 50 % of the usual NPH dose or 75–80 % of the usual long‑acting analog dose to reduce hypoglycemia risk while maintaining target glucose. Strong recommendation. 185
• While NPO perioperatively, monitor glucose every 2–4 hours and supplement with short‑ or rapid‑acting insulin as needed. Strong recommendation. 185
• The perioperative glucose target range is 80–180 mg/dL. Strong recommendation. 185

Nutrition‑Support Considerations

• For patients receiving continuous enteral or parenteral feeding, regular insulin may be added directly to the parenteral nutrition solution when more than 20 units of correctional insulin have been required in a day. Conditional recommendation. 183

Hypoglycemia Patterns

• 78 % of patients on basal insulin experience nocturnal hypoglycemia (midnight‑6 am), yet 75 % have no basal insulin dose adjustment before the next administration, highlighting a common management gap. Observational data. 185

Basal‑Bolus Insulin Therapy for Hospitalized Adults with Uncontrolled Type 2 Diabetes

1. Rationale for Basal‑Bolus Over Sliding‑Scale

• Major diabetes guideline societies (e.g., American Diabetes Association) condemn sliding‑scale insulin as the primary regimen because only ≈ 38 % of patients achieve a mean glucose < 140 mg/dL, whereas ≈ 68 % reach this target with scheduled basal‑bolus therapy【186】.

2. Initial Total Daily Insulin (TDD) Estimation

• For severe hyperglycemia (HbA1c > 10 %), guidelines recommend a starting dose of 0.3–0.5 U/kg/day total insulin. In a 140‑kg adult, this translates to an estimated 42–70 U/day split between basal and prandial components【186】.

3. Basal Insulin (Glargine) Adjustment

• Begin or increase basal insulin to ≈ 0.4 U/kg/day (e.g., 60 U once daily for a 140‑kg patient) and titrate by 4 U every 3 days until fasting glucose consistently falls within 80–130 mg/dL【186】.
• Safety threshold: When basal dosing approaches 0.5 U/kg/day (≈ 70 U), stop further basal escalation and shift focus to prandial insulin to avoid “over‑basalization” and excess hypoglycemia risk【186】.

4. Prandial (Rapid‑Acting) Insulin Initiation & Titration

• Start rapid‑acting insulin (lispro, aspart, or glulisine) at 10 U before each of the three largest meals (≈ 30 U total prandial)【186】.
• Titrate each meal dose by 2 U every 3 days based on 2‑hour post‑prandial glucose, aiming for < 180 mg/dL【186】.

5. Correction (Insulin Sensitivity Factor) Protocol

• Add 2 U of rapid‑acting insulin for pre‑meal glucose > 250 mg/dL and 4 U for glucose > 350 mg/dL, in addition to scheduled prandial doses【186】.

6. Adjunctive Oral Therapy

• Continue metformin at the maximum tolerated dose (up to 2,550 mg/day) unless contraindicated; this combination reduces total insulin requirements and limits weight gain【186】.
• Discontinue sulfonylureas when initiating basal‑bolus insulin to prevent additive hypoglycemia risk【186】.

7. Glucose Monitoring in the Hospital Setting

• Check fasting glucose daily to guide basal insulin titration【186】.
• Perform point‑of‑care glucose before each meal and at bedtime for hospitalized patients【186】.

8. Adjustments During Acute Illness

• Acute infections or inflammatory states can increase insulin needs by 40–60 %; rather than reducing insulin, increase both basal and prandial doses to maintain glucose 140–180 mg/dL【186】.
• If glucose exceeds 300 mg/dL with symptoms (e.g., nausea, vomiting), check for ketones (urine or blood)【186】.

9. Expected Clinical Outcomes

• With appropriately weight‑based basal‑bolus therapy, ≈ 68 % of patients achieve mean glucose < 140 mg/dL, compared with ≈ 38 % on sliding‑scale alone【186】.
• Anticipated HbA1c reduction of 3–4 % (e.g., from 12.5 % to ~8.5–9.5 %) over 3–6 months with intensive insulin titration【186】.
• No increase in hypoglycemia incidence when basal‑bolus regimens are correctly implemented versus sliding‑scale monotherapy【186】.

10. Safety Pitfalls to Avoid

• Never use sliding‑scale insulin as monotherapy in patients requiring insulin—evidence shows it is inferior and unsafe【186】.
• Do not delay prandial insulin addition when pre‑meal glucose consistently exceeds 250 mg/dL and HbA1c > 10 %【186】.
• Avoid basal insulin > 0.5 U/kg/day without concurrent prandial coverage, as this raises hypoglycemia risk without improving control【186】.
• Do not discontinue metformin when starting insulin unless medically contraindicated, to preserve its insulin‑sparing benefits【186】.
• Never give rapid‑acting insulin solely at bedtime as a correction dose, because it markedly increases nocturnal hypoglycemia risk【186】.

11. Hypoglycemia Management Protocol

• Treat any glucose < 70 mg/dL immediately with 15 g of fast‑acting carbohydrate, re‑check in 15 minutes, and repeat if needed【186】.
• If hypoglycemia occurs without an obvious precipitant, reduce the implicated insulin dose by 10–20 % promptly【186】.

All recommendations are derived from the 2025 Diabetes Care guideline synthesis (American Diabetes Association) and represent a Class I, high‑quality evidence level where explicitly stated.

Discharge Management of Severe Uncontrolled Type 2 Diabetes with Acute Infection

Immediate Insulin Regimen Restructuring

• Increase basal insulin to 70–80 U once daily (≈0.5 U/kg for a 140 kg adult) to achieve adequate fasting control. [187][188]189
• Initiate 10–12 U rapid‑acting insulin before each of the three main meals to provide prandial coverage. [187][188]
• Add correction insulin: 2 U for pre‑meal glucose > 250 mg/dL and 4 U for > 350 mg/dL, on top of scheduled prandial doses. [187][188]

Basal‑Insulin Escalation Threshold

• Do not increase basal insulin beyond 0.5–1.0 U/kg/day (70–140 U); higher doses lead to “over‑basalization” with increased hypoglycemia without improving glycaemia. [187][190][188][189]

Metformin Optimization

• Start or titrate metformin to 2000 mg daily (1000 mg BID) unless contraindicated by infection‑related renal impairment. [190][191]
• Metformin reduces total insulin requirements by 20–30 % and yields superior glycaemic control when combined with insulin. [190][191]

Basal‑Insulin Titration Protocol

• Fasting glucose 140–179 mg/dL: increase basal insulin by 2 U every 3 days.
• Fasting glucose ≥180 mg/dL: increase basal insulin by 4 U every 3 days.
• Target fasting glucose 80–130 mg/dL. [187][190]

Prandial‑Insulin Titration Protocol

• Check glucose 2 h after each meal.
• If post‑prandial glucose > 180 mg/dL consistently, increase the insulin dose for that meal by 2 U every 3 days.
• Target post‑prandial glucose < 180 mg/dL. 187

Hypoglycemia Management

• Treat any glucose < 70 mg/dL immediately with 15 g fast‑acting carbohydrate. [187][190]
• If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20 % promptly. [187][190]

Follow‑Up and Referral Schedule

• 1–2 weeks post‑discharge: primary‑care or endocrinology visit to assess glucose control and infection resolution. [190][191]
• Monthly visits until HbA1c falls below 9 %; thereafter every 3 months. [187][188]189
• Urgent endocrinology referral required for HbA1c > 9 % with unstable glucose. [187][188][189][192]

Expected Clinical Outcomes with Basal‑Bolus Therapy

• 68 % of patients achieve mean glucose < 140 mg/dL versus 38 % with sliding‑scale insulin alone. [187][188]
• HbA1c reduction of 3–4 % (from ~12 % to 8–9 %) is achievable within 3–6 months. 187
• Properly implemented basal‑bolus regimens do not increase hypoglycemia risk compared with inadequate sliding‑scale approaches. 187

Discharge Medication Reconciliation

Patient Education Essentials

• Insulin injection technique & site rotation to prevent lipohypertrophy. [190][191]
• Hypoglycemia recognition & treatment (symptoms, <70 mg/dL threshold, 15‑g carbohydrate rule). [190][191]
• Sick‑day management: continue insulin even if not eating, check glucose every 4 h, maintain hydration. [190][191]
• Glucose monitoring: at least four daily measurements during titration. [187][190]
• Ketone testing when glucose > 300 mg/dL with nausea/vomiting. 190

Insulin Management for Severe Hyperglycemia in Nursing‑Home Residents Receiving Continuous Tube Feeding

Assessment of Hyperglycemia

• The American Diabetes Association (ADA) states that blood glucose values of 200–400 mg/dL on continuous tube feeding represent therapeutic failure and require immediate intervention to prevent long‑term complications. 193

Inadequate Current Regimen

• The ADA notes that a total daily insulin dose of only 20 units (5 U lispro TID + 5 U glargine BID) is profoundly insufficient for a 72‑year‑old patient with type 2 diabetes on continuous enteral nutrition. 193, 194
• The ADA emphasizes that a lispro dose of 5 U TID (15 U total) does not cover the continuous carbohydrate load delivered by tube feeding. 193, 194

Insulin Dose Calculation for Tube Feeding

• The ADA recommends calculating insulin needs for continuous tube feeding at approximately 1 unit per 10–15 g of carbohydrate in the enteral formula, in addition to adequate basal insulin. 193, 194
• The ADA advises determining the total carbohydrate content of the tube‑feeding formula over 24 hours to guide dosing. 193, 194
• The ADA reports that standard enteral formulas contain ≈100–150 g of carbohydrate per 1000 mL; the specific intake for each patient should be calculated. 193, 194

Basal Insulin Recommendations

• The ADA suggests allocating ≈50 % of the total daily insulin dose to basal insulin, e.g., an initial glargine dose of 15–25 units once daily, with subsequent titration upward. 193, 194

Nutritional (Prandial) Insulin Strategies

• The ADA recommends starting NPH insulin every 12 hours or regular insulin every 6 hours to cover the continuous nutritional load from tube feeding. 193, 194
• The ADA advises an initial nutritional insulin dose of 1 unit per 10–15 g of carbohydrate (e.g., 120 g CHO/day → 8–12 units total, divided appropriately). 193, 194

Correction‑Dose Insulin

• The ADA endorses using regular insulin every 6 hours or rapid‑acting insulin (lispro) every 4 hours as correction doses in addition to scheduled basal and nutritional insulin. 193, 194

Continuation of Basal Insulin When Feeding Is Interrupted

• The ADA advises continuing basal insulin even if tube feeding is stopped to prevent hyperglycemia and ketosis. 193, 194

Insulin Glargine Dosing and Titration in Hospitalized Patients with Type 2 Diabetes

Initial Dose Selection for High‑Risk Patients

• For hospitalized adults with type 2 diabetes who are considered high‑risk (e.g., age > 65 years, renal impairment, poor oral intake), start with a total daily dose of 0.1–0.25 U/kg/day (split basal‑bolus) to minimize hypoglycemia risk. 195

Basal‑Insulin (Glargine) Administration

• Administer 50 % of the total daily insulin dose as glargine once daily, preferably at 20:00 h, using a sub‑cutaneous abdominal, thigh, or deltoid site. 196

Prandial‑Insulin Administration

• Deliver the remaining 50 % of the total daily dose as rapid‑acting insulin divided among three meals, given 0–15 minutes before each meal. 195

Basal‑Insulin Titration Protocol

• If fasting glucose is 140–179 mg/dL, increase the glargine dose by 2 U every 3 days. 195
• If fasting glucose is ≥180 mg/dL, increase the glargine dose by 4 U every 3 days. 195
• Target fasting glucose range is 80–130 mg/dL. 195

Prandial‑Insulin Titration Protocol

• Based on the 2‑hour post‑prandial glucose, increase each meal dose by 1–2 U (≈10–15 %) every 3 days. 195
• Target post‑prandial glucose is <180 mg/dL. 195

Glucose Monitoring Frequency

• Patients with regular oral intake: measure capillary glucose before every meal and at bedtime. 195
• Patients who are NPO or have poor intake: measure glucose every 4–6 hours. 195

Critical Threshold for Basal‑Insulin Escalation

• When the glargine dose approaches 0.5–1.0 U/kg/day without meeting glycemic targets, add or intensify prandial insulin rather than further increasing basal insulin. 195

Management of Unexplained Hypoglycemia

• If a hypoglycemic episode occurs without a clear cause, reduce the implicated insulin dose by 10–20 % immediately. 195

Common Errors to Avoid

• Do not use rapid‑acting insulin at bedtime as a sole correction dose; this markedly raises the risk of nocturnal hypoglycemia. 195
• Do not continue increasing basal insulin beyond 0.5–1.0 U/kg/day without adding prandial coverage, as this leads to over‑basalization and higher hypoglycemia risk. 195

Insulin Management During Fasting in LADA

Basal Insulin Continuation

• Maintain basal insulin at a reduced dose (approximately 75 %–80 % of the usual total daily dose) throughout the fasting period to suppress hepatic glucose production even in the absence of food intake. This approach is supported by evidence from Diabetes Care (2024) and the British Journal of Anaesthesia (2016) and is considered a standard practice for patients with autoimmune diabetes. 197, 198

Prandial Insulin Holding

• Suspend all rapid‑acting (prandial) insulin doses during fasting hours because food‑stimulated glucose excursions are absent, and continuing prandial insulin increases the risk of hypoglycemia. This recommendation is based on the guideline presented in Diabetes Care (2024). 197

Prevention of Ketoacidosis

• Do not discontinue basal insulin entirely during fasting, as complete cessation can precipitate diabetic ketoacidosis in individuals with autoimmune diabetes. Continuous basal insulin, even at a reduced dose, provides essential suppression of lipolysis and ketogenesis. This safety measure is endorsed by both Diabetes Care (2024) and the British Journal of Anaesthesia (2016). 197, 198

Blood Glucose Notification and Management Guidelines for Patients on Basal Insulin

Critical Notification Thresholds

• Immediate provider notification is required when a patient’s blood glucose falls below 70 mg/dL or rises above 300 mg/dL; persistent hyperglycemia above 180 mg/dL also mandates notification. – American Diabetes Association 199

Hypoglycemia Notification Protocol

• Blood glucose <70 mg/dL should be treated promptly with 15 g fast‑acting carbohydrate and the healthcare team notified. – American Diabetes Association 199
• Blood glucose <54 mg/dL constitutes clinically significant hypoglycemia that requires urgent provider notification and insulin dose adjustment. – American Diabetes Association 200
• Any hypoglycemic episode must trigger a 10–20 % reduction in the implicated basal insulin dose before the next administration. – American Diabetes Association 199
• Every hypoglycemic event must be recorded in the medical record and tracked for quality‑improvement purposes. – American Diabetes Association 201
• 75 % of hospitalized patients who experience hypoglycemia receive no basal insulin dose adjustment before the next dose, underscoring the need for systematic notification. – American Diabetes Association 199

Hyperglycemia Notification Protocol

• Fasting glucose ≥180 mg/dL warrants notification for basal insulin titration, with an increase of 4 units every 3 days. – American Diabetes Association 199
• Random glucose ≥300 mg/dL requires immediate provider notification to evaluate for diabetic ketoacidosis, especially if accompanied by nausea, vomiting, or altered mental status. – American Diabetes Association 199
• Blood glucose >250 mg/dL with symptoms should prompt ketone testing (urine or blood) and urgent provider contact. – American Diabetes Association 199
• Fasting glucose 140–179 mg/dL on ≥2 occasions per week triggers notification for basal insulin adjustment, with an increase of 2 units every 3 days. – American Diabetes Association 199
• Persistent glucose >180 mg/dL despite optimized basal insulin indicates the need to consider adding prandial insulin. – American Diabetes Association 199

Hospital‑Specific Glucose Targets and Notification

Non‑Critically Ill Patients

• Target glucose range: 140–180 mg/dL for most non‑critically ill hospitalized patients. – American Diabetes Association 201
• Pre‑meal glucose <140 mg/dL with random glucose <180 mg/dL is reasonable if safely achievable. – American Diabetes Association 201
• More stringent targets of 110–140 mg/dL may be appropriate for selected stable patients with a history of tight control. – American Diabetes Association 201

Critically Ill Patients

• Initiate insulin therapy when glucose persistently exceeds 180 mg/dL. – American Diabetes Association 201
• Recommended target range: 140–180 mg/dL for the majority of critically ill patients. – American Diabetes Association 201
• More stringent goals of 110–140 mg/dL may be used for selected patients if achievable without significant hypoglycemia. – American Diabetes Association 201

Monitoring Frequency Requirements

Outpatient Setting

• Patients on basal insulin should check fasting glucose daily during the titration phase. – American Diabetes Association 200
• Patients on intensive insulin regimens may need 6–10 glucose checks per day (pre‑meal, bedtime, occasional post‑prandial, pre‑exercise, or when hypoglycemia is suspected). – American Diabetes Association 200
• For basal‑insulin‑only regimens, daily fasting glucose assessment is essential to guide dose adjustments. – American Diabetes Association 200

Inpatient Setting

• All hospitalized patients with diabetes must have glucose monitoring orders with results visible to the entire healthcare team. – American Diabetes Association 201
• Patients eating regular meals: check glucose before each meal and at bedtime. – American Diabetes Association 199
• Patients with poor oral intake or NPO: check glucose every 4–6 hours. – American Diabetes Association 199

Basal Insulin Escalation and “Over‑Basalization” Notification

• When basal insulin dose reaches 0.5–1.0 units/kg/day without achieving glycemic targets, the provider should be notified to consider adding prandial insulin rather than further basal escalation. – American Diabetes Association 199
• Clinical signals of “over‑basalization” that require notification include:
  
  • Basal dose >0.5 units/kg/day
  • Bedtime‑to‑morning glucose differential ≥50 mg/dL
  • Any hypoglycemia episodes
  • High glucose variability

Special Situations Requiring Immediate Notification

• Detectable ketones (urine or blood) with glucose >300 mg/dL mandate immediate provider notification to assess for diabetic ketoacidosis. – American Diabetes Association 199
• For patients with type 1 diabetes, ketone testing should be performed immediately if glucose >250 mg/dL with accompanying symptoms. – American Diabetes Association 199

Common Pitfalls to Avoid

• Do not delay notification when glucose consistently exceeds 180 mg/dL, as prolonged hyperglycemia increases complication risk. – American Diabetes Association 199
• Do not rely solely on correction insulin without notifying the provider about inadequate basal coverage; scheduled insulin doses must be adjusted. – American Diabetes Association 199
• Do not wait for multiple hypoglycemic episodes; a single unexplained glucose <70 mg/dL warrants immediate dose reduction and provider notification. – American Diabetes Association 199
• Never use sliding‑scale insulin as monotherapy without basal insulin coverage; this practice is condemned by major diabetes guidelines. – American Diabetes Association 199

Correction Insulin Dosing and Regimen Recommendations for Hyperglycemia

Correction Dose Recommendations

• For an adult with a random glucose of 327 mg/dL who is already on a scheduled basal‑bolus insulin regimen, administer 2 units of regular insulin as a correction dose. (American Diabetes Association) 202
• In a simplified sliding‑scale approach, a pre‑meal glucose >250 mg/dL warrants 2 units of short‑ or rapid‑acting insulin. (American Diabetes Association) 203
• A pre‑meal glucose >350 mg/dL warrants 4 units of short‑ or rapid‑acting insulin. (American Diabetes Association) 203
• Because 327 mg/dL falls between 250 mg/dL and 350 mg/dL, the appropriate correction dose is 2 units of regular insulin. (American Diabetes Association) 202

Sliding‑Scale Limitations and Guideline Stance

• All major diabetes guidelines condemn sliding‑scale insulin used as monotherapy, recommending it never be the sole treatment. (American Diabetes Association; American College of Physicians) [204][205]

Components of a Comprehensive Insulin Regimen

• Basal insulin (e.g., glargine, detemir, degludec) provides continuous background coverage and should be part of every insulin‑requiring patient’s regimen. (American Diabetes Association) [204][206]
• Prandial insulin (regular or rapid‑acting) is required to cover meal‑related glucose excursions. (American Diabetes Association) [204][206]
• Correction insulin must be administered in addition to scheduled basal and prandial doses; it is not a replacement for them. (American Diabetes Association) 204

Timing and Administration of Regular Insulin

• Regular insulin should not be given at bedtime as a sole correction dose, because this markedly increases the risk of nocturnal hypoglycemia. (American Diabetes Association) 202
• In hospitalized patients, correction insulin should be given subcutaneously every 6 hours using regular insulin. (American Diabetes Association) 204

Hospitalized Patient Management

• For patients eating regular meals, glucose should be checked before each meal and at bedtime. (American Diabetes Association) 204
• For patients with poor oral intake or NPO status, glucose should be checked every 4–6 hours. (American Diabetes Association) 204

Initiation of Basal‑Bolus Therapy for Severe Hyperglycemia

• When initiating therapy for severe hyperglycemia, start with a total daily dose of 0.3–0.5 units/kg/day. (American Diabetes Association) 206
• Split the total dose 50 % as basal insulin (once daily) and 50 % as prandial insulin divided among three meals. (American Diabetes Association) [204][206]

Assessment of Very High Glucose Levels

• If glucose exceeds 300 mg/dL with symptoms, evaluate for ketones (urine or blood) and consider diabetic ketoacidosis. (Anaesthesia) 207

Insulin Lispro Dosing and Management Guidelines

Initial Use and Indications

• For adults with type 2 diabetes, add lispro when basal insulin alone fails to meet glycemic targets after 3–6 months of optimization or when basal insulin exceeds 0.5 units/kg/day; initiate with 4 units before the largest meal or 10 % of the current basal dose【208】.
• In patients with severe hyperglycemia (HbA1c ≥ 9 % or glucose ≥ 300 mg/dL), start a basal‑bolus regimen immediately using a total dose of 0.3–0.5 units/kg/day split 50 % basal and 50 % prandial【208】.

Timing of Administration

• Inject lispro 0–15 minutes before meals—ideally immediately before eating—to achieve optimal post‑prandial glucose control【208】.

Prandial Dose Titration

• Increase each meal dose by 1–2 units (or 10–15 %) every 3 days based on the 2‑hour post‑prandial glucose; aim for post‑prandial glucose < 180 mg/dL【208】.
• If an unexplained hypoglycemic episode occurs, reduce the implicated dose by 10–20 % immediately【208】.

Carbohydrate‑Based Dosing

• Calculate an insulin‑to‑carbohydrate ratio (ICR) as 450 ÷ total daily insulin dose; e.g., a total daily dose of 45 units yields an ICR of 1 unit per 10 g carbohydrate【208】.
• Adjust the ICR if post‑prandial glucose consistently misses the target【208】.

Correction (Supplemental) Dosing

• Add 2 units for pre‑meal glucose > 250 mg/dL and 4 units for > 350 mg/dL (simplified sliding scale)【208】.
• For individualized correction, use an insulin sensitivity factor (ISF) = 1500 ÷ total daily insulin dose; correction dose = (Current glucose – Target glucose) ÷ ISF【208】.
• Correction insulin must always supplement a scheduled basal‑bolus regimen; it should never be used as monotherapy【208】.

Monitoring Requirements

• Check fasting glucose daily during titration to guide basal adjustments【208】.
• Measure pre‑meal glucose immediately before each meal to calculate correction doses【208】.
• Obtain a 2‑hour post‑prandial glucose to assess prandial adequacy and guide further titration【208】.
• Reassess HbA1c every 3 months during intensive titration【208】.

Limits on Basal Insulin Escalation

• When basal insulin reaches 0.5–1.0 units/kg/day without achieving targets, add or intensify prandial lispro rather than further increasing basal dose【208】.
• Indicators of “over‑basalization” include basal > 0.5 units/kg/day, bedtime‑to‑morning glucose drop ≥ 50 mg/dL, hypoglycemia, or high glucose variability【208】.

Hypoglycemia Management

• Treat glucose < 70 mg/dL promptly with 15 g fast‑acting carbohydrate, recheck in 15 minutes, and repeat if needed【208】.
• Never administer lispro at bedtime as a sole correction dose, as this markedly raises nocturnal hypoglycemia risk【208】.

Hospitalized (Non‑Critical) Patients

• Use a total insulin dose of 0.3–0.5 units/kg/day (50 % basal, 50 % prandial) divided among three meals for patients eating regular meals【208】.
• For high‑risk inpatients (age > 65, renal impairment, poor oral intake), start with 0.1–0.25 units/kg/day【208】.
• Check glucose before each meal and at bedtime; for NPO patients, monitor every 4–6 hours【208】.

Special Situations

• Continuous tube feeding: Approximate insulin need at 1 unit per 10–15 g carbohydrate in the formula; use NPH every 12 hours or regular insulin every 6 hours rather than lispro【208】.
• Glucocorticoid therapy: Increase prandial and correction insulin by 40–60 % in addition to basal insulin【208】.
• Concentrated U‑200 lispro: Available only in prefilled pens; consider when total daily lispro exceeds 60–80 units to reduce injection volume【208】.

Combination Therapy Considerations

• Continue metformin at the maximum tolerated dose (up to 2,000–2,550 mg/day) when adding lispro; metformin reduces total insulin requirements by 20–30 % and improves glycemic control【208】.
• Discontinue sulfonylureas when initiating basal‑bolus insulin to avoid additive hypoglycemia risk【208】.
• When basal insulin exceeds 0.5 units/kg/day, a GLP‑1 receptor agonist may be used instead of lispro, offering comparable post‑prandial control with less hypoglycemia and weight gain【208】.

Safety and Pitfalls

• Sliding‑scale insulin used as monotherapy is condemned by major diabetes guidelines as ineffective and unsafe【208】.
• Do not delay adding prandial insulin when basal insulin exceeds 0.5 units/kg/day without achieving targets【208】.
• Do not rely solely on correction doses without adjusting scheduled basal and prandial insulin, as this perpetuates inadequate control【208】.

Expected Clinical Outcomes

• With properly implemented basal‑bolus therapy using lispro, 68 % of patients achieve mean glucose < 140 mg/dL versus 38 % with sliding‑scale insulin alone【208】.
• HbA1c reductions of 2–3 % (or 3–4 % in severe hyperglycemia) are observed over 3–6 months with intensive titration【208】.
• Correctly executed basal‑bolus regimens do not increase overall hypoglycemia incidence compared with inadequate sliding‑scale approaches【208】.

Transitioning from Intravenous to Subcutaneous Basal‑Bolus Insulin in Severe Hyperglycemia

Dosing Calculations

• The American Diabetes Association (ADA) recommends initiating total daily insulin at 0.3–0.5 units/kg/day for patients with severe hyperglycemia (A1c ≥ 9 % or glucose ≥ 300 mg/dL)【209】.
• In a 122 kg patient, this weight‑based range corresponds to 37–61 units/day, but the observed IV insulin requirement (16 U/h) indicates markedly higher insulin resistance, justifying an initial subcutaneous total daily dose of ≈ 192 units【209】.

Basal Insulin (Long‑Acting)

• 50 % of the total daily dose should be given as basal insulin once daily; for a 192‑unit total dose this equals ≈ 96 units of insulin glargine (Lantus)【209】.
• When the basal dose approaches 0.5–1.0 units/kg/day (≈ 61–122 units for this patient), the ADA advises adding or intensifying prandial insulin rather than further increasing basal insulin alone【210】【209】.

Prandial (Rapid‑Acting) Insulin

• The remaining 50 % of the total daily dose is allocated to rapid‑acting insulin divided across three meals, yielding ≈ 96 units total or ≈ 32 units per meal【209】.
• Rapid‑acting analogs (lispro, aspart, glulisine) should be administered 0–15 minutes before meals to achieve optimal post‑prandial glucose control【209】.

Titration Protocols

Basal Insulin Titration

• Increase basal insulin by 2 units every 3 days if fasting glucose is 140–179 mg/dL【210】【209】.
• Increase basal insulin by 4 units every 3 days if fasting glucose is ≥ 180 mg/dL【210】【209】.
• Target fasting glucose range is 80–130 mg/dL【210】【209】.
• If unexplained hypoglycemia occurs, reduce the current basal dose by 10–20 % immediately【210】【209】.

Prandial Insulin Titration

• Adjust each prandial dose by 1–2 units (≈ 10–15 %) every 3 days based on the 2‑hour post‑prandial glucose reading【210】【209】.
• Target post‑prandial glucose is < 180 mg/dL【210】【209】.

Monitoring

• Daily fasting glucose checks are required during titration to guide basal insulin adjustments【210】【209】.

Safety Considerations

• Avoid using basal insulin > 0.5 units/kg/day (≈ 61 units) without concurrent prandial insulin, as this increases hypoglycemia risk without improving glycemic control【210】【209】.

Hypoglycemia Management

• Treat glucose < 70 mg/dL with 15 g of fast‑acting carbohydrate, re‑check in 15 minutes, and repeat if needed【210】【209】.
• When hypoglycemia occurs without an obvious precipitant, reduce the implicated insulin dose by 10–20 % promptly【210】【209】.

Special Patient Considerations

• In patients with BMI ≈ 41 kg/m² (severe obesity), insulin resistance is higher than predicted by weight‑based formulas, necessitating larger insulin doses【209】.

Implementation of Basal‑Bolus Insulin Therapy for Hospitalized Patients

Guideline Position on Sliding‑Scale Insulin

• The American Diabetes Association (ADA) condemns sliding‑scale insulin used as monotherapy because it reacts to hyperglycemia rather than preventing it, leading to dangerous glucose fluctuations. 211
• Only ≈38 % of patients treated with sliding‑scale alone achieve a mean glucose < 140 mg/dL, compared with ≈68 % when a scheduled basal‑bolus regimen is used. 211

Indications for Regimen Change

• In a patient whose six glucose readings include four values > 180 mg/dL, the pattern indicates inadequate basal insulin coverage and a complete lack of prandial insulin. 211
• A solitary fasting glucose of 125 mg/dL suggests marginal basal adequacy, but daytime values 202–244 mg/dL demonstrate the need for scheduled mealtime insulin. 211

Immediate Medication Adjustments

Discontinue Sliding‑Scale Monotherapy

• The ADA advises stopping correction‑only sliding‑scale insulin and transitioning immediately to a scheduled basal‑bolus regimen. 211
• Correction insulin should be used in addition to, not as a replacement for, scheduled basal and prandial doses. 211

Basal Insulin Titration (Insulin Glargine)

• Increase the basal dose by 4 units every 3 days until fasting glucose consistently falls within 80–130 mg/dL. 211
• Cease basal escalation when the dose approaches 0.5 units/kg/day; further glucose control should then be achieved by adding prandial insulin to avoid “over‑basalization.” 211

Initiate Scheduled Prandial Insulin

• Begin rapid‑acting insulin (lispro, aspart, or glulisine) at 4 units before each of the three largest meals. 211
• An alternative starting dose is ≈10 % of the current basal dose (≈3 units per meal). 211
• Administer the rapid‑acting insulin 0–15 minutes before meals for optimal post‑prandial control. 211

Correction‑Insulin Protocol (Adjunct to Prandial)

• Add 2 units of rapid‑acting insulin for pre‑meal glucose > 250 mg/dL. 211
• Add 4 units for pre‑meal glucose > 350 mg/dL. 211

Detailed Titration Protocols

Basal Insulin (Glargine)

Prandial Insulin

• Adjust each meal dose by 1–2 units (≈10–15 %) every 3 days based on the 2‑hour post‑prandial glucose.
• Target post‑prandial glucose < 180 mg/dL. 211

Monitoring Requirements

• Check fasting glucose daily to guide basal adjustments. 211
• Measure pre‑meal glucose before each meal to calculate correction doses. 211
• Obtain a 2‑hour post‑prandial glucose after each meal to assess prandial adequacy. 211
• Record a bedtime glucose to evaluate overall daily pattern. 211

Expected Clinical Outcomes

• With a properly implemented basal‑bolus regimen, ≈68 % of patients achieve a mean glucose < 140 mg/dL versus ≈38 % on sliding‑scale alone. 211
• Basal‑bolus therapy does not increase hypoglycemia incidence compared with inadequate sliding‑scale approaches. 211
• For non‑critically ill hospitalized patients, the ADA target glucose range is 140–180 mg/dL. 211

Safety Pitfalls to Avoid

• Do not continue sliding‑scale insulin as the sole regimen when glucose values repeatedly exceed 180 mg/dL; this strategy is inferior and unsafe. 211
• Do not delay adding prandial insulin when daytime glucose values are in the 200 s, as this clearly indicates the need for meal‑time coverage. 211
• Avoid using rapid‑acting insulin only at bedtime for correction, because it markedly raises nocturnal hypoglycemia risk. 211
• Do not increase basal insulin beyond 0.5–1.0 units/kg/day without addressing post‑prandial hyperglycemia, to prevent over‑basalization and hypoglycemia. 211

Hypoglycemia Management

• Treat any glucose < 70 mg/dL immediately with 15 g of fast‑acting carbohydrate, recheck in 15 minutes, and repeat if necessary. 211
• If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20 % promptly. 211

Adjunctive (Foundation) Therapy Considerations

• Continue metformin at the maximum tolerated dose (up to 2,550 mg/day) unless contraindicated; this combination reduces total insulin requirements by 20–30 %. 211
• Discontinue sulfonylureas when initiating basal‑bolus insulin to avoid additive hypoglycemia risk. 211

Initial Insulin Selection for Adults with Type 2 Diabetes – Evidence‑Based Recommendations

Indications for Initiating Basal Insulin Glargine

• In adults with type 2 diabetes whose HbA1c is ≥ 9 % or ≥ 8 % with hyperglycaemic symptoms, basal insulin glargine should be started at ≈ 10 units once daily (or 0.1–0.2 U/kg/day) while continuing metformin unless contraindicated【212】.
• When fasting plasma glucose remains > 180 mg/dL despite optimized oral therapy, basal insulin glargine is indicated as the initial insulin regimen【212】.

Contraindications and Safety Risks of Premixed 70/30 Insulin

• Premixed 70/30 insulin is contraindicated in hospitalized patients because randomized trials showed a 64 % hypoglycaemia rate versus 24 % with basal‑bolus therapy, leading to early trial termination【213】【214】.
• The same inpatient data suggest that premixed formulations carry an excessive hypoglycaemia risk even in outpatient settings【213】【214】.
• Fixed basal‑to‑prandial ratio (70 % : 30 %) cannot be adjusted independently, increasing hypoglycaemia risk when meal intake varies【213】【214】.
• Premixed 70/30 insulin requires twice‑daily injections (before breakfast and dinner), reducing dosing flexibility【212】.
• Use of premixed insulin mandates consistent meal timing and carbohydrate intake, limiting its suitability for patients with variable eating patterns【213】【214】.
• Major diabetes guideline bodies do not recommend premixed 70/30 insulin for initial insulin therapy or for use in hospitals【213】【214】.

Titration, Escalation, and Combination Strategies for Basal Insulin Glargine

• Systematic titration: increase glargine by 2 U every 3 days if fasting glucose is 140–179 mg/dL, or by 4 U every 3 days if fasting glucose is ≥ 180 mg/dL, aiming for a fasting target of 80–130 mg/dL【212】.
• When the basal dose reaches ≈ 0.5 U/kg/day (or up to 1.0 U/kg/day) without achieving HbA1c goals, add prandial insulin (e.g., 4 U before the largest meal) rather than further basal escalation【212】.
• Stepwise intensification is supported: basal insulin can be increased up to 0.5 U/kg/day; beyond this threshold, prandial insulin should be introduced to address post‑prandial hyperglycaemia【212】.

Economic Impact of Hypoglycaemia Associated with Premixed Insulin

• Although premixed insulin may appear less expensive per unit, the higher hypoglycaemia rates generate substantial additional healthcare costs from emergency visits and hospitalisations【213】【214】.

*All statements are derived from peer‑reviewed evidence (Lancet Diabetes & Endocrinology 2021; Diabetes Care 2018). Strength of evidence is high for safety outcomes (randomised controlled trials) and moderate for dosing algorithms (clinical practice guidelines).

Basal‑Bolus Insulin Therapy for Non‑Critically Ill Hospitalized Adults

Guideline Recommendation

• The American Diabetes Association (ADA) explicitly condemns the use of sliding‑scale insulin as monotherapy for hospitalized patients because it reacts to hyperglycemia rather than preventing it, leading to wide glucose fluctuations and poorer outcomes【215】.

Comparative Efficacy

• In non‑critically ill hospitalized adults, only ≈38 % of patients managed with sliding‑scale insulin alone achieve a mean glucose < 140 mg/dL, whereas ≈68 % reach this target when a scheduled basal‑bolus regimen is used, without an increase in hypoglycemia when the regimen is correctly applied【215】.
• Treatment failure (defined as > 2 consecutive glucose readings > 240 mg/dL) occurs in 0–2 % of patients on basal‑bolus therapy versus ≈19 % on sliding‑scale insulin alone【215】.

Contraindication of Metformin in the Hospital Setting

• The ADA advises that metformin should be withheld in hospitalized patients with acute infection (e.g., cellulitis) because the combination of hypoperfusion, renal impairment, and tissue hypoxia markedly raises the risk of lactic acidosis【215】.
• The most common risk factors for metformin‑associated lactic acidosis—cardiac disease, hypoperfusion, renal insufficiency, and acute illness—are substantially more prevalent during inpatient stays, reinforcing the contraindication【215】.
• Metformin’s delayed onset of action (days to weeks) makes it insufficient for rapidly lowering glucose levels in the 300–320 mg/dL range observed in acute hospital hyperglycemia【215】.

Initial Basal‑Bolus Dosing (Adult Approx. 70 kg)

• For an adult patient weighing ~70 kg with admission glucose 300–320 mg/dL, start with a total daily insulin dose of 0.3–0.5 U/kg (≈ 21–35 U/day)【215】.
• Allocate 50 % of the total dose to basal insulin (e.g., glargine or detemir) → ≈ 11–18 U once daily【215】.
• Allocate the remaining 50 % to prandial insulin (rapid‑acting analogues) → ≈ 11–18 U divided across three meals (≈ 4–6 U per meal)【215】.
• Add correction dosing: 2 U for pre‑meal glucose > 250 mg/dL; 4 U for glucose > 350 mg/dL【215】.

Titration Protocol

• Basal insulin: increase by 2 U every 3 days if fasting glucose is 140–179 mg/dL; increase by 4 U every 3 days if fasting glucose ≥ 180 mg/dL【215】. Target fasting glucose: 80–130 mg/dL【215】.
• Prandial insulin: increase each meal dose by 1–2 U every 3 days based on 2‑hour post‑prandial glucose; target post‑prandial glucose < 180 mg/dL【215】.
• Hypoglycemia management: for glucose < 70 mg/dL, treat with 15 g fast‑acting carbohydrate and reduce the implicated insulin dose by 10–20 %【215】.

Monitoring Requirements

• Measure capillary glucose before each meal and at bedtime (minimum four times daily) to guide insulin adjustments【215】.
• Use daily fasting glucose to titrate basal insulin and 2‑hour post‑prandial glucose to titrate prandial doses【215】.

Expected Clinical Outcomes

• With properly implemented basal‑bolus therapy, ≈68 % of non‑critically ill hospitalized adults achieve mean glucose < 140 mg/dL, compared with ≈38 % on sliding‑scale alone【215】.
• The incidence of hypoglycemia does not increase when basal‑bolus regimens are correctly applied versus sliding‑scale monotherapy【215】.

All statements are derived from ADA guideline recommendations (Diabetes Care, 2008) and represent strong guideline consensus, though specific evidence grading was not provided in the source material.

Transition from Intravenous Insulin Infusion to Subcutaneous Basal‑Bolus Therapy

Total Daily Subcutaneous Dose Calculation

• In an adult patient with severe insulin resistance, the total daily subcutaneous insulin dose (TDD) should be set equal to the 24‑hour IV insulin amount delivered during the stable‑control period (e.g., 6.5 U/h × 24 h = 156 U/day). 216

Basal Insulin (Glargine) Dosing

• Allocate 50 % of the TDD to basal insulin, resulting in an initial glargine dose of approximately 78 U once daily. 216
• Administer the basal injection 2–4 hours before stopping the IV insulin infusion and continue the IV infusion for an additional 1–2 hours to ensure adequate subcutaneous absorption. 216

Prandial (Rapid‑Acting) Insulin Dosing

• Allocate the remaining 50 % of the TDD to prandial insulin, dividing the total (≈78 U) equally among three meals (≈26 U per meal). 216
• Use a rapid‑acting analog (lispro, aspart, or glulisine) administered 0–15 minutes before meals. 216

Simplified Correction Scale (Pre‑Meal Hyperglycemia)

• Add 2 U of rapid‑acting insulin for pre‑meal glucose >250 mg/dL and 4 U for glucose >350 mg/dL, in addition to the scheduled prandial dose. 216

Monitoring Requirements During Transition

• Perform capillary glucose checks before each meal and at bedtime (minimum four times daily). 216
• Measure fasting glucose daily to guide basal insulin titration. 216
• Monitor serum potassium every 2–4 hours while transitioning, because insulin drives potassium intracellularly. 216

Basal Insulin Titration Protocol

• Increase basal glargine by 2 U every 3 days if fasting glucose is 140–179 mg/dL. 216
• Increase basal glargine by 4 U every 3 days if fasting glucose is ≥180 mg/dL. 216
• Target fasting glucose 80–130 mg/dL; reduce basal dose by 10–20 % immediately if unexplained hypoglycemia (<70 mg/dL) occurs. 216

Prandial Insulin Titration Protocol

• Adjust each meal’s rapid‑acting dose by 1–2 U (≈10–15 %) every 3 days based on the 2‑hour post‑prandial glucose reading. 216
• Target post‑prandial glucose <180 mg/dL. 216

Critical Threshold for Basal Insulin Escalation

• When basal insulin reaches 0.5–1.0 U/kg/day (≈61–122 U for a 122‑kg patient), stop further basal increases and focus on prandial dose escalation to avoid “over‑basalization” and heightened hypoglycemia risk. 216

Hypoglycemia Management

• Treat glucose <70 mg/dL promptly with 15 g of fast‑acting carbohydrate, rechecking in 15 minutes and repeating if needed. 216
• Avoid using rapid‑acting insulin as a sole bedtime correction dose, as this markedly raises nocturnal hypoglycemia risk. 216

Common Pitfalls to Avoid

• Do not discontinue the IV insulin infusion without first overlapping with a subcutaneous basal dose given 2–4 hours earlier; failure to do so is the most frequent cause of recurrent diabetic ketoacidosis. 216
• Do not rely on sliding‑scale insulin alone; correction doses must supplement a scheduled basal‑bolus regimen. 216
• Do not continue escalating basal insulin beyond 0.5–1.0 U/kg/day without addressing post‑prandial hyperglycemia, to prevent over‑basalization and associated hypoglycemia. 216

Rapid‑Acting Insulin Management for Steroid‑Induced Hyperglycemia

Pathophysiology of Steroid‑Induced Hyperglycemia

• High‑dose glucocorticoid therapy (e.g., morning prednisone) predominantly raises blood glucose in the afternoon and evening, with the hyperglycemic peak occurring 4–12 hours after the dose【217】 (American Diabetes Association, ADA).
• Steroid‑related insulin resistance typically necessitates a 40–60 % increase in prandial and correction insulin requirements compared with a patient’s baseline regimen【217】 (ADA).

Initial Rapid‑Acting Insulin Dosing

• Lunch: Begin with ~6 units of rapid‑acting insulin administered 0–15 minutes before the meal; this approximates 10 % of the basal NPH dose plus additional units to counteract steroid effect【217】【218】 (ADA).
• Correction for pre‑lunch glucose >200 mg/dL: Add 2 units of rapid‑acting insulin【217】 (ADA).
• Total lunch dose: Approximately 8 units (carbohydrate coverage + correction)【217】 (ADA).
• Dinner: Start with 6 units of rapid‑acting insulin before the meal【217】 (ADA).
• Correction for pre‑dinner glucose >300 mg/dL: Add 4 units (2 units for >250 mg/dL plus an additional 2 units for >300 mg/dL)【217】 (ADA).
• Total dinner dose: Approximately 10 units (carbohydrate coverage + correction)【217】 (ADA).

Carbohydrate‑to‑Insulin Ratio (CIR)

• A 1:10 ratio (1 unit per 10 g carbohydrate) is a reasonable starting point, but steroid‑induced resistance often requires tightening the ratio to 1:8 or even 1:6–7 for lunch and dinner【219】【217】 (ADA).

Correction‑Insulin Protocol

• Pre‑meal glucose 201–250 mg/dL → add 2 units rapid‑acting insulin【217】 (ADA).
• Pre‑meal glucose 251–350 mg/dL → add 4 units rapid‑acting insulin【217】 (ADA).
• Pre‑meal glucose >350 mg/dL → add 6 units rapid‑acting insulin and evaluate for ketones【217】 (ADA).
• These correction units are in addition to the carbohydrate‑coverage dose【217】 (ADA).

Titration & Monitoring Schedule

• Every 3 days: Increase the lunch dose by 2 units if the 2‑hour post‑lunch glucose is consistently >180 mg/dL; similarly increase the dinner dose by 2 units under the same condition【217】【218】【220】 (ADA).
• Target: 2‑hour post‑prandial glucose <180 mg/dL【217】 (ADA).
• Hypoglycemia response: For glucose <70 mg/dL, treat with 15 g fast‑acting carbohydrate and reduce the implicated meal dose by 10–20 % (≈1–2 units)【217】 (ADA).
• Glucose monitoring: Check glucose before each meal and at bedtime (≥4 times daily), obtain 2‑hour post‑prandial values after lunch and dinner, and measure fasting glucose daily to guide basal adjustments【217】 (ADA).

Basal (NPH) Insulin Adjustment

• The standard 20 units NPH at 8 AM is often insufficient for adequate daytime basal coverage in the setting of high‑dose steroids【217】 (ADA).
• Increase NPH to 24–28 units (increment of 4 units every 3 days) if fasting glucose remains >130 mg/dL【217】 (ADA).
• Alternative regimen: Split NPH into twice‑daily dosing (e.g., 14 units morning, 10 units bedtime) to improve afternoon/evening basal support【217】 (ADA).
• Morning NPH dosing is specifically recommended to align basal insulin with the steroid’s peak effect【217】 (ADA).

Safety & Practical Pitfalls

• Do not rely solely on correction insulin; scheduled prandial doses are required to address persistent hyperglycemia【217】 (ADA).
• Do not delay initiation of prandial insulin when pre‑meal glucose repeatedly exceeds 180 mg/dL on high‑dose steroids【217】 (ADA).
• Avoid increasing NPH beyond 0.5 units/kg/day (≈35–40 units for most adults) without concurrently managing post‑prandial hyperglycemia【217】 (ADA).
• Sliding‑scale insulin as monotherapy is discouraged by major diabetes guidelines due to erratic glucose control【217】 (ADA).
• Never use rapid‑acting insulin as a sole bedtime correction dose, as this markedly raises the risk of nocturnal hypoglycemia【217】 (ADA).

Expected Clinical Outcomes

• When basal‑bolus therapy is appropriately adjusted for steroid effect, ≈68 % of patients achieve a mean glucose <140 mg/dL, compared with ≈38 % using sliding‑scale insulin alone【217】 (ADA).
• Total daily insulin requirements may be 40–60 % higher than baseline, often reaching 10–15 units per meal after full titration【217】 (ADA).

Guidelines for Tapering Insulin Glargine (Lantus)

Indications for Tapering

• Tapering Lantus is recommended when improved glucose control makes the current dose cause hypoglycemia or when patients are transitioning from insulin back to oral agents after resolution of acute hyperglycemia. 221

Immediate Dose‑Reduction Protocol

Hypoglycemia‑Driven Reductions

• Reduce the basal insulin dose by 10–20 % immediately if any unexplained hypoglycemic episode (glucose < 70 mg/dL) occurs. 221, 222
• If more than two fasting glucose values per week fall below 80 mg/dL, decrease the basal dose by 2 units. 221
• For recurrent nocturnal hypoglycemia (midnight–6 AM), reduce the evening Lantus dose by 10–20 % and reassess within 3 days. 221, 222

Adjustments for High‑Risk Populations

• In elderly patients (>65 years), those with renal impairment (eGFR < 45 mL/min), or patients with poor oral intake, target a basal dose of 0.1–0.25 units/kg/day to minimize hypoglycemia risk. 221
• For hospitalized patients on high‑dose home insulin (≥0.6 units/kg/day), reduce the total daily dose by 20 % upon admission. 221
• In CKD stage 5, reduce total daily insulin by 50 % for type 2 diabetes and by 35–40 % for type 1 diabetes. 221

Transitioning Off Insulin Therapy

After Acute Illness in Type 2 Diabetes

• Begin tapering Lantus by 10–15 % every 3–7 days while simultaneously optimizing oral therapy (e.g., metformin up to 2000 mg daily). 221, 222
• Monitor fasting glucose daily; if fasting glucose stays 80–130 mg/dL for three consecutive days, continue tapering by another 10–15 %. 221
• Discontinue Lantus completely when fasting glucose remains <130 mg/dL on a dose ≤10 units/day for one week and oral agents are optimized. 221

Glucocorticoid‑Induced Hyperglycemia

• As steroid doses are tapered or stopped, reduce Lantus proportionally—typically by 40–60 % reflecting the waning steroid effect. 221

Peri‑operative or NPO Situations

• On the morning of surgery or when a patient becomes NPO, administer 75–80 % of the usual long‑acting analog dose (or 50 % of an NPH dose) to maintain basal coverage while lowering hypoglycemia risk. 221, 222
• Never fully discontinue basal insulin in patients with type 1 diabetes or insulin‑dependent type 2 diabetes, even when NPO, to prevent diabetic ketoacidosis. 221, 222

Monitoring Requirements During Tapering

• Check fasting glucose daily to guide basal insulin adjustments. 221
• Measure glucose before each meal and at bedtime for patients consuming regular meals. 221
• For patients with poor oral intake or NPO status, check glucose every 4–6 hours. 221
• Reassess HbA1c every 3 months throughout and after tapering to ensure sustained glycemic control. 221

Adjunctive Therapies

Optimizing Oral Agents

• Continue or maximize metformin (up to 2000–2550 mg daily) as Lantus is tapered; this combination typically reduces insulin requirements by 20–30 %. 221

Adding GLP‑1 Receptor Agonists

• When basal insulin exceeds 0.5 units/kg/day and HbA1c remains above target, consider adding a GLP‑1 receptor agonist to enable insulin dose reduction while maintaining control. 221, 222, 223

Critical Thresholds & Warning Signs of Over‑Basalization

• Basal insulin dose >0.5 units/kg/day without achieving glycemic targets. 221
• Bedtime‑to‑morning glucose differential ≥50 mg/dL, indicating excess overnight basal insulin. 221
• Recurrent hypoglycemia (glucose < 70 mg/dL) or high glucose variability signals the need to taper. 221
• When any of these signs are present, reduce basal insulin by 10–20 % and add prandial insulin or a GLP‑1 RA rather than further escalating basal dose. 221

Common Pitfalls to Avoid

• Do not abruptly discontinue Lantus in type 1 diabetes or insulin‑dependent type 2 diabetes, as this can precipitate diabetic ketoacidosis. 221, 222
• Do not delay dose reduction when hypoglycemia occurs; studies show 75 % of hospitalized patients with hypoglycemia receive no basal insulin adjustment before the next dose. 221
• Do not taper Lantus without first optimizing oral agents (especially metformin), which can lead to inadequate glycemic control. 221
• Do not rely solely on correction insulin after basal taper; scheduled insulin or oral agents must be adjusted to maintain control. 221

Special Populations

Palliative Care & End‑of‑Life

• In older adults receiving palliative care, simplify regimens by tapering or discontinuing Lantus, focusing on comfort and preventing symptomatic hyperglycemia (>250 mg/dL) or hypoglycemia. 222
• Adjust insulin doses every 2 weeks based on finger‑stick glucose testing in this population. 222

Postpartum Period

• Immediately after delivery, reduce Lantus by 50 % and titrate further based on glucose patterns, reflecting the dramatic postpartum decline in insulin requirements. 221

Immediate Insulin Correction and Post‑Prandial Management in Adults with Type 1 Diabetes

Immediate Correction Dose

• In adults with type 1 diabetes, a rapid‑acting insulin correction should be given promptly when a glucose reading exceeds 180 mg/dL, because hyperglycemia above this threshold warrants immediate intervention. 224

Post‑Prandial Glucose Monitoring

• After each meal, a 2‑hour post‑prandial glucose check is recommended for adults with type 1 diabetes; the target value is < 180 mg/dL to confirm adequate prandial insulin coverage. 224

Physical Activity Considerations

• If moderate‑to‑vigorous physical activity occurs within 1–2 hours of a mealtime insulin dose, the insulin amount should be reduced (to lower hypoglycemia risk); this adjustment is not applicable when the primary issue is persistent post‑prandial hyperglycemia. 225

Insulin Dose Adjustment When Initiating GLP‑1 Receptor Agonist and Metformin

Initial Basal Insulin Reduction

• The American College of Cardiology recommends reducing the basal insulin (insulin glargine) dose by approximately 20 %—for example, from 132 units to ≈ 105 units—on the day semaglutide (Ozempic) and metformin are started, then titrate based on glucose monitoring to avoid hypoglycemia. 226, 227

Rationale for Reducing Basal Insulin (Avoiding Over‑basalization)

• A 20 % reduction is specifically advised because reductions greater than 20 % may lead to rebound hyperglycemia, while no reduction leaves patients at high risk of hypoglycemia when two additional glucose‑lowering agents are added. 226
• Fasting glucose levels around 215 mg/dL indicate insufficient basal coverage; adding GLP‑1 agonist and metformin without adjusting insulin markedly increases hypoglycemia risk. 226, 227
• Basal insulin exceeding ≈ 0.5 units/kg/day (roughly 60–80 units for most adults) is considered “over‑basalization”; at this threshold, adding a GLP‑1 receptor agonist is preferred to further insulin escalation. 226

Titration Protocol for Basal Insulin

• Increase the basal insulin dose by 4 units every 3 days if fasting glucose remains ≥ 180 mg/dL. 226
• Increase the basal insulin dose by 2 units every 3 days if fasting glucose is 140–179 mg/dL. 226
• Aim for a target fasting glucose of 80–130 mg/dL. 226
• If any unexplained hypoglycemia (< 70 mg/dL) occurs, immediately reduce the basal insulin dose by 10–20 %. 226

Monitoring Requirements

• Check fasting glucose daily during the first 3–4 weeks after initiating the combination therapy. 226, 227
• Any fasting glucose reading < 70 mg/dL should prompt immediate contact with a healthcare provider. 226
• Persistent nausea, vomiting, or abdominal pain—potential signs of pancreatitis or ketoacidosis—also warrants prompt medical evaluation. 226, 227

Role of Metformin in Combination Therapy

• Metformin should be started at ≈ 2000 mg daily (typically 1000 mg twice daily with meals) to provide insulin‑sparing effects. 228
• Metformin reduces total insulin requirements by 20–30 % and offers complementary glucose‑lowering mechanisms, making it a foundational therapy when adding GLP‑1 agonists. 228
• Metformin should not be discontinued after initiation unless contraindicated, as it continues to provide essential insulin‑sparing benefits. 228

Adverse Effects of Semaglutide (Ozempic)

• Transient nausea occurs in ≈ 21–22 % of patients receiving semaglutide; starting at the lowest dose (0.25 mg weekly) and gradual up‑titration, along with smaller meals, can minimize this side effect. 227

Insulin Lispro Dosing Guidelines for Adults with Type 1 Diabetes

Total Daily Insulin Requirements

• Adults with type 1 diabetes need 0.4–1.0 units/kg/day of total insulin; a starting dose of 0.5 units/kg/day is recommended for metabolically stable individuals. 229
• 50–60 % of the total daily dose should be allocated to prandial (mealtime) insulin, with the remaining 40–50 % given as basal insulin. 229
• Higher total daily doses (up to 1.5 units/kg/day) are required during puberty, pregnancy, or acute illness. 229

Initial Prandial Lispro Dose Calculation

• For an adult weighing approximately 70 kg on a total daily dose of 0.5 units/kg/day (≈35 units), allocate ≈18–21 units to prandial insulin, resulting in ≈6–7 units per meal across three meals. 229

Timing of Lispro Administration

• Lispro should be injected 0–15 minutes before meals (ideally immediately before eating) to achieve optimal post‑prandial glucose control. 229
• Lispro must not be used at bedtime as a sole correction dose, as this markedly raises the risk of nocturnal hypoglycemia. 229

Dose Titration and Glycemic Targets

• Adjust each meal dose by 1–2 units (≈10–15 %) every 3 days based on the 2‑hour post‑prandial glucose reading. 229
• Aim for a post‑prandial glucose <180 mg/dL. 229
• If an unexplained hypoglycemic episode (<70 mg/dL) occurs, reduce the implicated dose by 10–20 % immediately. 229

Monitoring Requirements

• Perform daily fasting glucose checks to guide basal insulin adjustments. 229
• Basal insulin (e.g., glargine, detemir, degludec) supplies the remaining 40–50 % of total daily insulin via once‑ or twice‑daily injections. 229

Safety and Clinical Pitfalls

• Sliding‑scale insulin should not be used as monotherapy in type 1 diabetes, as it can precipitate diabetic ketoacidosis. 229
• Avoid administering lispro at bedtime for correction alone, due to the heightened risk of nocturnal hypoglycemia. 229

Special Situations

Carbohydrate‑to‑Insulin Ratio (CIR) Variability

• The CIR often varies throughout the day; greater insulin per gram of carbohydrate is typically needed at breakfast because of counter‑regulatory hormones (cortisol, growth hormone). 230

Insulin Pump Therapy

• In pump therapy, the basal rate accounts for ≈40–60 % of total daily insulin, with the remainder delivered as mealtime and correction boluses. 230
• The pump’s on‑board calculator uses pre‑programmed CIR and insulin sensitivity factor (ISF) to compute bolus doses, incorporating “insulin on board” to prevent dose stacking. 230

Flexible Meal Timing with Lispro

• Lispro’s rapid onset permits flexible meal timing; patients can inject immediately before eating without the 30–45‑minute waiting period required for regular insulin. 230
• Doses can be adjusted based on the actual carbohydrate content of the meal using the individualized CIR. 230

Assessment and Escalation Criteria for Severe Hyperglycemia

Ketone Evaluation in High‑Risk Patients

• In patients with type 1 diabetes or who are insulin‑dependent, clinicians should check urine or blood ketones—especially when nausea, vomiting, abdominal pain, or altered mental status are present—to promptly identify early diabetic ketoacidosis. 231

Glucose Thresholds Prompting Immediate Provider Notification

• For any inpatient with a random blood glucose < 70 mg/dL (3.9 mmol/L), the care team must contact the treating provider immediately to address potential hypoglycemia. 232
• If a patient’s glucose exceeds 250 mg/dL at any point within a 24‑hour period, the provider should be notified as soon as possible to evaluate for worsening hyperglycemia or impending emergency. 232
• When glucose values remain > 300 mg/dL on two consecutive days, the provider must be called to consider escalation of care (e.g., assessment for DKA/HHS, insulin regimen adjustment). 232

Evidence‑Based Management of Uncontrolled Type 2 Diabetes on Metformin

Medication Initiation and Dosing

• Restart sitagliptin 100 mg once daily in addition to metformin; this combination yields an additional 0.5–0.8 % reduction in HbA1c when added to metformin therapy【233】.
• Continue metformin at a total daily dose of 2000 mg (1000 mg twice daily) as the foundational therapy for type 2 diabetes【234】【233】.
• Initiate basal insulin glargine at 10 units once daily at bedtime (approximately 0.1–0.2 units/kg) for patients whose fasting glucose remains 200–300 mg/dL despite metformin【233】.

Guideline Recommendations

• The American Diabetes Association (ADA) recommends early insulin initiation when fasting glucose exceeds 180 mg/dL despite oral agents【233】.
• Clinical guidelines explicitly endorse the combination of metformin plus basal insulin for patients requiring intensified glucose control【234】【233】.

Role of Metformin When Adding Insulin

• Metformin reduces total insulin requirements by 20–30 % and achieves superior glycemic control compared with insulin alone【234】.
• It provides weight‑neutral or modest weight‑loss effects and improves cardiovascular outcomes【235】.
• Discontinuation of metformin when insulin is added leads to higher insulin doses and greater weight gain; therefore, metformin should be maintained unless contraindicated【234】【233】.
• The drug should be titrated to the maximum tolerated dose (up to 2000–2550 mg daily) when combined with insulin【234】.

Basal Insulin Efficacy and Targets

• Adding basal insulin contributes an additional 1.5–2.0 % HbA1c reduction on top of metformin (and sitagliptin, if used)【233】.
• The target fasting glucose for titration is 80–130 mg/dL【233】.

Rationale for Prioritizing Insulin Over SGLT2i/GLP‑1 RA in Severe Hyperglycemia

• Although SGLT2 inhibitors and GLP‑1 receptor agonists confer cardiovascular and renal benefits【236】【234】, patients with fasting glucose 200–300 mg/dL (or HbA1c ≥ 9 %) require more aggressive glucose‑lowering, for which insulin is the most effective agent【235】【233】.

Alternative Second‑Line Options (When Sitagliptin Not Used)

• Empagliflozin 10 mg daily or canagliflozin 100 mg daily lower HbA1c by 0.5–0.7 % and provide cardiovascular/renal protection; they can be combined with metformin and insulin【236】【234】.
• SGLT2 inhibitors are especially beneficial in patients with established cardiovascular disease, heart failure, or chronic kidney disease【236】【234】.

Monitoring and Titration (Evidence‑Based Protocol)

• Daily fasting glucose checks are recommended during basal insulin titration to guide dose adjustments【233】.
• Target fasting glucose range: 80–130 mg/dL【233】.

All facts are derived from peer‑reviewed sources indicated by the citation IDs. Strength of evidence was not explicitly stated in the source material.

Insulin Management for Steroid‑Induced Hyperglycemia in Type 2 Diabetes

Initiation of Therapy

• Begin basal insulin (glargine or detemir) at 10 U once daily (≈0.1–0.2 U/kg) for patients on prednisone with fasting glucose ≥ 180 mg/dL or symptomatic hyperglycemia, while continuing metformin unless contraindicated. – American Diabetes Association (ADA) recommendation. 237
• Add rapid‑acting insulin (lispro, aspart, or glulisine) 4–6 U before lunch and dinner to counter the afternoon/evening glucose peak caused by morning prednisone dosing. – ADA recommendation. 238
• For severe hyperglycemia (random glucose > 300 mg/dL or A1C ≥ 9 %), start a higher total dose of 0.3–0.5 U/kg/day split between basal and prandial insulin. – ADA recommendation. 237

Basal‑Insulin Titration

• Increase basal insulin by 4 U every 3 days if fasting glucose remains ≥ 180 mg/dL; increase by 2 U every 3 days if fasting glucose is 140–179 mg/dL, targeting a fasting range of 80–130 mg/dL. – ADA recommendation. 238
• When basal insulin approaches 0.5 U/kg/day without achieving targets, prioritize intensifying prandial insulin rather than further basal escalation to avoid “over‑basalization” and hypoglycemia. – ADA recommendation. 239

Prandial‑Insulin Titration

• Increase prandial insulin by 2 U every 3 days based on 2‑hour post‑prandial glucose values, aiming for post‑prandial glucose < 180 mg/dL. – ADA recommendation. 237

Integration of Metformin

• Continue metformin at the maximum tolerated dose (up to ~2500 mg/day) when insulin is added; the combination reduces total insulin requirements by 20–30 % and yields superior glycemic control versus insulin alone. – ADA recommendation. 240
• Do not discontinue metformin when initiating insulin unless specific contraindications exist (e.g., acute infection, renal impairment, tissue hypoxia). – ADA recommendation. 240

Monitoring Protocol

• Check fasting glucose daily during titration to guide basal adjustments; also measure pre‑meal glucose before lunch and dinner and obtain 2‑hour post‑prandial values after those meals to guide prandial titration. – ADA recommendation. 238
• If any glucose reading falls < 70 mg/dL, reduce the implicated insulin dose by 10–20 % and treat with ~15 g of fast‑acting carbohydrate. – ADA recommendation. 238

Adjunct Oral Agents & Safety Adjustments

• Discontinue or reduce sulfonylureas by 50 % when starting insulin to prevent additive hypoglycemia risk. – ADA recommendation. 237

Expected Clinical Outcomes

• Weight‑based basal‑bolus therapy enables approximately 68 % of patients to achieve mean glucose < 140 mg/dL, compared with 38 % using sliding‑scale insulin alone. – ADA data. 237
• An A1C reduction of 2–3 % is achievable within 3–6 months with intensive insulin titration combined with metformin. – ADA data. 238

Critical Pitfalls to Avoid

• Do not delay insulin initiation in patients whose glucose consistently exceeds 250 mg/dL on oral agents alone; prolonged hyperglycemia raises complication risk. – ADA warning. 237
• Never discontinue metformin when starting insulin unless contraindicated, as this leads to higher insulin requirements and greater weight gain. – ADA warning. 240
• Avoid reliance solely on correction (sliding‑scale) insulin without scheduled basal and prandial doses; this reactive strategy is condemned by major diabetes guidelines and causes dangerous glucose fluctuations. – ADA warning. 238
• Do not continue escalating basal insulin beyond 0.5–1.0 U/kg/day without addressing post‑prandial hyperglycemia; over‑basalization increases hypoglycemia risk and yields suboptimal control. – ADA warning. 239
• Never use rapid‑acting insulin at bedtime as a sole correction dose, as it markedly raises nocturnal hypoglycemia risk. – ADA warning. 237

Basal Insulin Titration Limits and Over‑basalization in Type 2 Diabetes

Glycemic Targets and HbA1c

• The American Diabetes Association (ADA) recommends an HbA1c < 7% for most adults with type 2 diabetes; an HbA1c of 6.7% indicates that further aggressive basal insulin escalation may be unnecessary and could increase hypoglycemia risk. 241

Basal Insulin Dose Thresholds

• When the basal insulin dose approaches ~0.5 units/kg/day (approximately 20–35 units for most adults) without reaching fasting glucose targets, clinicians should stop additional basal dose increases and consider adding prandial insulin or a GLP‑1 receptor agonist instead. 241

Indicators of Over‑basalization

• Clinical signals that basal insulin has become excessive include: dose > 0.5 units/kg/day, bedtime‑to‑morning glucose differential ≥ 50 mg/dL, any hypoglycemia episodes, or high glucose variability; these warrant cessation of basal escalation. 241

Safety Recommendations for Insulin Escalation

• Basal insulin should not be escalated beyond 0.5–1.0 units/kg/day without addressing post‑prandial hyperglycemia, as this can cause over‑basalization, raise hypoglycemia risk, and result in suboptimal glycemic control. 241

Maximum Dose and Individualized Dosing of NovoLog (Insulin Aspart)

Dose Limits and Individualization

• The FDA does not impose a maximum dose for NovoLog; dosing is individualized according to metabolic needs, body weight, illness severity, and concomitant medications, and can exceed 1 unit/kg/day in severe insulin resistance or acute illness. 242, 243 – American Diabetes Association (ADA) – High‑quality evidence.
• No absolute ceiling exists; clinicians should adjust the total daily dose based on patient‑specific factors rather than a preset limit. 242, 243 – ADA – High‑quality evidence.

Insulin Requirements by Diabetes Type

Type 1 Diabetes

• Total daily insulin requirement typically ranges 0.4–1.0 units/kg/day, with ≈50–60 % allocated to prandial (including NovoLog) and ≈40–50 % to basal insulin. 244, 243 – ADA – Moderate‑quality evidence.
• A common starting point for metabolically stable patients is 0.5 units/kg/day. 244, 243 – ADA – Moderate‑quality evidence.
• During puberty, pregnancy, or acute illness, doses may rise to up to 1.5 units/kg/day. 243 – ADA – Moderate‑quality evidence.

Type 2 Diabetes

• Patients usually need ≥1 unit/kg/day total daily insulin because of insulin resistance, and they experience lower hypoglycemia rates than type 1 patients. 242, 243 – ADA – High‑quality evidence.
• Initial prandial dosing can start at 4 units per meal or 10 % of the current basal dose, then titrated to post‑prandial glucose values. 242, 243 – ADA – High‑quality evidence.

Criteria for Adding Prandial NovoLog

• Introduce prandial insulin when basal insulin exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day without achieving glycemic targets, to avoid “over‑basalization.” 242, 243 – ADA – High‑quality evidence.
• Indicators of over‑basalization include:

Initial Prandial Dosing and Timing

• Begin with 4 units of NovoLog before the largest or most glucose‑raising meal. 242, 243 – ADA – High‑quality evidence.
• An alternative start is 10 % of the current basal insulin dose (e.g., 40 units basal → 4 units prandial). 242, 243 – ADA – High‑quality evidence.
• Administer NovoLog 0–15 minutes before meals (ideally immediately before eating) for optimal post‑prandial control. 244, 243 – ADA – Moderate‑quality evidence.

Systematic Titration Algorithm

• Increase each meal dose by 1–2 units (≈10–15 %) every 3 days based on 2‑hour post‑prandial glucose readings. 242, 243 – ADA – High‑quality evidence.
• Target post‑prandial glucose <180 mg/dL. 242, 243 – ADA – High‑quality evidence.
• If unexplained hypoglycemia (<70 mg/dL) occurs, reduce the implicated dose by 10–20 % immediately. 242, 243 – ADA – High‑quality evidence.

Carbohydrate‑Based Dosing

• Calculate an insulin‑to‑carbohydrate ratio (ICR) as 450 ÷ total daily insulin dose for rapid‑acting analogs such as NovoLog. 243 – ADA – Moderate‑quality evidence.
• Example: a total daily dose of 45 units yields an ICR of 1 unit per 10 g carbohydrate. 243 – ADA – Moderate‑quality evidence.

Dosing in Severe Hyperglycemia

• For HbA1c ≥ 9 % or glucose ≥ 300 mg/dL, start with 0.3–0.5 units/kg/day total insulin, split 50 % basal / 50 % prandial. 242, 243 – ADA – High‑quality evidence.
• In a 70‑kg individual, this equals 21–35 units/day total, with ≈11–18 units allocated to NovoLog across three meals. 242, 243 – ADA – High‑quality evidence.

Safety, Monitoring, and Hypoglycemia Management

• Treat glucose <70 mg/dL with 15 g fast‑acting carbohydrate, recheck in 15 minutes, repeat if needed. 242, 243 – ADA – High‑quality evidence.
• Never use NovoLog as a sole bedtime correction dose because it markedly raises nocturnal hypoglycemia risk. 242, 243 – ADA – High‑quality evidence.
• Monitoring schedule:

Correction (Supplemental) Dosing

• Add 2 units for pre‑meal glucose >250 mg/dL and 4 units for >350 mg/dL (simplified sliding scale). 242, 243 – ADA – High‑quality evidence.
• For individualized correction, compute Insulin Sensitivity Factor (ISF) = 1500 ÷ total daily insulin dose; correction dose = (Current glucose – Target glucose) ÷ ISF. 243 – ADA – Moderate‑quality evidence.
• Correction insulin must supplement a scheduled basal‑bolus regimen and never be used as monotherapy. 242, 243 – ADA – High‑quality evidence.

Common Pitfalls to Avoid

• Do not employ sliding‑scale insulin as monotherapy; major diabetes guidelines condemn this reactive approach. 242, 243 – ADA – High‑quality evidence.
• Do not delay adding prandial insulin when basal > 0.5 units/kg/day without achieving targets. 242, 243 – ADA – High‑quality evidence.
• Do not continue escalating basal insulin beyond 0.5–1.0 units/kg/day without addressing post‑prandial hyperglycemia, as this leads to over‑basalization and hypoglycemia risk. 242, 243 – ADA – High‑quality evidence.
• Do not rely solely on correction doses without adjusting scheduled basal and prandial insulin. 243 – ADA – High‑quality evidence.

Expected Clinical Outcomes

• Basal‑bolus therapy with NovoLog enables ≈68 % of patients to achieve mean glucose <140 mg/dL, versus ≈38 % with sliding‑scale insulin alone. 243 – ADA – High‑quality evidence.
• HbA1c reductions of 2–3 % (or 3–4 % in severe hyperglycemia) are observed over 3–6 months with intensive titration. 243 – ADA – High‑quality evidence.
• Properly executed basal‑bolus regimens do not increase overall hypoglycemia incidence compared with inadequate sliding‑scale approaches. 243 – ADA – High‑quality evidence.

Combination Therapy Considerations

• Continue metformin at the maximum tolerated dose (≈2,000–2,550 mg/day) when adding NovoLog; metformin reduces total insulin requirements by 20–30 %. 243 – ADA – Moderate‑quality evidence.
• Discontinue sulfonylureas when initiating basal‑bolus insulin to avoid additive hypoglycemia risk. 243 – ADA – Moderate‑quality evidence.
• When basal insulin exceeds 0.5 units/kg/day, a GLP‑1 receptor agonist may replace prandial insulin, offering comparable post‑prandial control with less hypoglycemia and weight gain. 243 – ADA – Moderate‑quality evidence.

Adjusting Basal Insulin to Prevent Early‑Morning and Nocturnal Hypoglycemia

1. Basal Insulin Dose Reduction

• Reduce the evening long‑acting insulin dose by 10–20 % (e.g., from 36 U to approximately 29–32 U) to eliminate early‑morning hypoglycemia while preserving 24‑hour basal coverage. 245
• Any unexplained hypoglycemic event (glucose < 70 mg/dL) should trigger an immediate 10–20 % reduction of the implicated insulin dose before the next administration. 245
• Recurrent nocturnal hypoglycemia (midnight–6 AM) specifically warrants a 10–20 % reduction of the evening basal dose with reassessment within 3 days. 245

2. Evidence of the Problem in Hospitalized Patients

• 78 % of hospitalized patients receiving basal insulin experience nocturnal hypoglycemia, yet 75 % receive no basal‑insulin dose adjustment before the next dose, highlighting a common management gap. 245

3. Monitoring During Titration

• Daily fasting glucose should be measured to guide further basal‑insulin adjustments. 245
• Pre‑meal and bedtime glucose (minimum four checks per day) are required to detect patterns of hypo‑ or hyperglycemia. 245
• If fasting glucose rises > 180 mg/dL after dose reduction, increase the basal dose by 2 U every 3 days until fasting glucose returns to the target range of 80–130 mg/dL. 245

4. Prandial (Rapid‑Acting) Insulin Management

• Continue rapid‑acting insulin (e.g., lispro) at the usual 10 U before each meal unless post‑meal hypoglycemia occurs; then reduce the specific meal dose by 1–2 U (10–15 %). 245
• Administer rapid‑acting insulin 0–15 minutes before meals (ideally immediately before eating) for optimal post‑prandial control. 245
• If post‑prandial glucose consistently exceeds 180 mg/dL, increase the corresponding meal dose by 1–2 U every 3 days. 245

5. Use of Correction (Sliding‑Scale) Insulin

• Correction insulin must supplement a scheduled basal‑bolus regimen; it must never replace basal or prandial insulin. 245
• Apply correction doses only when pre‑meal glucose exceeds defined thresholds (e.g., 2 U for > 250 mg/dL, 4 U for > 350 mg/dL) in addition to the scheduled prandial dose. 245
• Sliding‑scale insulin used as monotherapy is discouraged by major diabetes guidelines because it reacts to hyperglycemia rather than preventing it, leading to dangerous glucose fluctuations. 245

6. Immediate Hypoglycemia Management

• Treat any glucose < 70 mg/dL promptly with 15 g of fast‑acting carbohydrate (e.g., 4 glucose tablets or 4 oz juice), recheck after 15 minutes, and repeat if needed. 245

7. Alternative Basal‑Insulin Timing (When Dose Reduction Fails)

• If early‑morning hypoglycemia persists despite dose reduction, consider administering the long‑acting insulin in the morning rather than the evening to shift insulin activity away from the overnight period. 246
• Morning administration can reduce the risk of early‑morning hypoglycemia by aligning peak basal coverage with daytime meals and activity. 246

8. Common Pitfalls to Avoid

• Do not delay basal‑insulin dose reduction after a hypoglycemic event; failure to adjust contributes to the high proportion of patients who receive no dose change before the next dose. 245
• Do not rely solely on correction insulin without adjusting scheduled basal and prandial doses; this reactive approach is unsafe. 245
• Never use rapid‑acting insulin at bedtime as a sole correction dose, as it markedly increases nocturnal hypoglycemia risk. 245
• Never discontinue basal insulin entirely in type 1 diabetes, even when hypoglycemia occurs, to avoid precipitating diabetic ketoacidosis. 245

9. Expected Clinical Outcomes

• After a 10–20 % basal‑dose reduction, fasting glucose should stabilize within 80–130 mg/dL in 3–7 days without further hypoglycemic episodes. 245
• If hyperglycemia persists, titrate the basal dose upward by 2 U every 3 days until the fasting target is achieved. 245
• Properly adjusted basal insulin provides consistent 24‑hour coverage without causing nocturnal hypoglycemia or early‑morning hyperglycemia. 245

10. General Principles for Type 1 Diabetes Management

• Metformin is not indicated in type 1 diabetes because patients have absolute insulin deficiency. 245
• The cornerstone of therapy is a basal‑bolus insulin regimen with individualized dose titration to prevent both hyper‑ and hypoglycemia. 245

Standard of Care for Inpatient Diabetes Management: Basal‑Bolus Regimen Over Sliding‑Scale Insulin

Guideline Stance

• The American Diabetes Association (ADA) and all major diabetes guideline societies explicitly condemn the use of sliding‑scale insulin as the sole regimen—including at bedtime—as being outside the standard of care for hospitalized patients. Strong recommendation. 247
• The ADA strongly discourages prolonged sole use of sliding‑scale insulin in the inpatient setting. Strong recommendation. 248

Efficacy of Basal‑Bolus Compared with Sliding‑Scale

• In hospitalized patients, only ≈38 % achieve a mean glucose < 140 mg/dL with sliding‑scale insulin alone, versus ≈68 % when a scheduled basal‑bolus regimen is used. Moderate‑quality evidence from guideline‑supported studies. 249
• Randomized controlled trials in general‑surgery patients with type 2 diabetes show that basal‑bolus therapy improves overall glycemic control and reduces hospital complications compared with sliding‑scale insulin. High‑quality evidence (RCT). 247

Recommended Regimens

Patients Eating Regular Meals

• The preferred regimen for non‑critically ill hospitalized patients with adequate oral intake is a basal‑prandial‑correction insulin regimen (basal + rapid‑acting prandial + correction doses). Strong recommendation. 248
• Basal insulin (e.g., glargine, detemir, degludec) given once daily provides continuous background coverage and suppresses hepatic glucose production. Strong recommendation. 249
• Prandial insulin (rapid‑acting analogs such as lispro, aspart, or glulisine) administered 0–15 minutes before each meal covers meal‑related glucose excursions. Strong recommendation. 247
• Correction insulin is used only as a supplement to scheduled doses when pre‑meal glucose exceeds predefined thresholds; it is not a replacement for scheduled insulin. Strong recommendation. 247

Patients with Poor Oral Intake or NPO

• For non‑critically ill patients with limited intake or who are NPO, a basal‑only or basal‑plus‑correction regimen is preferred; basal insulin must never be completely withheld because it suppresses hepatic glucose production independent of food intake. Strong recommendation. 248

Initial Dosing and Titration

Initial Dosing

• Insulin‑naïve or low‑dose home patients: start with a total daily dose of 0.3–0.5 U/kg/day, allocating 50 % to basal (once daily) and 50 % to prandial (divided among three meals). Strong recommendation. 247
• High‑risk patients (age > 65 yr, renal impairment, poor intake): use a lower starting dose of 0.1–0.25 U/kg/day to minimize hypoglycemia risk. Strong recommendation. 247

Titration Protocol

• Basal insulin: increase by 2 U every 3 days if fasting glucose is 140–179 mg/dL; increase by 4 U every 3 days if fasting ≥ 180 mg/dL. Target fasting glucose 80–130 mg/dL. Strong recommendation. 247
• Prandial insulin: increase each meal dose by 1–2 U (≈10–15 %) every 3 days based on 2‑hour post‑prandial glucose. Target post‑prandial glucose < 180 mg/dL. Strong recommendation. 247

Monitoring Requirements

• Patients eating regular meals: check capillary glucose before each meal and at bedtime (minimum 4 times daily). Strong recommendation. 248
• Patients with poor intake or NPO: check glucose every 4–6 hours. Strong recommendation. 249
• Daily fasting glucose is essential during titration to guide basal‑insulin adjustments. Strong recommendation. 247

Hypoglycemia Management

• Treat any glucose < 70 mg/dL immediately with 15 g of fast‑acting carbohydrate, recheck in 15 minutes, and repeat if needed. Strong recommendation. 247
• If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20 % before the next administration. Strong recommendation. 247
• Document every hypoglycemic episode in the medical record and track it for quality‑improvement purposes. Strong recommendation. 247
• Each hospital should adopt a standardized hypoglycemia‑management protocol. Strong recommendation. 247

Specific Concerns About Bedtime Sliding‑Scale

• Administering rapid‑acting insulin at bedtime as a sole correction dose is explicitly contraindicated because it markedly raises the risk of nocturnal hypoglycemia. Strong recommendation. 247
• The ADA specifically warns against the use of bedtime rapid‑acting insulin as a sole correction. Strong recommendation. 247

Transition from Intravenous to Subcutaneous Insulin

• When discontinuing IV insulin, give subcutaneous basal insulin 2–4 hours before stopping the IV infusion to prevent rebound hyperglycemia and recurrent ketoacidosis. Strong recommendation. 247
• Convert to basal insulin at 60–80 % of the total daily IV infusion dose. Strong recommendation. 247

Common Pitfalls to Avoid

• Never use sliding‑scale insulin as monotherapy in hospitalized patients; this approach is condemned by all major diabetes guideline societies. Strong recommendation. 249
• Never give rapid‑acting insulin at bedtime as a sole correction dose; doing so markedly increases nocturnal hypoglycemia risk. Strong recommendation. 247

All facts are derived from guideline‑endorsed evidence and peer‑reviewed studies cited above.

Rapid‑Acting Insulin Dose‑Adjustment Timing

Standard 3‑Day Adjustment Interval

• The American Diabetes Association recommends increasing the rapid‑acting insulin dose for a specific meal by 1–2 units (≈10–15 %) every 3 days, using the 2‑hour post‑prandial glucose value for that meal as the decision point. 250
• This 3‑day interval is applicable to all rapid‑acting analogues—including lispro, aspart, glulisine, and regular insulin—regardless of concurrent basal insulin or correction‑dose therapy. 250

Rationale for the 3‑Day Interval

• Rapid‑acting insulin reaches steady‑state pharmacokinetics within 24–48 hours; a full 3‑day period of consistent dosing provides enough data to isolate the true effect on post‑prandial glucose and avoid day‑to‑day variability. 250

Monitoring Requirements During Titration

• Check the 2‑hour post‑prandial glucose after each meal to guide that meal’s insulin adjustment. 250
• Aim for a post‑prandial glucose target < 180 mg/dL for each meal. 250
• In addition, monitor pre‑meal glucose to calculate separate correction doses when needed. 250
• Perform daily fasting glucose checks to inform basal‑insulin titration, which follows the same 3‑day schedule. 250

Immediate Exceptions to the 3‑Day Rule

Hypoglycemia‑Driven Reductions

• If any glucose reading falls < 70 mg/dL, reduce the implicated insulin (prandial or basal) by 10–20 % immediately—do not wait for the next 3‑day interval. 250
• Treat the hypoglycemia with ≈15 g of fast‑acting carbohydrate, re‑check glucose in 15 minutes, and repeat if necessary. 250

Severe Hyperglycemia‑Driven Escalation (Basal Insulin)

• When fasting glucose ≥ 180 mg/dL, increase basal insulin by 4 units every 3 days (instead of the standard 2‑unit increase used for fasting glucose 140–179 mg/dL). 250
• For rapid‑acting insulin, retain the standard 1–2 unit increase every 3 days even with marked post‑prandial hyperglycemia, to limit hypoglycemia risk. 250

Practical 3‑Day Titration Algorithm (Prandial Insulin)

When to Stop Basal Escalation and Add Prandial Coverage

• If basal insulin approaches 0.5–1.0 units/kg/day without achieving glycemic goals, the American Diabetes Association advises adding or intensifying prandial insulin rather than further basal increases. 250
• Clinical signals of “over‑basalization” include:
  
  • Basal dose > 0.5 units/kg/day. 250
  • Bedtime‑to‑morning glucose differential ≥ 50 mg/dL. 250
  • Episodes of hypoglycemia despite overall hyperglycemia. 250
  • High day‑to‑day glucose variability. 250

Common Pitfalls to Avoid

• Do not adjust prandial insulin daily based on a single glucose value; this leads to erratic dosing and increased hypoglycemia risk. 250
• Do not substitute scheduled prandial doses with correction (sliding‑scale) insulin; correction doses should supplement, not replace, scheduled insulin. 250
• Avoid giving rapid‑acting insulin at bedtime as a sole correction dose, as it markedly raises nocturnal hypoglycemia risk. 250
• Do not continue basal‑insulin titration beyond 0.5–1.0 units/kg/day without addressing post‑prandial hyperglycemia with prandial insulin. 250

Application in Hospital Settings

• The 3‑day titration schedule is applicable to both in‑patient and out‑patient populations. 250
• For hospitalized patients consuming regular meals, obtain glucose before each meal and at bedtime (minimum four checks daily). 250
• For patients with poor oral intake or NPO status, check glucose every 4–6 hours and employ a basal‑plus‑correction regimen rather than scheduled prandial insulin. 250

Carbohydrate‑to‑Insulin Ratio (CIR) Adjustments

• Once a stable prandial dose is established, calculate the CIR as 450 ÷ total daily insulin dose for rapid‑acting analogues. 250
• If post‑prandial glucose consistently misses target despite adhering to the 3‑day titration rule, adjust the CIR (e.g., from 1:10 to 1:8) instead of further increasing the fixed dose. 250
• CIR modifications also follow the 3‑day observation rule before reassessment. 250

Long‑Acting Basal Insulin Titration Guidelines

Starting Dose for Insulin‑Naïve Patients

• Initiate basal insulin with 10 units once daily or 0.1–0.2 units/kg/day in adults with type 2 diabetes who have not previously used insulin, administered at the same time each day【251】.

Patient‑Specific Starting Dose Adjustments

• Elderly adults (>65 years) – begin with 0.1–0.25 units/kg/day to reduce hypoglycemia risk due to increased insulin sensitivity【251】.
• Renal impairment (eGFR < 60 mL/min/1.73 m²) – start with 0.1–0.25 units/kg/day and increase glucose monitoring because insulin clearance is reduced【251】.
• Hospitalized patients with limited oral intake – use a baseline of 0.1–0.25 units/kg/day as basal insulin only; give correction doses only when fasting glucose exceeds 180 mg/dL【251】.
• Patients already using high‑dose insulin at home (≥0.6 units/kg/day) – reduce the total daily dose by 20 % upon admission to prevent inpatient hypoglycemia【251】.

Standard Titration Algorithm

• If fasting glucose 140–179 mg/dL, increase the basal dose by 2 units every 3 days【251】.
• If fasting glucose ≥180 mg/dL, increase the basal dose by 4 units every 3 days【251】.
• Target fasting glucose: 80–130 mg/dL (4.4–7.2 mmol/L)【251】.
• If any unexplained hypoglycemia (glucose < 70 mg/dL) occurs, reduce the current dose by 10–20 % immediately rather than waiting for the next scheduled change【251】.

When to Stop Basal Escalation (“Over‑Basalization”)

• Cease further basal increases once the dose reaches 0.5–1.0 units/kg/day without achieving target glucose; add prandial insulin or a GLP‑1 receptor agonist instead【251】.
• Clinical signals that basal escalation should stop include:

Monitoring Requirements

• Daily fasting glucose checks during active titration to guide dose adjustments【251】.
• Reassess the basal dose every 3 days while titrating【251】.
• HbA1c measurement every 3 months during intensive titration phases【251】.

Combination Therapy with Metformin

• Continue metformin (up to 2,000–2,550 mg daily) throughout basal insulin titration; its use lowers total insulin requirements by 20–30 % and yields superior glycemic control【251】.

Key Clinical Pitfalls to Avoid

• Do not delay initiation of basal insulin in patients who fail to meet glycemic goals with oral agents, as prolonged hyperglycemia increases complication risk【251】.
• Never continue escalating basal insulin beyond 0.5–1.0 units/kg/day without addressing post‑prandial hyperglycemia; this leads to over‑basalization, higher hypoglycemia risk, and suboptimal control【251】.
• Avoid withholding basal insulin completely in type 1 diabetes or insulin‑dependent type 2 diabetes, even when patients are NPO, to prevent ketoacidosis【251】.
• Recognize that 75 % of hospitalized patients who experience hypoglycemia receive no basal insulin dose adjustment before the next dose; proactive adjustment is essential to improve safety【251】.

Scheduled Basal‑Bolus Insulin Therapy Replaces Sliding‑Scale Insulin in Hospitalized Adults

Rationale for Replacing Sliding‑Scale Insulin

• The American Diabetes Association and other major diabetes societies explicitly condemn sliding‑scale insulin (SSI) as monotherapy for hospitalized adults, recommending immediate discontinuation in favor of scheduled basal‑bolus regimens. Strong guideline recommendation. 252
• SSI treats hyperglycemia reactively after glucose spikes, producing wide glucose fluctuations that increase both hyper‑ and hypoglycemia risk. Strong evidence from guideline review. 252
• Only ≈ 38 % of patients managed with SSI achieve a mean glucose < 140 mg/dL, versus ≈ 68 % with a scheduled basal‑bolus approach, demonstrating superior efficacy of basal‑bolus therapy. Level A evidence (large observational cohort). 252

Initial Dosing Recommendations

• Standard‑risk patients (insulin‑naïve or low‑dose home therapy): start total daily dose (TDD) 0.3–0.5 U/kg/day, split 50 % basal (once daily) and 50 % prandial (divided among three meals). Class I recommendation. 252
• High‑risk patients (age > 65 yr, renal impairment, poor oral intake): initiate TDD 0.1–0.25 U/kg/day to limit hypoglycemia. Class I recommendation. 252
• Patients on high‑dose home insulin (≥ 0.6 U/kg/day): reduce inpatient TDD by ≈ 20 % on admission to avoid overtreatment. Class II recommendation. 252

Basal Insulin Titration

• If fasting glucose 140–179 mg/dL, increase basal dose by 2 U every 3 days. Class II recommendation. 252
• If fasting glucose ≥ 180 mg/dL, increase basal dose by 4 U every 3 days. Class II recommendation. 252
• Target fasting glucose 80–130 mg/dL for non‑critically ill patients. Class I recommendation. 252
• When basal insulin reaches 0.5–1.0 U/kg/day without achieving target fasting glucose, stop further basal escalation and add prandial insulin to prevent “over‑basalization.” Class II recommendation. 252

Prandial Insulin Initiation and Titration

• Begin rapid‑acting insulin (lispro, aspart, or glulisine) with 4 U before each of the three largest meals (or ≈ 10 % of the current basal dose). Class I recommendation. 252
• Administer prandial insulin 0–15 minutes before meals for optimal post‑prandial control. Class I recommendation. 252
• Titrate each meal dose by 1–2 U (≈ 10–15 %) every 3 days based on 2‑hour post‑prandial glucose values. Class II recommendation. 252
• Target post‑prandial glucose < 180 mg/dL. Class I recommendation. 252

Correction Insulin Use (Adjunct Only)

• Add 2 U rapid‑acting insulin for pre‑meal glucose > 250 mg/dL. Class II recommendation. 252
• Add 4 U for pre‑meal glucose > 350 mg/dL. Class II recommendation. 252
• Correction doses must supplement—not replace—scheduled basal and prandial insulin. Class I recommendation. 252

Glucose Monitoring Protocol

• Patients eating regular meals: check glucose before each meal and at bedtime (minimum 4 times daily). Class I recommendation. 252
• Patients with poor intake or NPO: check glucose every 4–6 hours. Class I recommendation. 252
• Use daily fasting glucose to guide basal insulin adjustments. Class I recommendation. 252
• Obtain 2‑hour post‑prandial glucose after each meal to assess prandial adequacy. Class I recommendation. 252

Clinical Outcomes of Basal‑Bolus vs Sliding‑Scale

• Glycemic control: 68 % of patients on basal‑bolus achieve mean glucose < 140 mg/dL versus 38 % on SSI alone. Level A evidence (large cohort). 252
• Hypoglycemia: Properly implemented basal‑bolus regimens do not increase hypoglycemia incidence compared with SSI. Level A evidence. 252
• Recommended target glucose range for non‑critically ill hospitalized patients is 140–180 mg/dL. Class I recommendation. 252

Transition Criteria from Basal‑Only to Basal‑Bolus

• When basal insulin dose approaches 0.5–1.0 U/kg/day without reaching fasting glucose targets, add prandial insulin. Class II recommendation. 252
• Additional signals for “over‑basalization” include:
  
  • Basal dose > 0.5 U/kg/day,
  • Bedtime‑to‑morning glucose differential ≥ 50 mg/dL,
  • Episodes of hypoglycemia despite overall hyperglycemia,
  • High day‑to‑day glucose variability. Class II recommendation. 252

Hypoglycemia Management

• Treat glucose < 70 mg/dL immediately with 15 g fast‑acting carbohydrate, recheck in 15 minutes, repeat if needed. Class I recommendation. 252
• If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20 % promptly. Class II recommendation. 252
• Avoid using rapid‑acting insulin at bedtime as a sole correction dose, as it markedly raises nocturnal hypoglycemia risk. Class I recommendation. 252

Common Pitfalls and Safety Alerts

• Do not continue SSI as monotherapy when glucose repeatedly exceeds 180 mg/dL; it is inferior and unsafe. Class I recommendation. 252
• Do not delay adding prandial insulin when basal insulin alone fails to achieve target fasting glucose. Class I recommendation. 252
• Do not increase basal insulin beyond 0.5–1.0 U/kg/day without addressing post‑prandial hyperglycemia, to prevent over‑basalization and hypoglycemia. Class I recommendation. 252
• Do not rely solely on correction doses without adjusting scheduled basal and prandial insulin. Class I recommendation. 252

Basal Insulin Timing for Steroid‑Induced Hyperglycemia

Immediate Basal Insulin Adjustment

• In patients experiencing acute hyperglycemia after intra‑articular corticosteroid injections, the increased Lantus dose should be administered at the usual bedtime to ensure continuous 24‑hour basal insulin coverage during the steroid‑induced insulin‑resistant period. [253] [254]

Intensive Basal‑Insulin Titration for Severe Uncontrolled Diabetes

Basal‑Insulin Titration Protocol

• Initiate aggressive dose escalation with a systematic titration plan aiming for fasting glucose 80–130 mg/dL within 2–3 weeks. [255][256]
• Increase basal insulin (e.g., insulin glargine) by 4 units every 3 days while fasting glucose remains ≥ 180 mg/dL; this corrects profound under‑dosing when fasting values are ≥ 171 mg/dL. [255][256]
• If fasting glucose is 140–179 mg/dL, increase basal insulin by 2 units every 3 days. [255][256]
• Reduce the total basal dose by 10–20 % promptly if any glucose reading falls below 70 mg/dL to avoid hypoglycemia. [255][256]
• Target fasting glucose range is 80–130 mg/dL for all patients. [255][256]

Weight‑Based Dosing Expectations

• For insulin‑naïve adults, start basal insulin at 0.1–0.2 units/kg/day. [255][257]
• Patients presenting with glucose 200–300 mg/dL often require 0.3–0.5 units/kg/day (approximately 21–40 units) to achieve control. [255][256]

Transition to Prandial Insulin (When Basal Dose ≈ 0.5 units/kg/day)

• Cease further basal escalation once the dose approaches 0.5 units/kg/day (≈ 35–40 units for a typical adult) without meeting targets; add prandial insulin to address post‑prandial hyperglycemia. [255][256]
• Signs of over‑basalization:
• Prandial initiation: start 4 units rapid‑acting insulin (lispro, aspart, or glulisine) before the largest meal, or alternatively use 10 % of the current basal dose as the initial prandial amount. [255][256]
• Administer prandial insulin 0–15 minutes before meals for optimal post‑prandial control. [255][256]
• Titrate each prandial dose by 1–2 units every 3 days based on the 2‑hour post‑prandial glucose reading. [255][256]

Metformin Optimization

• Continue or up‑titrate metformin to at least 1000 mg twice daily (2000 mg total) unless contraindicated; this reduces total insulin requirements by 20–30 % and yields superior glycemic control versus insulin alone. [255][257]
• Metformin should not be discontinued during insulin intensification unless specific contraindications exist (e.g., renal impairment, acute illness, tissue hypoxia). [255][257]
• The maximum effective daily dose of metformin is up to 2500 mg. [255][257]

Monitoring During Titration

• Daily fasting glucose measurement guides basal insulin adjustments. [255][256]
• When prandial insulin is added, obtain pre‑meal glucose before each meal and a 2‑hour post‑prandial glucose after meals. [255][256]
• Perform a minimum of four glucose checks per day during the intensive titration phase. [255][256]
• Reassess insulin dose every 3 days while actively titrating. [255][256]
• Measure HbA1c every 3 months until stable control is achieved. [255][256]
• Refer urgently to endocrinology if HbA1c > 9 % or glucose remains uncontrolled after 3–6 months of titration. 255

Expected Clinical Outcomes

• Approximately 68 % of patients achieve mean glucose < 140 mg/dL with scheduled basal‑bolus therapy, compared with 38 % when dosing is inadequate. [255][256]
• Basal insulin optimization alone can produce an HbA1c reduction of 1.5–2.0 %. [255][257]
• Adding prandial insulin can yield an additional 2–3 % HbA1c reduction. [255][256]
• Properly implemented regimens do not increase hypoglycemia risk relative to under‑dosed insulin. [255][256]

Common Pitfalls to Avoid

• Do not delay basal dose escalation when fasting glucose consistently exceeds 180 mg/dL; prolonged hyperglycemia raises complication risk. 255
• Avoid continuing basal escalation beyond 0.5–1.0 units/kg/day without addressing post‑prandial hyperglycemia, as this leads to over‑basalization and higher hypoglycemia risk. [255][256]
• Do not discontinue metformin during insulin intensification unless contraindicated; omission increases insulin needs and worsens outcomes. [255][257]
• Never rely on sliding‑scale insulin as monotherapy; correction doses must supplement scheduled basal insulin. [255][256]

Patient Education Essentials

• Hypoglycemia treatment: consume ~15 g fast‑acting carbohydrate when glucose < 70 mg/dL, recheck in 15 minutes. [255][256]
• Teach proper insulin injection technique and site rotation to prevent lipohypertrophy. 255
• Provide a self‑titration algorithm empowering patients to adjust basal dose based on fasting glucose values. 255
• Sick‑day guidance: continue insulin even if oral intake is limited, check glucose every 4 hours, and maintain adequate hydration. 255

Alternative to Prandial Insulin: GLP‑1 Receptor Agonist

• If basal insulin exceeds 0.5 units/kg/day without achieving targets, consider adding a GLP‑1 receptor agonist (e.g., semaglutide) instead of prandial insulin; this approach offers comparable post‑prandial control with lower hypoglycemia risk and weight loss rather than weight gain. [255][256]

Management of Post‑prandial Glucose Around 74 mg/dL in Diabetes

Target Post‑prandial Range

• The American Diabetes Association (ADA) recommends a 2‑hour post‑prandial glucose target of < 180 mg/dL for most adults with diabetes【258】【259】.

Hypoglycemia Threshold

• The ADA defines the hypoglycemia alert threshold as < 70 mg/dL; a value of 74 mg/dL is above this threshold and does not constitute hypoglycemia【259】【258】.

Insulin‑to‑Carbohydrate Ratio Guidance

• An initial insulin‑to‑carbohydrate ratio of 1 unit per 10 g of carbohydrate is a standard starting point for carbohydrate counting in insulin‑treated diabetes【259】.
• When the ratio yields a 2‑hour post‑prandial glucose of 74 mg/dL, it indicates that the mealtime insulin dose is appropriately matched to the carbohydrate intake【259】.

Immediate Clinical Actions

• No insulin correction or additional carbohydrate intake is required for a 2‑hour post‑prandial glucose of 74 mg/dL【258】【259】.
• Patients should continue normal activities unless they develop symptoms suggestive of hypoglycemia【259】.

Monitoring and Symptom‑Driven Management

• If symptoms such as shakiness, sweating, confusion, or rapid heartbeat occur, glucose should be rechecked immediately【259】.
• Treatment is indicated only when glucose falls below 70 mg/dL, using approximately 15 g of fast‑acting carbohydrate (e.g., glucose tablets or juice) and rechecking after 15 minutes【259】.

Pitfalls to Avoid

• Do not administer correction insulin for a glucose of 74 mg/dL, as this can precipitate hypoglycemia【259】.
• Avoid protein‑rich foods (e.g., nuts) as a treatment or preventive measure for hypoglycemia, because protein can stimulate insulin secretion in type 2 diabetes【259】.
• Do not modify the insulin‑to‑carbohydrate ratio based on a single post‑prandial reading; adjustments should be made only after observing a consistent pattern over ≥ 3 days【259】.

When to Adjust the Mealtime Insulin Regimen

• If the 2‑hour post‑prandial glucose is consistently < 70 mg/dL, reduce the mealtime insulin dose by 10–20 % (e.g., change ratio from 1:10 to 1:12)【259】.
• If the 2‑hour post‑prandial glucose is consistently > 180 mg/dL, increase the mealtime insulin by 1–2 units or 10–15 % every 3 days, guided by the readings【259】.

Special Populations

• For individuals with type 1 diabetes or insulin‑dependent type 2 diabetes, maintaining glucose ≥ 70 mg/dL is essential to prevent dangerous hypoglycemic episodes【259】.

Aggressive Basal‑Bolus Insulin Intensification for Severe Hyperglycemia

Basal Insulin Titration

Prandial Insulin Initiation

Rationale for Basal‑Bolus Therapy

Monitoring and Follow‑Up

Metformin Continuation

GLP‑1 Receptor Agonist Consideration

Pitfalls to Avoid

Hypoglycemia Management

Insulin Pump Prescription Guidelines – No Maximum Daily Dose Required

Dosing Considerations

• Insulin pumps provide continuously variable dosing based on programmed basal rates, carbohydrate‑to‑insulin ratios, and correction factors, making a single maximum daily dose impractical and unsafe. 261
• In pump therapy, basal insulin typically comprises 30–50 % of the total daily dose, with the remainder delivered as meal‑time and correction boluses; this proportion shifts dynamically with activity, illness, and diet. 261
• Real‑time dose adjustments are performed by on‑board calculators that integrate active insulin, carbohydrate intake, and current glucose levels; imposing a maximum dose would hinder necessary dose escalation. 261
• Carbohydrate‑to‑insulin ratios differ by meal: breakfast often uses a ratio of ≈1 unit per 10 g carbohydrate (derived from 300 ÷ TDD), whereas lunch and dinner use ≈1 unit per 13–15 g carbohydrate (derived from 400 ÷ TDD). 261
• Insulin sensitivity (correction) factors are calculated as 1500 ÷ TDD and must be individualized; fixed maximum doses cannot accommodate these adjustments. 261
• Rapid‑acting analogs delivered by pumps have an action duration of approximately 3–5 hours; pump algorithms account for “insulin on board” to avoid stacking, requiring flexible dosing. 261

Prescription Content

• The prescription should specify a rapid‑acting insulin analog (e.g., NovoRapid®, Humalog®, Apidra®) for pump use. 261
• The delivery method must be identified as continuous subcutaneous insulin infusion (insulin pump). (derived from overall guidance; no separate citation needed)
• Quantity should be expressed as “sufficient supply for the prescribed treatment period (e.g., cartridges/vials as needed for pump therapy).” (derived from overall guidance; no separate citation needed)

Clinical Rationale

• Pump therapy emulates physiological insulin secretion by providing a continuous basal infusion plus on‑demand boluses, necessitating instantaneous dose changes that cannot be predetermined. 261

Safety and Monitoring

• Patients (or their caregivers) must demonstrate the ability to operate the pump safely after comprehensive education on pump management. 262
• Glycemic control should be evaluated at least every 3 months using HbA1c measurements to verify appropriate overall insulin dosing. 262

Patient Selection & Contraindications

• Pump therapy is unsuitable for individuals unable to perform self‑monitoring of glucose, conduct carbohydrate counting, or troubleshoot pump issues; such patients should be managed with multiple daily injections. 262

Intensification of Basal‑Bolus Insulin Therapy for Severe Hyperglycemia

Assessment of Current Regimen

• A total daily insulin dose of roughly 2 U/kg/day (≈115 U) falls within the range expected for severe hyperglycemia but is insufficient to achieve glycemic control when A1C exceeds 11 %【263】.

Basal Insulin Titration

• Aggressive titration: increase long‑acting insulin (e.g., Toujeo) by 4 U every 3 days until fasting glucose consistently reaches 80–130 mg/dL【263】.
• The American Diabetes Association (ADA) recommends this titration schedule for patients whose fasting glucose is ≥180 mg/dL【263】.
• Upper limit: stop basal escalation when the dose approaches 0.5–1.0 U/kg/day (≈27–54 U for a 55‑kg adult) to avoid “over‑basalization,” which raises hypoglycemia risk without improving control【263】.
• Clinical signs of over‑basalization include basal dose > 0.5 U/kg/day, bedtime‑to‑morning glucose differential ≥ 50 mg/dL, hypoglycemia episodes, and high glucose variability【263】.

Prandial Insulin Titration

• Increase each rapid‑acting insulin dose by 1–2 U (≈10–15 %) every 3 days based on 2‑hour post‑prandial glucose values【263】.
• Target post‑prandial glucose < 180 mg/dL【263】.
• Administer rapid‑acting insulin 0–15 minutes before meals for optimal post‑prandial control【263】.

Role of Metformin (Foundation Therapy)

• Continue or up‑titrate metformin to at least 1 000 mg twice daily (≈2 000 mg total) unless contraindicated【263】.
• Metformin reduces total insulin requirements by 20–30 % and provides superior glycemic control compared with insulin alone【263】.
• The maximum effective daily dose of metformin is up to 2 500 mg【263】.

Monitoring During Titration

• Daily fasting glucose to guide basal adjustments【263】.
• Pre‑meal glucose before each meal to calculate correction doses【263】.
• 2‑hour post‑prandial glucose after each meal to assess prandial adequacy【263】.
• Bedtime glucose to evaluate overall daily pattern【263】.
• Reassess insulin doses every 3 days while actively titrating【263】.
• Check A1C every 3 months until stable control is achieved【263】.

Expected Clinical Outcomes

• Approximately 68 % of patients achieve mean glucose < 140 mg/dL with a properly scheduled basal‑bolus regimen, versus 38 % when dosing is inadequate【263】.
• An A1C reduction of 3–4 % (e.g., from >11 % to ≈7–8 %) is achievable within 3–6 months of intensive insulin titration combined with metformin【263】.
• Properly implemented basal‑bolus therapy does not increase hypoglycemia risk relative to under‑dosed insulin【263】.

GLP‑1 Receptor Agonist as an Alternative to Further Prandial Insulin

• If basal insulin exceeds 0.5 U/kg/day without reaching targets, add a GLP‑1 receptor agonist (e.g., semaglutide, dulaglutide) instead of further prandial insulin escalation【263】.
• The basal‑insulin + GLP‑1 RA combination provides potent glucose‑lowering effects with less weight gain and lower hypoglycemia risk compared with intensified basal‑bolus regimens【263】.
• GLP‑1 RAs can achieve A1C reductions of 2–3 % from baseline levels ≥9 % while promoting weight loss【263】.

Critical Pitfalls to Avoid

• Do not delay insulin intensification when A1C is >11 %; prolonged hyperglycemia increases complication risk【263】.
• Do not discontinue metformin during insulin intensification unless contraindicated, as omission raises insulin needs and worsens outcomes【263】.
• Never rely on sliding‑scale insulin as monotherapy; correction doses must supplement a scheduled basal‑bolus regimen【263】.
• Avoid continuing basal insulin escalation beyond 0.5–1.0 U/kg/day without addressing post‑prandial hyperglycemia, to prevent over‑basalization and hypoglycemia【263】.

Hypoglycemia Management

• Treat glucose < 70 mg/dL promptly with 15 g of fast‑acting carbohydrate, recheck in 15 minutes, and repeat if needed【263】.
• If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20 % immediately【263】.
• Provide comprehensive patient education on hypoglycemia recognition, treatment, proper injection technique, and sick‑day management【263】.

Aggressive Basal‑Bolus Therapy and GLP‑1 RA Alternatives for Severe Hyperglycemia

Basal‑Bolus Initiation in Patients with Very High A1C

• In individuals with an A1C ≈ 11 % (indicating severe fasting hyperglycemia and marked post‑prandial excursions), immediate initiation of an aggressive basal‑bolus insulin regimen—rather than basal‑only titration—is recommended to achieve adequate glycemic control. 264

GLP‑1 Receptor Agonist as an Adjunct When Basal Insulin Is Insufficient

• When basal insulin requirements exceed 0.5 U/kg/day without reaching glycemic targets, adding a GLP‑1 receptor agonist (e.g., semaglutide) is advised; this combination yields strong glucose‑lowering effects while producing less weight gain and a lower risk of hypoglycemia compared with further escalation of prandial insulin. 264

Insulin Therapy Recommendations Supported by Cited Evidence

Indications for Initiating Insulin

• In patients with suspected type 1 diabetes, those who are underweight, or who have an acute illness, insulin should be used as the preferred glucose‑lowering agent. 265

Pre‑Insulin Initiation Considerations

• GLP‑1 receptor agonists ought to be evaluated in all eligible patients before starting insulin because they enable lower glycemic targets, reduce injection burden, and lower the risk of hypoglycemia. 265

Choice of Basal Insulin

• Long‑acting basal insulin analogues (insulin glargine, detemir, or degludec) are recommended over NPH insulin due to a lower incidence of overall and nocturnal hypoglycemia when titrated to the same fasting glucose goal. 265
• These basal analogues may be administered at any time of day; however, bedtime dosing remains the traditional practice. 265

Expanding to Prandial (Mealtime) Insulin

• When additional meals need coverage, prandial insulin should be added sequentially to the second and third meals according to the patient’s glucose pattern. 265

Basal‑Bolus Insulin Regimen for Hospitalized and Outpatient Diabetes Management

Efficacy & Safety

• In randomized trials, scheduled basal‑bolus therapy enables ≈68 % of patients to achieve mean glucose < 140 mg/dL, compared with ≈38 % using less intensive or sliding‑scale approaches. This reflects superior glycemic control. [266][267]
• In hospitalized elderly patients, premixed insulin (e.g., Mixtard) produces a three‑fold higher rate of hypoglycemia than basal‑bolus regimens. [266][267]
• Basal‑bolus therapy does not increase hypoglycemia incidence when titrated according to protocol, unlike inadequate or sliding‑scale regimens. [266][267]
• Use of basal‑bolus insulin reduces hospital complications (post‑operative wound infection, pneumonia, bacteremia, acute renal/respiratory failure) relative to sliding‑scale or other inadequate insulin strategies. [266][267]

Guideline Recommendations

• Major diabetes guideline societies (e.g., the American Diabetes Association and other international bodies) explicitly advise against the use of premixed insulin in hospital settings because of the unacceptable hypoglycemia risk. [266][267]
• Sliding‑scale insulin as monotherapy is condemned by these guidelines; it achieves target glucose in only ~38 % of patients versus ~68 % with scheduled basal‑bolus therapy. [266][267]

Initiation Dosing

• For patients with inadequate control on oral agents or moderate hyperglycemia, start total daily insulin at 0.3–0.5 U/kg.
• Allocate 50 % of the total dose to a long‑acting basal insulin (e.g., glargine, detemir, degludec) once daily.
• Allocate the remaining 50 % to rapid‑acting prandial insulin divided equally among three meals (lispro, aspart, or glulisine) administered 0–15 min before eating.
• In high‑risk groups (age > 65 yr, renal impairment, poor oral intake), initiate at a lower dose of 0.1–0.25 U/kg/day. [266][267]

Titration Protocol

• Basal insulin: increase by 2 U every 3 days if fasting glucose 140–179 mg/dL; increase by 4 U every 3 days if fasting ≥180 mg/dL.
• Target fasting glucose: 80–130 mg/dL.
• Prandial insulin: increase each meal dose by 1–2 U (≈10–15 %) every 3 days based on the 2‑hour post‑prandial glucose.
• Target post‑prandial glucose: <180 mg/dL. 266

Critical Thresholds & Over‑Basalization

• When basal insulin approaches 0.5–1.0 U/kg/day without achieving targets, add or intensify prandial insulin rather than continuing basal escalation.
• Signs of over‑basalization include basal dose > 0.5 U/kg/day, a bedtime‑to‑morning glucose differential ≥ 50 mg/dL, recurrent hypoglycemia, or high glucose variability. 266

Monitoring Requirements

Expected Clinical Outcomes

• With properly implemented basal‑bolus therapy, ≈68 % of patients achieve mean glucose < 140 mg/dL, compared with only ≈38 % on inadequate regimens. [266][267]
• When titrated according to the protocol, hypoglycemia rates remain low and do not exceed those seen with less intensive regimens. [266][267]

Insulin Aspart Should Be Used Only as a Correction Component Within a Scheduled Basal‑Bolus Regimen (Sliding‑Scale Monotherapy Is Contra‑Indicated)

Definition and Risks of Sliding‑Scale Insulin (SSI)

Role of Insulin Aspart for Correction Doses

Recommended Basal‑Bolus Regimen

Titration and Dosing Guidance

Safety and Hypoglycemia Management

Guideline Recommendations (American Diabetes Association)

Evidence‑Based Outcomes

Determining Insulin‑to‑Carbohydrate Ratio and Total Mealtime Dose for Regular Insulin

Insulin‑to‑Carbohydrate Ratio (ICR)

• The insulin‑to‑carbohydrate ratio for regular (short‑acting) insulin is calculated as 500 divided by the total daily insulin dose (TDD); this formula is endorsed in pediatric diabetes guidelines. 269
• Applying the formula to a patient with a TDD of 60 U yields an ICR of approximately 1 U per 8 g of carbohydrate (rounded to a practical 1:8 or 1:10 ratio). 269

Calculation of Total Mealtime Insulin

• The total pre‑meal insulin dose is obtained by adding the carbohydrate‑coverage dose (based on the ICR) to the correction dose; the two components are calculated independently before summation. 269

Example of Complete Mealtime Dose (Illustrative)

• For a patient planning to consume a meal containing ≈60 g of carbohydrate:
  
  • Carbohydrate coverage = 60 g ÷ 8 g per unit ≈ 7.5 U, rounded to 8 U.
  • Correction dose (using an ISF of 25 mg/dL per unit) = (current glucose – target glucose) ÷ ISF = (200 – 100) ÷ 25 = 4 U.
  • Total pre‑meal dose = 8 U + 4 U = 12 U of regular insulin. 269

Management of Severe Hyperglycemia with a Normal Anion Gap

Clinical Assessment

• In patients who present with markedly elevated glucose levels (e.g., >350 mg/dL) but have a normal anion gap and bicarbonate, diabetic ketoacidosis can be ruled out, permitting treatment with aggressive subcutaneous insulin titration rather than intravenous insulin. 270

Therapeutic Recommendations

• The American Diabetes Association advises that sliding‑scale insulin must not be employed as monotherapy because it addresses hyperglycemia only after it occurs, leading to hazardous glucose variability. 270

Optimizing Insulin‑Based Therapy for Persistent Hyperglycemia

Modification of Sulfonylurea (Glimepiride) When Initiating Basal‑Bolus Insulin

• Reducing or discontinuing glimepiride by approximately 50 % at the start of basal‑bolus insulin therapy is recommended to lower the combined risk of hypoglycemia, because both agents independently increase hypoglycemia potential. 271

Incorporation of GLP‑1 Receptor Agonists as an Alternative to Prandial Insulin

• When basal insulin dosing reaches roughly 0.5 units/kg/day without achieving glycemic targets, adding a GLP‑1 receptor agonist (e.g., semaglutide, dulaglutide) is advised as an alternative to further prandial insulin escalation. 271
• The basal‑insulin + GLP‑1 RA regimen provides post‑prandial glucose control comparable to that of basal‑plus‑prandial insulin, but with a lower incidence of hypoglycemia and an associated weight‑loss effect rather than weight gain. 271
• This strategy is especially advantageous for patients who prioritize weight management or have heightened concerns about hypoglycemia. 271

Importance of Prompt Insulin Dose Escalation

• Clinicians should avoid delaying insulin dose escalation when fasting glucose consistently exceeds 180 mg/dL (10 mmol/L), as sustained hyperglycemia is linked to an increased risk of diabetes‑related complications. 271

Management of Pre‑Dinner Hyperglycemia and Insulin Regimen Optimization

Immediate Correction Dose

• Administer a correction dose of 2 units of rapid‑acting insulin (lispro, aspart, or glulisine) immediately, then give the scheduled sulfonylurea‑metformin combination at the evening meal, and reassess the insulin regimen within 24–48 hours because a pre‑dinner glucose of ≈13.5 mmol/L signals inadequate basal coverage and the need for scheduled prandial insulin. [272][273]

Rationale for Regimen Failure

• A pre‑dinner glucose of ≈13.5 mmol/L indicates that the current regimen (morning basal insulin plus evening sulfonylurea‑metformin) is fundamentally inadequate and requires immediate restructuring. 272
• Such hyperglycemia reflects insufficient basal insulin throughout the day and absence of scheduled prandial insulin to blunt meal‑related glucose excursions. 272

Basal Insulin Adjustment

• Increase the basal insulin dose from the current amount to 28–32 units (≈+4 units) and shift administration to bedtime to improve overnight and daytime basal coverage. 272
• If fasting glucose remains ≥180 mg/dL (10 mmol/L), titrate basal insulin by 4 units every 3 days, aiming for a fasting range of 80–130 mg/dL (4.4–7.2 mmol/L). 272

Initiation of Scheduled Prandial Insulin

• Start a scheduled prandial dose of ≈4 units of rapid‑acting insulin before dinner (about 10 % of the basal dose) rather than using it only for correction. 272
• Titrate the dinner prandial dose by 1–2 units every 3 days based on 2‑hour post‑prandial glucose, targeting values <180 mg/dL (<10 mmol/L). 272

Monitoring Requirements

• Check fasting glucose daily to guide basal insulin adjustments. 272
• Obtain a 2‑hour post‑prandial glucose after dinner to assess adequacy of the prandial dose. 272
• Reassess the entire insulin regimen every 3 days while active titration is ongoing. 272

Critical Threshold Warning (Avoid Over‑Basalization)

• When basal insulin approaches 0.5 units/kg/day (≈35–40 units for most adults) without achieving glycemic targets, stop further basal escalation and focus on intensifying prandial insulin to prevent over‑basalization. 272

Hypoglycemia Management

• Treat any glucose <70 mg/dL (<3.9 mmol/L) promptly with ≈15 g of fast‑acting carbohydrate, recheck in 15 minutes, and repeat if needed. 272
• If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20 % before the next administration. 272

Common Pitfalls to Avoid

• Do not delay adding prandial insulin when pre‑meal glucose consistently exceeds 180 mg/dL (10 mmol/L); prolonged hyperglycemia raises the risk of complications. 272

Management of Severe Hyperglycemia with Ketosis in Insulin‑Resistant Adults

1. Immediate Risk Assessment

• In an insulin‑resistant adult with markedly elevated glucose (≈13.8 mmol/L) and ketones (≈1.6 mmol/L), a single 6‑unit subcutaneous insulin dose carries minimal immediate hypoglycemia risk but is profoundly inadequate to correct the metabolic disturbance. 274
• Ketone concentrations ≥1.6 mmol/L together with glucose >13 mmol/L constitute clinically significant ketosis that warrants urgent evaluation for diabetic ketoacidosis (DKA). 275
• Immediate laboratory assessment (venous pH, bicarbonate, anion‑gap) is required to exclude DKA when these thresholds are met. 275

2. Guideline‑Based Initial Insulin Strategy

• Total daily insulin dose: For severe hyperglycemia with ketosis, major diabetes societies (EASD) recommend initiating 0.3–0.5 U/kg/day of insulin, divided between basal and prandial components. 274
• Basal insulin: Begin a long‑acting insulin (e.g., glargine or detemir) at 10–15 U once daily for a typical adult; titrate upward by 4 U every 3 days until fasting glucose reaches 5–7 mmol/L. 274
• Prandial insulin: Add 4–6 U rapid‑acting insulin before each meal, adjusting by 1–2 U every 3 days to keep 2‑hour post‑prandial glucose <10 mmol/L. 274
• Correction doses: Use 2 U for glucose >13.9 mmol/L (≈250 mg/dL) and 4 U for glucose >19.4 mmol/L (≈350 mg/dL), administered in addition to scheduled basal‑bolus insulin. 274

3. Limitations of Sliding‑Scale (Correction‑Only) Therapy

• Sliding‑scale insulin as monotherapy is discouraged by both EASD and ADA guidelines because it reacts to hyperglycemia rather than preventing it, leading to wide glucose variability. [274][276]
• Only ≈38 % of patients achieve mean glucose <140 mg/dL with sliding‑scale alone, versus ≈68 % when a scheduled basal‑bolus regimen is used. 274
• A solitary 6‑unit correction dose without basal coverage fails to suppress hepatic glucose output, guaranteeing persistent hyperglycemia and worsening ketosis. 274

4. Escalation to Intravenous Insulin

• If DKA criteria are met (pH < 7.3, bicarbonate < 18 mEq/L, anion gap > 12), initiate a continuous IV insulin infusion at 0.1 U/kg/h (≈7–10 U/h for most adults). 275
• Even when DKA is excluded, persistent ketones > 1.0 mmol/L or rising values 2–4 h after subcutaneous insulin mandate escalation to IV insulin therapy. 275

5. Monitoring and Safety

• During titration, check capillary glucose before each meal and at bedtime (minimum four times daily). 274
• Re‑measure ketones 2–4 h after insulin administration; if they remain ≥1.0 mmol/L, intensify insulin therapy promptly. 275

6. Expected Clinical Outcomes

• With a basal‑bolus regimen of 0.3–0.5 U/kg/day, glucose is expected to fall to <10 mmol/L (≈180 mg/dL) within 24–48 h. 274
• Adequate insulin and hydration typically clear ketosis within 12–24 h. 275
• Approximately 68 % of patients achieve mean glucose <140 mg/dL using basal‑bolus therapy, compared with 38 % when only correction‑only dosing is employed. 274

Initiation and Titration of NPH Insulin in Adults with Type 2 Diabetes

Initial Dose and Timing

• For insulin‑naïve adults with type 2 diabetes, start NPH insulin at 10 units once daily or 0.1–0.2 units/kg body weight per day, administered at bedtime to optimize basal glucose control【277】.

Titration Protocol

• Increase the total daily NPH dose by 2 units every 3 days when fasting glucose is 140–179 mg/dL【277】.
• Increase the total daily NPH dose by 4 units every 3 days when fasting glucose is ≥180 mg/dL【277】.
• Target fasting glucose range is 80–130 mg/dL【277】.
• If unexplained hypoglycemia (glucose < 70 mg/dL) occurs, reduce the current dose by 10–20 % immediately【277】.

Twice‑Daily NPH Regimen (When Needed)

• If a twice‑daily schedule is required, allocate roughly 2/3 of the total dose in the morning and 1/3 at night【277】.

Combination with Other Antidiabetic Agents

• Continue metformin (unless contraindicated) when initiating NPH; this combination typically reduces total insulin requirements by 20–30 %【277】.
• Titrate metformin to the maximum tolerated dose (up to ~2000–2500 mg daily) when used together with insulin【277】.
• Discontinue sulfonylureas when starting a basal‑bolus regimen to avoid additive hypoglycemia risk【277】.

Monitoring During Titration

• Perform daily fasting glucose checks to guide dose adjustments【277】.
• Review insulin dose adequacy at each clinical visit【277】.
• Re‑evaluate and modify the insulin regimen every 3–6 months to prevent therapeutic inertia【277】.

Threshold for Adding Prandial Insulin

• Add rapid‑acting (prandial) insulin when the basal NPH dose approaches 0.5–1.0 units/kg/day without achieving glycemic targets【277】.
• Clinical signs of “over‑basalization” include high basal dose, large night‑to‑morning glucose differentials, recurrent hypoglycemia, and high glucose variability【277】.

Initiation of Prandial (Rapid‑Acting) Insulin (If Required)

• Begin with 4 units of rapid‑acting insulin before the largest meal, or use 10 % of the basal dose as an alternative【277】.
• Administer rapid‑acting insulin 0–15 minutes before meals【277】.
• Titrate each mealtime dose by 1–2 units every 3 days based on 2‑hour post‑prandial glucose values【277】.
• Target post‑prandial glucose is <180 mg/dL【277】.

Hospitalized Patients (Limited Oral Intake)

• Use an initial dose of 0.1–0.25 units/kg/day for adults with restricted oral intake to minimize hypoglycemia risk【277】.
• For patients previously on high‑dose insulin at home (≥0.6 units/kg/day), reduce the total daily dose by 20 % upon hospital admission【277】.

High‑Risk Populations (Elderly, Renal Impairment, Poor Intake)

• Initiate NPH at a lower range of 0.1–0.25 units/kg/day in older adults (>65 years), those with renal dysfunction, or with inadequate oral intake【277】.

Common Errors to Avoid

• Do not postpone insulin initiation when oral agents fail to meet targets; delay prolongs hyperglycemia exposure【277】.
• Do not discontinue metformin when starting insulin unless contraindicated; doing so raises insulin needs and weight gain【277】.
• Do not continue escalating NPH beyond 0.5–1.0 units/kg/day without adding prandial insulin, as this increases hypoglycemia risk【277】.
• Avoid premixed 70/30 insulin in hospitalized patients because it is associated with a markedly higher hypoglycemia rate (≈64 % vs 24 % with basal‑bolus)【277】.
• Do not rely on a sliding‑scale insulin alone; only about 38 % achieve mean glucose < 140 mg/dL with sliding scale versus 68 % with a structured basal‑bolus regimen【277】.

Hypoglycemia Management

• Treat any glucose < 70 mg/dL immediately with 15 g of rapid‑acting carbohydrate, re‑check in 15 minutes, and repeat if needed【277】.
• If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20 % before the next administration【277】.
• Prescribe emergency glucagon for all patients at high risk of severe hypoglycemia【277】.

Expected Clinical Outcomes

• Properly implemented basal‑bolus therapy enables ≈68 % of patients to achieve mean glucose < 140 mg/dL, compared with ≈38 % using inadequate regimens【277】.
• Basal‑bolus regimens do not increase overall hypoglycemia incidence relative to poorly executed sliding‑scale approaches【277】.

Metformin Optimization and Prandial Insulin Strategy in Type 2 Diabetes

Metformin Dosing

• Increase metformin to 1000 mg twice daily (total 2000 mg) for adults when current dosing is ≤500 mg twice daily, because lower doses leave roughly half of the drug’s glucose‑lowering potential untapped. – American Diabetes Association (ADA) guideline, strong recommendation (Grade A)【278】

Metformin‑Insulin Interaction

• Adding metformin to an insulin regimen reduces the total daily insulin requirement by approximately 20–30 % and yields superior overall glycemic control compared with insulin alone. – ADA guideline, strong recommendation (Grade A)【278】
• Metformin should be continued when intensifying insulin therapy; discontinuation leads to higher insulin needs and greater weight gain. – ADA guideline, strong recommendation (Grade A)【278】
• When used with insulin, metformin is weight‑neutral or can produce modest weight loss, whereas insulin monotherapy is associated with weight gain. – ADA guideline, strong recommendation (Grade A)【278】

Prandial Insulin Approach

• The use of sliding‑scale insulin as the sole prandial strategy is explicitly condemned by the ADA and other major diabetes societies; scheduled basal‑bolus therapy is the recommended approach for post‑prandial glucose control. – ADA guideline, strong recommendation (Grade A)【278】

Guideline for Rechecking Blood Glucose After Subcutaneous Rapid‑Acting Insulin Correction Doses

Monitoring Timing

Interpretation of Results

Correction Dose Protocols

Special Considerations for High‑Risk Patients

Common Pitfalls

Hypoglycemia Management After Correction

Immediate Insulin Dose Reduction to Prevent Severe Hypoglycemia

1. Safety‑First Dose Adjustment

• Reduce the morning rapid‑acting insulin by 20–30% (≈14–16 U) and the evening dose by ~25% (≈3 U) in an elderly patient with LADA and renal impairment to avoid glucose values <70 mg/dL. [American Diabetes Association] [280]281
• In patients ≥ 65 years with eGFR ≈ 30 mL/min/1.73 m², start insulin at 0.1–0.25 U/kg/day rather than higher conventional doses. [International Diabetes Federation] [281]
• 75 % of hospitalized individuals who experience hypoglycemia receive no basal‑insulin adjustment before the next dose, underscoring the need for immediate reduction. [International Diabetes Federation] [281]
• For CKD stage 3b–4, total daily insulin should be lowered by 25–50 % compared with patients with normal renal function. [International Diabetes Federation] [281]

2. Structured Basal‑Bolus Regimen for LADA

• Allocate 40–50 % of the total daily dose to basal insulin and 50–60 % to prandial insulin (type‑1‑diabetes‑like pattern). [American Diabetes Association] [280]281
• Initial total daily dose for a 50–60 kg individual: 0.3–0.4 U/kg/day (≈15–24 U), split evenly between basal and prandial components. [International Diabetes Federation] [281]

3. Basal‑Insulin Titration After Reduction

• Start basal insulin at ~14–16 U once daily (bedtime or morning depending on hypoglycemia timing). [American Diabetes Association] [280]281
• If early‑morning hypoglycemia persists, shift the long‑acting insulin to the morning to move peak activity away from overnight. [International Diabetes Federation] [281]
• Increase basal insulin by 2 U every 3 days when fasting glucose is 140–179 mg/dL (7.8–9.9 mmol/L). [American Diabetes Association] [280]281
• Increase basal insulin by 4 U every 3 days when fasting glucose ≥180 mg/dL (≥10 mmol/L). [American Diabetes Association] [280]281
• Target fasting glucose 80–130 mg/dL (4.4–7.2 mmol/L). [American Diabetes Association] [280]281
• If any reading falls <70 mg/dL, reduce the current basal dose by 10–20 % immediately. [American Diabetes Association] [280]281
• Stop basal escalation once the dose approaches 0.5 U/kg/day (≈25–30 U for a 50–60 kg patient) without reaching targets, and focus on prandial addition to avoid “over‑basalization.” [American Diabetes Association] [280]281
• Signs of over‑basalization: basal > 0.5 U/kg/day, bedtime‑to‑morning glucose gap ≥ 50 mg/dL, recurrent hypoglycemia, high glucose variability. [American Diabetes Association] [280]281

4. Adding Scheduled Prandial Insulin

• HbA1c ≈ 9 % signals inadequate fasting and post‑prandial control; combined basal‑bolus therapy is required. [American Diabetes Association] [280]281
• Begin with 4 U rapid‑acting insulin before the largest meal (≈10 % of the basal dose). [American Diabetes Association] [280]281
• Administer prandial insulin 0–15 minutes before meals for optimal post‑prandial glucose reduction. [American Diabetes Association] [280]281
• Titrate each mealtime dose by 1–2 U every 3 days based on 2‑hour post‑prandial glucose values. [American Diabetes Association] [280]281
• Target post‑prandial glucose < 180 mg/dL (<10 mmol/L). [American Diabetes Association] [280]281
• Example regimen after titration: basal 16–20 U once daily; prandial 4–6 U before breakfast, lunch, and dinner; total daily insulin ≈28–38 U (≈0.5–0.6 U/kg/day for a 50–60 kg patient). [American Diabetes Association] [280]281

5. Monitoring & Safety Protocols

• Daily glucose checks: fasting, pre‑meal, 2‑hour post‑prandial, and bedtime to guide titration and detect nocturnal hypoglycemia. [American Diabetes Association] [280]281
• Treat any glucose < 70 mg/dL with 15 g fast‑acting carbohydrate (e.g., 4 glucose tablets or 4 oz juice), re‑check in 15 minutes, repeat if needed. [American Diabetes Association] [280]281
• After a hypoglycemic episode, reduce the implicated insulin dose by 10–20 % before the next administration. [American Diabetes Association] [280]281
• Provide a glucagon emergency kit and educate caregivers for severe hypoglycemia. [American Diabetes Association] [280]281
• Reassess renal function (eGFR) every 3–6 months; in CKD stage 4–5 (eGFR < 30 mL/min/1.73 m²) reduce total insulin by 35–50 % compared with baseline. [International Diabetes Federation] [281]

6. Expected Clinical Outcomes

7. Interaction with Pancreatic Enzyme Replacement (Creon)

• Optimizing Creon dosing (25,000–40,000 lipase units per meal) improves nutrient absorption, which may increase post‑prandial glucose excursions and therefore require closer prandial‑insulin monitoring. [American Diabetes Association] [280]281

Key Take‑away: Prompt reduction of excessive insulin, followed by a structured basal‑bolus titration algorithm, daily glucose monitoring, and attention to renal function and pancreatic enzyme therapy, safely brings an elderly patient with LADA from severe hypoglycemia toward target glycemic control.

Transition from Sliding‑Scale to Basal‑Bolus Insulin in Hospitalized Type 2 Diabetes

Contraindication of Premixed 70/30 Insulin

• Premixed human insulin 70/30 is linked to an unacceptably high iatrogenic‑hypoglycemia rate (≈64 % vs 24 % with basal‑bolus) in hospitalized patients, leading to early trial termination; therefore it should not be used in the hospital setting. 282
• The fixed 70 % intermediate‑acting / 30 % short‑acting ratio cannot be adjusted independently, increasing hypoglycemia risk when meals are irregular. 282
• Major diabetes guideline societies (American Diabetes Association and European Association for the Study of Diabetes) explicitly advise against using premixed insulin in inpatient care because of the excessive hypoglycemia risk. 282
• Premixed insulin requires twice‑daily injections timed to breakfast and dinner and assumes consistent carbohydrate intake, making it unsuitable for patients with variable eating patterns. 282

Inadequacy of Sliding‑Scale Insulin Monotherapy

• All major diabetes guidelines condemn sliding‑scale insulin as monotherapy because it reacts to hyperglycemia rather than preventing it, resulting in wide glucose fluctuations. 282
• Only about 38 % of patients on sliding‑scale alone achieve mean glucose < 140 mg/dL, compared with roughly 68 % when a scheduled basal‑bolus regimen is used. 282
• Sliding‑scale provides no basal insulin to suppress hepatic glucose production, leading to persistent fasting hyperglycemia. 282
• Absence of scheduled prandial insulin causes post‑prandial spikes that are later corrected with large reactive doses, creating a cycle of hyper‑ → hypoglycemia → rebound hyperglycemia. 282

Recommended Basal‑Bolus Regimen

Initial Dosing

• Discontinue sliding‑scale insulin immediately and start a scheduled basal‑bolus approach for patients with glucose consistently 190–350 mg/dL. 282
• Begin with a total daily insulin dose of 0.3–0.5 U/kg, split 50 % as basal (once daily long‑acting analog) and 50 % as prandial (divided among three meals). 282
• Basal insulin: long‑acting analog (e.g., glargine, detemir, degludec) at ≈0.15–0.25 U/kg once daily (≈10–20 U for a 70‑kg adult). 282
• Prandial insulin: rapid‑acting analog (lispro, aspart, or glulisine) at ≈4 U before each of the three largest meals, administered 0–15 min before eating. 282
• Correction doses: add 2 U for pre‑meal glucose > 250 mg/dL and 4 U for glucose > 350 mg/dL, on top of scheduled prandial insulin. 282

Titration Protocol

• Basal insulin: increase by 4 U every 3 days if fasting glucose ≥ 180 mg/dL; increase by 2 U every 3 days if fasting glucose 140–179 mg/dL. Target fasting glucose 80–130 mg/dL. 282
• Prandial insulin: increase each meal dose by 1–2 U every 3 days based on 2‑hour post‑prandial glucose. Target post‑prandial glucose < 180 mg/dL. 282
• If hypoglycemia occurs (glucose < 70 mg/dL), reduce the implicated insulin dose by 10–20 % immediately. 282

Monitoring Requirements

• Measure fasting glucose daily to guide basal adjustments. 282
• Record pre‑meal glucose before each meal for correction calculations. 282
• Obtain 2‑hour post‑prandial glucose after each meal to assess prandial adequacy. 282
• Check bedtime glucose to evaluate overall daily pattern. 282
• Reassess and adjust insulin doses every 3 days while titrating. 282

Expected Clinical Outcomes

• Approximately 68 % of patients on a properly titrated basal‑bolus regimen achieve mean glucose < 140 mg/dL, versus 38 % with sliding‑scale alone. 282
• When titrated per protocol, basal‑bolus therapy does not increase hypoglycemia incidence compared with inadequate or sliding‑scale regimens. 282
• HbA1c reductions of 2–3 % are achievable within 3–6 months with intensive insulin titration. 282

Critical Pitfalls to Avoid

• Do not add premixed 70/30 insulin to patients with glucose 190–350 mg/dL; the fixed ratio and high hypoglycemia risk make it unsuitable. 282
• Do not continue sliding‑scale insulin as monotherapy when glucose repeatedly exceeds 180 mg/dL; it is inferior and unsafe. 282
• Do not delay adding prandial insulin when basal insulin alone fails to meet fasting glucose targets. 282
• Never use rapid‑acting insulin at bedtime as a sole correction dose, as it markedly raises nocturnal hypoglycemia risk. 282

Hypoglycemia Management

• Treat any glucose < 70 mg/dL immediately with 15 g of fast‑acting carbohydrate (e.g., 4 glucose tablets or 4 oz juice), recheck in 15 minutes, and repeat if needed. 282
• If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20 % before the next administration. 282

Adjunctive Therapy

• Continue metformin at the maximum tolerated dose (up to ≈2,500 mg daily) when initiating insulin; metformin reduces total insulin requirements by 20–30 % and improves glycemic control. 282
• Discontinue sulfonylureas when starting basal‑bolus insulin to avoid additive hypoglycemia risk. 282